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Abstract
Many xenobiotics are known to induce liver enlargement and hepatocarcinogenesis in 
rats, by mechanisms that remain largely undefined. As several of these compounds 
have significant human exposure, this has been cause for concern. The aim of this 
study, by investigating changes in gene expression occurring in conjunction with 
compound-induced increases in liver weight, was to identify molecular markers for 
the prediction of compound-induced hepatomegaly and hepatocarcinogenesis in vivo. 
The effects of four hepatomegalic compounds, namely phénobarbital, Wy-14,643, 
dexamethasone and cyproterone acetate were investigated in male Sprague-Dawley 
rats over a 72-hour time-course. The gene-hunting technique suppression subtractive 
hybridisation (SSH) isolated many potential differentially expressed gene transcripts 
from rat liver following Wy-14,643 treatment. Quantitative RT-PCR methods 
demonstrated four of these transcripts, namely carboxylesterase (Carb), cathepsin H 
{CatH), a Kupffer cell-surface receptor {KCB^ and ubiquitin activating enzyme E l 
(Ub), none of which have previously been reported to be involved in liver growth, to 
be differentially expressed following each of the compound treatments. KCR mRNA 
was demonstrated to be liver-specific, levels being down-regulated following 
treatment with three of the compounds. By analysis of liver sections, the cause of this 
down-regulation was attributed to decreased Kupffer cell numbers per field. 
Following dexamethasone treatment, this was correlated to substantial hepatocyte 
hypertrophy. However, the Wy-14,643 and cyproterone acetate-induced changes in 
Kupffer cell number are due to either a reduction in Kupffer cell number, or a change 
in their distribution due to the hyperplastic effects of these compounds. Kupffer cells 
are essential in the maintenance of liver homeostasis, capable of secreting various 
cytokines and growth factors, as well as antitumour agents, on activation. Recently, 
Kupffer cell-release of mitogenic cytokines was shown to be responsible for Wy- 
14,643-induced cell proliferation. A working hypothesis incorporating a novel role of 
Kupffer cells in xenobiotic-induced liver growth and hepatocarcinogenesis is 
therefore proposed.
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Chapter 1
Introduction
1.1 The Liver
The liver is the largest gland in the body. It is a highly specialised organ performing 
an astonishingly large number of vital tasks that impact all body systems. It is 
involved in many essential metabolic, anabolic and catabolic fimctions. The major 
metabolic functions of the liver can be summarised into three main categories, namely 
carbohydrate, fat and protein metabolism (Wilson, 1990). Without the role of the 
liver in protein metabolism, with the subsequent removal of ammonia from the body, 
death would occur within a few days. The liver is a richly vascularised organ, and so 
is responsible for the regulation of various components in the blood. Vital roles 
involve monitoring and controlling the plasma concentrations of molecules involved 
in metabolism, filtering various materials from the bloodstream, as well as 
metabolising and detoxifying xenobiotics, certain hormones and drugs (Tortora and 
Grabowski, 1989).
1.1.1 Structure
Four lobes constitute the liver -  two principle lobes, the right and the left lobe as well 
as the caudate and quadrate lobes on the posterior surface (Marieb, 1999). The right 
lobe is by far the largest and is visible on all liver surfaces. The lobes of the liver are 
made up of many hexagonal functional units called lobules and each lobule consists of 
specialised epithelial cells, termed hepatocytes (parenchymal cells) (section 1.1.2.1), 
with portal triads at the vertices and a central vein in the middle (Tortora and 
Grabowski, 1989). Portal triads contain a bile duct and a terminal branch of the 
hepatic artery and portal vein. The continuous mass of epithelial cells is therefore 
tunnelled by sinusoids through which blood passes, as well as lymphatic vessels and 
nerve fibres (Pansky, 1975). They receive blood from terminal branches of the 
hepatic artery and portal vein at the periphery of lobules and deliver it into central 
veins. The sinusoids are lined with a discontinuous endothelium consisting of several 
distinct populations of cells (section 1.1.2). This endothelium rests on a basement 
membrane, separated from the parenchymal cells by the perisinusoidal space known 
as the Space of Disse (Pansky, 1975).
1.1.2 Cells of the liver
The liver is comprised of five major cell types, namely the hepatocytes, endothelial 
cells, Kupffer cells, Ito (fat-storing) cells and the bile duct cells. Hepatocytes are by 
far the most prominent component of liver parenchyma in terms of both volume and 
membrane surface area. In rats and mice, hepatocytes constitute around 80% of the 
liver cell mass (Alison, 1986). As such a large percentage of the liver is made up of 
hepatocytes, it has followed that most liver studies have concentrated solely on these 
cells and often the potential role of other cells being ignored. However, the intimate 
association of parenchymal and non-parenchymal cells makes it unlikely that these 
cells act independently of each other. More recent studies have provided evidence 
which suggests that interactions between all types of liver cells, especially between 
Kupffer cells and hepatocytes, play roles in normal liver physiology, in the normal 
response of the liver in disease states, and perhaps even in hepatic dysfimction or 
injury (Peterson, 1992).
1.1.2.1 Hepatocytes (Parenchymal cells)
Hepatocytes make up most of the liver mass and have a polyhedral form. These cells 
contain a nucleus/nuclei and cytoplasm rich in mitochondria, rough and smooth 
endoplasmic reticulum, Golgi apparatus, lysosomes, peroxisomes and various 
inclusions (lipid, glycogen, pigments, iron-containing). A majority of cells have a 
single nucleus, but binucleate cells are common. Hepatocytes also exist in different 
states of ploidy. The proposed evolution of binucleated and polyploid hepatocytes in 
rats is illustrated in Figure 1.1. Following exposure of rats to various xenobiotics, 
changes in ratios of hepatocytes in the various states of nuclearity and ploidy, as well 
as susceptibility of specific cell states to xenobiotic-actions have been indicated 
(Digemes, 1980; Bohm and Noltemeyer, 1981; Styles et a/., 1985; 1988; Gerlyng et 
al, 1993).
Hepatocytes perform a number of vital functions, being exceptionally active in the 
synthesis of proteins and lipids for export. Roles include the production of bile, the 
processing of blood-borne nutrients (such as the storage of glucose as glycogen and 
the usage of ammo acids to make plasma proteins), the storage of fat-soluble vitamins, 
as well as important roles in detoxification (such as the removal of ammonia firom the 
blood and its conversion to urea). In addition, as indicated by the lobular structure of 
the liver and the existence of portal triads and sinusoids, these cells maintain a
constant interchange with the biliary and vascular systems. The liver has been 
described as a ‘biliovascular tree’ in which the interspaces between the branches 
are filled with parenchyma (Pansky, 1975).
Figure 1.1 Diagram illustrating the proposed evolution of binucleated and 
polyploid hepatocytes in rats
(Taken from Styles et a i, 1987)
S phase ^ no cvtokinesi^
Cytokinesis
Cytokinesis
No mitosisS phase
1.1.2.2 Bile duct cells
The biliary system is a series of channels and ducts that conveys bile, a secretory and 
excretory product of hepatocytes, from the liver into the lumen of the small intestine. 
Bile is partially an excretory product and partially a digestive secretion, consisting 
mostly of water and bile acids, bile salts, cholesterol, lecithin, bile pigments and 
several ions (Tortora and Grabowski, 1989). Hepatocytes secrete bile into the bile 
canaliculi, and those secretions run parallel to the sinusoids, but in the opposite 
direction that blood flows. The bile canaliculus is not a duct, but rather the dilated 
intercellular space between adjacent hepatocytes. At the ends of the canaliculi, bile 
flows into true ducts lined with epithelial cells. First bile enters the bile ductiles, 
which lead to smaller interlobular bile ducts, then into septal bile ducts, into large 
intrahepatic bile ducts, and finally into the major branches of the common bile duct. 
Bile ducts begin in very close proximity to the terminal branches of the portal vein 
and hepatic artery making up the portal triad as described. The cells of the biliary 
canals make up a cuboidal or columnal epithelium that is very different in appearance 
from that of the hepatocytes, with great elasticity. This biliary epithelium lies on a 
basement membrane whose thickness varies according to the level of the bile duct. 
(Pansky, 1975)
1.1.2.3 Ito cells
Usually known as Ito cells, they may also be referred to as hepatic stellate cells or 
fat-storing cells. Ito cells are mesenchymal cells located in the perisinusoidal Space 
of Disse separated from the flowing blood by a fenestrated endothelium. They 
comprise approximately half of the non-parenchymal cell population in normal liver 
(Giampieri et al, 1981). Ito cells consist of a cell body and several dendritic 
processes and they indent the underlying hepatocytes whose surface microvilli tend to 
be smoothed out over the area of contact. This creates close cell contacts between 
neighbouring cells and is likely to be important for efficient paracrine transport of 
solutes and cytokines (Wake, 1980).
In the normal liver, Ito cells appear to carry out two major functions, namely a major 
role in the transport and storage of vitamin A compounds (retinoids); and an equally 
important role in the production of hepatotrophic and homeostatic cytokines 
(Ankoma-Sey and Friedman, 1998).
Storage of vitamin A compounds in lipid droplets occurs within the cytoplasm of Ito 
cells. The composition of these droplets varies depending on dietary intake and they 
not only contain retinoids but also triglycerides, phospholipids, cholesterol and free 
fatty acids (Moriwaki et a l, 1988).
Cytokine secretion by Ito cells is important for both normal liver growth and 
regeneration, as well as for the response to injury. Ito cells express at least three 
major hepatocyte mitogens: transforming growth factor-alpha (TGFa), epidermal 
growth factor (EGF) and hepatocyte growth factor (HGF) (Bachem et a l, 1992; 
Maher, 1993; Mullhaupt et a l, 1994). TGFa and EGF also stimulate proliferation of 
the Ito cells themselves. Activated Ito cells express platelet derived growth factor 
(PDGF) which is the most potent Ito cell mitogen yet described (Pinzani et a l, 1991). 
Pro-inflammatory mediators such as macrophage colony stimulating factor (MCSF) 
and monocyte chemotactic peptide 1 are also secreted by Ito cells (Pinzani et al, 
1992) as well as platelet activating factor (Pinzani et a l, 1994) indicating a role in the 
amplification of the neutrophil inflammatory response. Other cytokines expressed 
include insulin-like growth factor I and II, acidic fibroblast growth factor, heparin 
binding growth factor 2, interleukin-6 (IL6) (acute phase response) and transforming 
growth factor-beta 1 (TGFgi) (in liver injury). Ito cells are also known to secrete 
apolipoprotein E, and various prostaglandins and leukotrienes following certain 
activation.
Like endothelial cells, Ito cells play a major role in extracellular matrix (ECM) 
production, being the primary matrix-producing cells in liver fibrosis. They produce a 
vast array of ECM constituents including various collagens, heparan, dermatan and 
chondroitin sulphate, proteoglycans, laminin, fibronectin, entactin, the matrix 
glycoproteins tenascin and undulin, and the proteoglycan core proteins hyaluronic 
acid, biglycan and decorin (Ankoma-Sey and Friedman, 1998).
1.1.2.4 Endothelial cells
Endothelial cells form the fenestrated walls of the liver sinusoids. They are 
characterised by a thin cytoplasm, flattened nuclei and numerous fenestrae grouped in 
sieve plates (Wisse, 1970). These allow open communication between the sinusoidal 
lumen and the Space of Disse so that solutes and particles up to a certain diameter can 
exchange freely between the blood and lymph within these two compartments
(Bradfield, 1984). The endothelial sieve plates therefore have the potential to select 
which particles come into contact with the underlying hepatocytes. It is possible for 
the size and number of fenestrae to vary in response to a number of factors, such as 
alcohol (Clarke et a l, 1988) and nicotine (Fraser et a l, 1988).
Endothelial cells and Kupffer cells have a wide range of functions in the normal liver, 
some of which overlap. These include roles in the process of endocytosis, antigen 
presentation as well as the secretion of bioactive molecules (Winwood and Arthur, 
1998).
Within the cytoplasm of endothelial cells are many endocytotic vesicles (Blouin, 
Bolender and Wiebel, 1977). Endothelial cell endocytosis is predominantly receptor- 
mediated, with capacities for a wide variety of molecules including caeruloplasmin, 
iron-transferrin, lactoferrin, hyaluronic acid and some glycoproteins. Endothelial 
cells have a particularly high endocytic capacity for colloids, notably albumin, heparin 
and lipoprotein.
Endothelial cells also synthesize and release a number of bioactive molecules 
including prostanoids and cytokines such as prostaglandin D2 and E2, thromboxane 
A2, tumour necrosis factor-alpha (TNFa), interleukin-6 (IL6) and interleukin-1 (ILl) 
(Eghom et a l, 1988; Schlayer et a l, 1988). Therefore, in combination with Kupffer 
cells, they may contribute to modulation of the acute-phase response by hepatocytes, 
(section 1.2.1.3).
Endothelial cells may also play key roles in lipoprotein and cholesterol metabolism 
via their fenestrae by controlling flow of various molecules through size selection 
(Naito and Wisse, 1978).
Additional roles of these cells lie in the synthesis of the extracellular matrix (ECM) as 
collagens and fibronectin have been demonstrated to be present in the endoplasmic 
reticulum of endothelial cells (Clement et a l, 1984; 1985; 1986).
1.1.2.5 Kupffer cells
Kupffer cells are phagocytic members of the reticulo-endothelial system, representing 
the largest pool of macrophages in the body. These cells lie on the luminal side of the 
sinusoidal endothelium attached by pseudopods, although some of their cytoplasmic 
processes insert focally between the endothelial cells. They originate from blood 
monocytes and it is generally accepted that they have limited capacity for further cell
division (Bradfield, 1984). However, some observations have indicated that Kupffer 
cells can divide locally, such as in the process of liver regeneration (section 1 .2 .1) 
(Widmann and Fahimi, 1975).
Kupffer cells play important roles in host defense, injury and repair, predominantly 
through the release of a vast array of bioactive substances (Decker, 1990), many of 
which are shown in Table 1.1.
Table 1.1 Secretory products of Kupffer cells
Product Example
Modulators of cell functions
Eicosanoids
Platelet activating factor 
Cytokines
Prostaglandins: PGI2, PGE2, PGD2, PFG2, TXA2 
Leukotrienes: LTB4, LTE4
Interleukins: IL-1, IL-6 ; interferons; 
Transforming growth factor a, p;
Hepatocyte growth factor; Epidermal growth 
factor; Platelet-derived growth factor
Defence mechanisms and cytotoxicity
Complement components 
Reactive oxygen intermediates 
Nitric oxide 
Lysozyme
Superoxide, hydrogen peroxide, hydroxyl radical
Lysosomal enzymes Plasminogen activator, 95kDa type IV 
collagenase/gelatinase p, interstitial collagenase
Other enzymes 
Apolipoprotein E 
ai iduronidase 
Phospholipase A2
(Adapted from Winwood and Arthur, 1998)
Compared with other macrophages, Kupffer cells are highly phagocytic (Laskin et a i, 
1988). Most phagocytosis is receptor-mediated, mostly via the Fc region of 
immunoglobulins, complement components (Clq, C3b) or glycoconjugates including 
sucrose, N-acetylgalactosamine and N-acetylglucosamine (mannose)-terminated 
glycoproteins.
Kupffer cells have also been shown to be capable of direct cytotoxicity, particularly to 
tumour cells. The mechanisms through which Kupffer cells may bring about 
cytotoxicity include tumour necrosis factor (TNFa)-dependent mechanisms, 
interactions with natural killer cells and the generation of free radicals (Decker, 1990).
1.1.3 Inter-cellular communication
The form of inter-cellular communication in the liver is via special plasma membrane 
structures called gap junctions. Gap junctions contain channels that connect and 
allow communication between adjacent cells, allowing the passage of ions and 
molecules up to 1000 Da (Simpson et a l, 1977).
Gap junctions are made up of proteins known as connexins, encoded by a multigene 
family. The family of connexin proteins includes at least 12 members in rodents 
(Kumar and Gilula, 1996). In rat liver, connexin proteins oligomerise into a 
hexameric ring surrounding a central pore within the plasma membrane of a cell, 
forming a connexon (Peterson, 1992). An individual connexon from one cell 
associates with a corresponding connexon on a neighbouring cell to form a gap 
junction channel, and multiple channels aggregate in the plane of the membrane to 
form gap junction plaques (Kumar and Gilula, 1996). The properties of the gap 
junction channels are defined by the specific connexins that form them.
There are three connexins present in rat liver, the major connexin being connexin 32 
which is responsible for about 95% of the hepatocyte gap junction channels (Kumar, 
1991). Connexin 26 comprises the remaining 5% of the channels of the hepatocyte 
junctional plaques, with connexin 43 being expressed in the bile duct epithelial cells, 
Kupffer cells and endothelial cells lining the venules.
In the liver, gap junctions are known to be important in the regulation of development 
(Warner, 1992), as well as cell growth and proliferation (Loewenstein, 1979). Gap 
junctional-mediated communication has been shown to diminish with increased 
proliferative activity of hepatocytes (Yamasaki et a l, 1993). This has been
demonstrated during the proliferative phases for rat hepatocytes following 70% partial 
hepatectomy, where changes in connexin 32 protein expression have been shown (see 
below; Neveu et aL, 1995). Gap junctions have also been shown to play a role in liver 
tumorigenesis, where a decrease in gap junction intercellular communication 
(Yamasaki et al, 1993), as well as a down-regulation of specific connexin expression 
has been demonstrated (Krutovskikh et a l, 1994; 1995).
Various hepatotoxic chemicals have shown to exert decreases in gap-junctional 
communication in rodents, suggesting that this may be a contributing factor in the 
initiation of carcinogenesis (Miyashita et a l, 1991; Neveu et a l, 1994).
In addition, growth factors, including HGF, EGF and PDGF, have been demonstrated 
to inhibit gap junctional communication in mammalian cells (Maldonado et a l, 1988; 
Ikejima et a l, 1995), and since Kupffer cells (Table 1.1) and Ito cells (section 1.1.2.3) 
are able to release/express these factors, such cells may therefore play a role in 
modulating this form of communication.
1.2 Liver growth
It is essential that the liver is able to maintain its size and fimctions, rapidly repairing 
any damage that may occur. One remarkable attribute of the liver is its ability to 
precisely regulate its growth and mass. For example, when the liver mass is 
significantly reduced (by surgery or toxin-induced cell death), the liver rapidly regains 
its normal size through a carefully controlled programme of cell division (section 
1.2.1; Fausto and Webber, 1993). Conversely, when the size of the liver exceeds the 
requirements of the body, such as following hepatic transplantation, a regulated 
schedule of apoptosis (programmed cell death) reduces the liver size to normal over a 
period of 1-2 weeks (Michalopoulos and De Frances, 1997). Control of growth of the 
whole organ is governed by complex signalling and transducing events that depend on 
the metabolic activity of the liver, on interactions of hepatocytes with non- 
parenchymal cells and extracellular matrix components, and on endocrine, paracrine, 
and neural regulatory circuits (Fausto and Webber, 1993).
Proliferative activity in the adult mammalian liver is normally very low (<0.1% of
cells); with most hepatocytes being in the Go phase (Alison, 1986). (Figure 1.2
illustrates general cell division applicable to all cell types within the body). However,
entry of hepatocytes into the Gi phase, and the resultant growth of the liver may occur
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under deleterious conditions. There are two recognised forms of liver growth 
regenerative and augmentative growth.
Figure 1.2 Diagrammatic representation of the cell cycle
G2
G1
PREPARATION 
FOR MITOSIS 
(2-6h)
DNA
REPLICATION
(6-8h)
GO
QUIESCENCE
(variable)
COMMITMENT TO DNA 
REPLICATION
MITOSIS AND CELL 
DIVISION 
(Ih)
Gi: the interval between completion o f mitosis and onset o f DNA synthesis 
S: the period during which DNA is replicated 
G2: the period between completion of DNA synthesis and mitosis 
M: mitosis (4 stages from prophase to telephase)
Go: temporary quiescence
1.2.1 Regenerative liver growth
This may also be termed compensatory regeneration or compensatory hyperplasia and 
may be induced following any change that results in the reduction of the total 
fimctioning mass of the liver. Regeneration may be caused by liver cell necrosis 
resulting from chemical, nutritional, vascular or virus-induced injury (Fausto and 
Webber, 1993; Columbano and Shinozuka, 1996; Fausto, 2000). Therefore, any 
insult that results in loss of functional mass stimulates cells in G o to enter the cell 
cycle. Replication continues until hepatic function has returned to normal, and so the 
idea of an optimal hepatic functional mass has evolved (Fausto and Webber, 1993).
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What triggers, maintains and terminates liver regeneration, a process which has been 
widely studied in rodents following chemical injury or by the surgical process known 
as partial hepatectomy (PH), has been an area of substantial investigation. Because 
rat liver is composed of several lobes, it is possible to remove entire lobes through 
ligation of their vascular pedicles, the remaining lobes are left intact and without 
damage. The growth response triggered by the decrease in liver mass involves the 
proliferation of cells in the remaining lobes, not regrowth of the exised tissue (Fausto 
and Webber, 1993; Michalopoulos and DeFrances, 1997).
Following 70% PH in rats, normal liver mass is regained within 5-10 days 
(Michalopoulos, 1990; Michalopoulos and DeFrances, 1997) and repopulation of the 
liver is due mainly to the replication of hepatocytes. There is an initial surge of DNA 
synthesis in the hepatocytes commencing at 12-16 hours which peaks at 24 hours, 
with a smaller peak between 36 and 48 hours. This early hepatocyte mitotic activity 
leads to the formation of hepatocyte clusters without sinusoids (Martinez-Hemandez 
et ah, 1991). It is not until day 6 that sinusoids are seen vascularising the hepatocyte 
clusters. However, between 24 and 48 hours following PH, intense activity is seen in 
the sinusoidal endothelial cells (Grisham, 1962), (characterised by an elongated shape, 
irregular cytoplasm bulging into the lumen and thin fenestrated processes), in 
conjunction with a peak in DNA synthesis in all non-parencyhmal cells and biliary 
epithelial cells. Many endothelial cells develop cellular projections which extend into 
the sinusoidal lumen and inter-hepatocellular spaces, forming new lumens with other 
projections. The Kupffer cell population expands predominantly as a result of local 
proliferation following PH but renewal may also occur via recruitment from 
circulating monocytes (Bouwens et ah, 1984). Ultimately, the regenerative process 
maintains the original ratio of cells.
The above response is remarkable for several reasons: -
- It occurs predictably and reproducibly in an organ in which mitotic activity is 
normally minimal in the adult
- New hepatocytes arise by proliferation of existing ones, despite the fact that 
these are cells with a wide range of specialised functions
- The proliferative response subsides when the original mass of the organ is 
restored
(MacSween et ah, 1987)
12
1.2.1.1 Priming and progression
The process of regeneration consists of two main phases, namely priming - an initial 
phase in which cells become primed to proliferate - and progression -  a second phase 
in which competent hepatocytes progress through Gi and undergo replication.
The presence and activation of growth factors are the basic requirements for growth. 
However, it has been well established that, in vitro and in vivo, normal hepatocytes 
are largely unresponsive to growth factors and must undergo a competence process 
known as ‘priming’. Priming sensitises the cells to growth factors but is ineffective in 
their absence. (Michalopoulos, 1990; Fausto and Webber, 1993)
Priming is a reversible process initiated by cytokines as well as nutritional and 
hormonal signals, which may be released following changes to the liver such as 
partial hepatectomy (Fausto, 2000). Cytokines shown to increase following PH and 
which play critical roles in the onset of liver regeneration include interleukin-6 (IL-6), 
interleukin-1 (ILl) and tumour necrosis factor-a (TNF-a) (Cressman et a l, 1996; 
Higashitsuji et al, 1995, Satoh et a l, 1991, respectively). Cytokines cause the 
activation and DNA binding of transcription factors such as nuclear factor kappa-B 
(NF-kB), signal transducer and activator of transcription-3 (STAT-3), and activator 
protein-1 (AP-1) (Cressman et a l, 1994; Webber et a l, 1998). The activation of 
these transcription factors results in the induction of a variety of specific genes (see 
below) (Fausto and Webber, 1993).
PH results in an increased metabolic demand on remaining hepatocytes to maintain 
homeostasis which, in conjunction with the release of TNF-a, generates an excess in 
reactive oxygen species (ROS) in the mitochondria (Goosens et a l, 1995). ROS also 
contributes to the activation of NF-kB.
PH causes the activation of growth factors especially hepatocyte growth factor (HGF) 
and transforming growth factor-alpha (TGF-a) (Michalopoulos and Zamegar, 1992; 
Webber et a l, 1993). It has been suggested that once priming has occurred and the 
Gq/Gi transition has begun, cells are responsive to growth factors (Fausto, 2000). 
Specific growth factors are therefore able to relieve hepatocytes from a mid-Gi 
restriction point and enable the cells to progress to the Gi/S boundary. Extensive 
studies using isolated hepatocytes in primary culture have identified various growth 
stimulatory factors. These include hormones (insulin and noradrenaline), nutrients, 
peptide growth factors and cytokines (Mead and Fausto, 1989; Michalopoulos, 1990).
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Such stimulatory factors have come to be known as complete mitogens or incomplete 
comitogens, and once the Go/Gi transition of hepatocytes has occurred, the expression 
of such factors must be increased, in order for the cells to progress into S phase.
1.2.1.2 Growth factors
Many growth factors bind to specific cell surface receptors on their target cells and 
initiate the intracellular reactions necessary to stimulate cell division. Several of the 
growth factor receptors are known to be capable of catalysing the phosphorylation of 
tyrosine residues on cytoplasmic membranes (Burgess, 1985). The tyrosine kinase 
activity of the growth factor receptors is known to be dependent on the binding of the 
appropriate growth factor, and appears to be an integral part of their function in 
altering specific gene expression and stimulating cellular proliferation. For example, 
binding of EGF to the EGF-receptor activates its intrinsic tyrosine kinase activity and 
results in many cellular alterations, including the generation of signals that activate 
transcription and the tyrosine phosphorylation of cytoplasmic proteins (Ruff-Jamison 
e ta l, 1993).
There are various different classes of growth factors, examples of which are listed in 
Table 1.2 and described below.
Complete mitogens are substances that are able, by themselves, in chemically defined 
media and in the absence of serum, to stimulate hepatocyte DNA synthesis and 
mitosis in otherwise quiescent hepatocyte populations (Michalopoulos, 1990). It has 
already been described that most growth factors do this via interaction with specific 
transmembrane receptors which affect gene expression (Cross and Dexter, 1991; 
Fausto et al., 1995).
Incomplete comitogens are also known as ‘progression factors’ or ‘growth triggers’. 
These substances express the potential to shift the balance between stimulatory and 
inhibitory growth factors. They affect hepatocyte growth in a positive direction but in 
an indirect manner and they may possess the following properties: -
- Ability to enhance the mitogenic effect of growth stimulators
- Ability to decrease the inhibitory effect of growth inhibitors
- Absence of direct mitogenic effects of their own in serum-free cultures 
(Michalopoulos, 1990; Fausto et ah, 1995)
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The final class of factors that affect this cell cycle progression are growth inhibitors. 
These are vital in the termination of liver growth, once the liver has regained its 
original, required mass.
Table 1.2 Examples of classes of factors controlling liver growth
(Michalopoulos, 1990; Fausto et a l, 1995)
Complete
mitogens Comitogens Growth inhibitors
Epidermal growth factor (EGF) Noradrenaline Transforming growth factor-
Transforming growth factor- Vasopressin; Angiotensin II; beta (TGF-P)
alpha (TGF-a) Angiotensin III Interleukin IB (IL-IB)
Hepatopoietin AJ Hepatocyte Estrogens Activin
growth factor (HGF) Insulin and Glucagon Hepatocyte Proliferation
Acidic HGF (HBGF-1) Augmenter of Liver Regeneration Inhibitor
Hepatopoietin B (HPTB) (ALR)
Hepatic Stimulatory Substance Hepatic Stimulatory Substance
Heparin Binding-EGF (HB- (HSS)
EGF)
Keratinocyte Growth Factor
(KGF)
1.2.1.2.1 Growth factors and their sources in liver regeneration
Various studies have been performed in an attempt to define the source of factors 
responsible for the control of the liver regeneration process. It is well-established that 
the source of the mitogenic signals is carried in the bloodstream. Although the source 
of the initiator for regeneration is extra-hepatic, it has now been shown that the liver, 
activated by PH or other forms of injury, actually generates growth factors itself. 
Non-parenchymal cells of the liver appear to play a vital role being primarily 
responsible for the release of the various cytokines and growth factors involved. In
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particular, it is known that Kupffer cells are able to release both stimulatory and 
inhibitory factors for hepatocyte DNA synthesis and regeneration (section 1.1.2.5). 
Kupffer cell release of cytokines such as IL-6, IL-1, and TNFa are known to activate 
the AP-1 transcriptional activity in hepatocytes as their effector mechanism (Hattori et 
al, 1993). It has been demonstrated that suppression of Kupffer cell activity by 
gadolinium chloride pretreatment 24 hours before PH, results in complete suppression 
of constitutive IL-1 mRNA expressions in non-parenchymal cells of the normal rat 
liver (Higashitsuji et al, 1995).
Complete mitogens
HGF has been described to be the key growth factor in the initiation of hepatocyte 
proliferation, and the most potent mitogen for both rat and human hepatocytes in 
culture (Michalopoulos and Zamegar, 1992). In normal liver, Ito cells appear to be 
the principal source of HGF. However, during liver regeneration it appears that 
although Ito cells as well as Kupffer cells are known to release HGF, most is derived 
from endothelial cells (Maher, 1993). Levels of HGF mRNA have been shown to rise 
6-fold in endothelial cells, peaking at 6 hours and returning to normal at 24 hours 
(Maher, 1993). During this time, endothelial cells synthesise more HGF than either 
Ito or Kupffer cells whose expression of HGF is unchanged. This early induction of 
HGF in endothelial cells which precedes hepatocyte DNA synthesis indicates a key 
role for these cells in the initiation of hepatocyte proliferation. In plasma, HGF levels 
have been shown to increase up to 17-fold prior to hepatic DNA synthesis, indicating 
there may be endocrine as well as paracrine regulation by HGF (Lindroos et a l,
1991). HGF levels return to lower values within 24 hours. Interestingly, HGF as well 
as EGF have been shown to influence proliferation and migration of microvascular 
endothelial cells in culture (Morimoto et a l, 1991).
In addition to HGF release, Kupffer cells release TGFa either concomitantly or 
shortly afterwards (Mead and Fausto, 1989). In cultured hepatocytes, TGFa appears 
to be the major factor in Kupffer cell conditioned media that increases DNA 
synthesis. TGFa mRNA is increased up to 9-fold following PH, peaking 
concomittantly with DNA synthesis (Mead and Fausto, 1989). Regenerating 
hepatocytes have also been reported to produce TGFa (Webber et a l, 1993). It has 
been hypothesised that during regeneration, hepatocytes first become primed by
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metabolic signals, then move from Go to the Gi phase of the cell cycle and start 
producing autocrine factors such as TGFa which cause hepatocyte DNA synthesis 
(Mead and Fausto, 1989). These growth factors are produced at the time of DNA 
synthesis and not before, and it is thought that these factors may influence later waves 
of hepatocyte mitogenesis. The mechanism of regulation of endothelial cell growth 
and sinusoidal formation in regenerating liver is unknown, but it has been suggested 
that this TGFa release may be for the paracrine stimulation of DNA synthesis in 
endothelial cells.
Comitogens
Noradrenaline (NA) has demonstrated to be one of the strongest comitogens for 
hepatocytes in culture, amplifying the mitogenic effect of HGF and EGF on 
hepatocytes (Lindroos et a l, 1991). Plasma levels of NA following PH follows 
similar kinetics as the rise of HGF (Cruise et a l, 1987). Lindroos et a l, 1991, 
hypothesised that the simultaneous elevation of HGF and NA very soon after PH 
provides the mitotic stimulus leading to liver regeneration.
Insulin has also been described as an essential co-mitogen required in the process of 
liver regeneration. Insulin binding to its receptor activates many of the same signal 
transduction pathways triggered by growth factors such as EGF, TGFa and HGF, 
(Bucher and Swaffîeld, 1975).
Growth inhibitors
The release of various inhibitory factors for hepatocyte DNA synthesis, such as 
TGFp, may play a role in the control and termination of liver regeneration. Kupffer 
cells and hepatocytes appear to be the main source of TGFp in regeneration. TGFP 
secretion initally decreases in the early stages of regeneration, but later after injury 
(48-168 hours) Kupffer cells release large quantities of TGFpi which inhibits the 
proliferation of hepatocytes (Strain et a l, 1987; Braun et a l, 1988). What causes this 
switch in release is not yet known. TGFp has been shown to affect immediate-early 
proto-oncogene expression with a 50-60% decrease in c-myc mRNA expression 
(Coffey et a l, 1988), and has also shown to regulate the Gi cyclin dependent kinases 
(section 1.2.1.3).
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1.2.1.3 Gene expression in liver regeneration
It has been shown that components of the cytokine and growth factor pathways 
converge to control common sets of genes functioning within the pre-replicative phase 
of cell growth (Ruff-Jamison et a l, 1993). The pattern of altered expression may be 
divided into two phases -  the early gene response and the delayed gene response 
(Fausto and Webber, 1993; Alberts et a l, 1994).
(a) Early gene response
There are at least 70 early gene products that have been identified in the regenerating 
liver following PH (Haber et a l, 1993). These are induced within minutes of growth 
factor treatment, without requirement of new protein synthesis for increased 
expression (Haber, 1993; Fausto, 2000). The rapidity of this event suggests that any 
growth factor involved in this signalling pathway must be readily available in the 
hepatic tissue at the time of PH. De novo synthesis of a factor or its accumulation in 
the blood would be too slow to account for changes occurring for at least the first 15 
minutes after PH. The genes induced include cytoskeletal components, secreted 
factors, as well as transcriptional regulators, which indicates that the initial gene 
response after PH is greatly extended and amplified by the products of the early 
response genes (Fausto et a l, 1995).
Immediate early transcription factors include activator protein-1 (AP-1) family 
members, CCAAT/enhancer binding proteins (C/EBP factors), NF-kB, as well as 
Myc and its related proteins.
Protoncogene expression is thought to prime hepatocytes for subsequent proliferation 
(Mead and Fausto, 1989) with the protooncogenes c-fos, c-jun, junB and c-myc being 
some of the first shown to be induced rapidly following PH. Their expression, in 
terms of steady-state mRNA changes, has shown to be rapid (increasing within 15-30 
minutes following PH), sequential, and transient. (Corral et a l, 1985; Fausto and 
Webber, 1993; Goyette et al, 1983; Ikeda et al, 1989; Thompson et a l, 1986).
A P -1
In the quiescent liver, AP-I mRNA levels are typically undetectable, but following 
PH the different AP-1 family members have distinct temporal patterns of induction. 
AP-1 genes are associated with the Gq/Gi transition, are activated by growth 
promoting agents, and several are required for cellular proliferation. AP-1-containing
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transcriptional complexes in the first hours following PH are composed primarily of 
c-jun and c-fos proteins; but at later time-points a shift to complexes composed of 
Liver Regeneration Factor (LRF-1) and JunB is seen (Hsu et a l, 1991).
N F -kB
NF-kB is a ubiquitous transcription factor that is activated by a variety of cytokines 
and mitogens (Baldwin et a l, 1991). It has shown to be dramatically affected 
following PH, its transcriptional targets including the genes for various cytokines, 
acute-phase proteins, immunoglobulins and cell adhesion molecules (Fausto, 2000). 
CÆBPs
The C/EBP class of transcription factors, comprising of C/EBP a, P, and 5, are all 
differentially regulated following PH (Flodby et al, 1993; Greenbaum et a l, 1995). 
Greenbaum and co-workers hypothesised that C/EBP proteins would be expressed 
throughout the period of liver regeneration following PH (Greenbaum et a l, 1995). 
In male rats, it has been demonstrated that a  and p proteins were present throughout 
the 7 day period after PH, but the ratio of p to a  increased during the first 24 hours. 
In situ hybridisation and immunocytochemistry studies have demonstrated expression 
of both a  and p to be compatible with immediate early protein expression and 
progression of hepatocytes into S phase of the cell cycle (Greenbaum et a l, 1995). 
c-Myc
c-myc is a proto-oncogene involved in a wide range of neoplasias (Westwick and 
Brenner, 1998). c-myc mRNA levels are regulated at both transcription initiation and 
mRNA elongation. An increase in c-myc mRNA levels in the regenerating liver is 
one of the earliest responses to PH. c-myc mRNA levels then decrease with a second 
phase of increased mRNA levels starting within 6-12 hours after PH and persisting 
into the S phase (Goyette et a l, 1983).
Following this multiple early-gene activation, the priming process is complete. The 
cells are now competent. The transition of quiescent hepatocytes from G o to G i has 
occurred, but further stages are involved in providing the cells with the ability to 
progress further in the cell cycle (Fausto et a l, 1995; Loyer et a l, 1996).
As the cells are now in the G% phase of the cell cycle, they are now able to respond to 
growth factors, pass into the S phase and progress through the rest of the cell cycle. 
The delayed-response genes are involved in this progression.
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(b) Delayed gene response
By contrast to early response genes, delayed genes are not induced until at least one 
hour after growth factor treatment and their induction requires protein synthesis. It 
seems that these delayed response genes are induced by the products of the early 
response genes. They are mainly growth-related genes which include various cyclin- 
dependent kinases and their cyclins, and the anti-apoptotic gene bclx (Fausto et a l,
1995). The control of cell cycle progression is mediated by a family of cyclin 
proteins that regulate the activity of cyclin-dependent kinases (Sherr, 1994). 
Expression of cyclin D1 signals the point in Gi/S at which cells can progress into 
DNA replication independently of the growth process (Loyer et a l, 1996). Within the 
catagory of delayed response genes, not only cell cycle stimulators but also repressors 
have been identified, such as p53 and p21 (Fausto, 2000). It may be that the dual 
activation of stimulators and repressors contributes to liver regeneration being a 
precisely regulated growth process shown to terminate once the liver has regained its 
appropriate size (Fausto, 2000).
The multi-step process of liver regeneration is summarised in Figure 1.3.
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1.2.2 Chemically induced liver growth and hepatocarcinogenesis
Xenobiotics may affect liver growth by a number of mechanisms, including liver 
regeneration similar to that previously discussed, direct hyperplasia, hypertrophy and 
hepatocarcinogenesis. Several hundreds of chemicals representing many chemical 
classes have been shown to cause liver growth and ultimately hepatocarcinogenesis in 
experimental animals (Schulte-Hermaim, 1974; Alison, 1986). Typically, this 
hepatocarcinogenic action is not known to occur in humans, but as many of these 
compounds are widely used, it is an area of grave concern. By discovery of the 
precise mechanisms underlying the observed liver growth and cancer in experimental 
animals, it may be possible to determine whether similar molecular and cellular 
changes exist in human tumours, and so aid in the assessment of human cancer risk. 
Some examples of such compounds shall be discussed below.
1.2.2.1 Liver growth
As indicated, a few compounds are capable of stimulating liver growth in the form of 
regeneration similar to that observed following partial hepatectomy (section 1.2.1). 
These include carbon tetrachloride (CCI4) and D-galactosamine, both of which 
initially cause hepatic necrosis (Columbano and Shinozuka, 1996). Some similarities 
as well as some differences compared to liver regeneration following PH have been 
noted. Compared to the regeneration observed following PH, there is a slight delay in 
hepatocyte proliferation following either treatment (Toumier et a l, 1988). Similar 
changes in growth factor expression in rat liver as seen following PH, such as a rapid 
increase in HGF and TGFa mRNA, and a later increase in TGFp levels have been 
observed following single dose administration of these compounds (Noji et a l, 1990; 
Webber et a l, 1993). HGF levels rise very soon following CCI4 intoxication and 
remain elevated for 24-36 hours and DNA synthesis follows with a peak at 48 hours 
after intoxication (Lindroos et a l, 1991). Increased expression of the growth inhibitor 
TGFp appears to occur later and is more prolonged following D-galactosamine 
administration than that seen following PH (Nakatsukasa et a l, 1990). In addition to 
this, an increase in expression of the five proto-oncogenes, c-fos, c-myc, c-jun, JunB 
and jun-D, has been shown to occur within 30 minutes to 1 hour following CCI4 
administration to male rats, similar to that following PH (Schmiedeberg et a l, 1993). 
However, this was not seen with D-galactosamine, where a much later and more
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prolonged expression of these protooncogenes was noted -  c-fos and c-myc peaked 
24-48 hours after injury. In conjunction with this, the amount of DNA synthesis and 
the degree of hepatocyte mitosis after D-galactosamine injury is decreased relative to 
that following CCI4 administration, indicating that protooncogene expression may 
affect the extent, but not the timing of the subsequent hepatocyte proliferation 
(Schmiedeberg et al, 1993). Overall, the mechanism of this compound-induced liver 
growth does appear to be similar to that seen following PH.
However, most chemically induced liver growth is typically of an augmentative 
nature occurring without the need for cell loss. Such growth of the liver may exhibit 
itself as hyperplasia -  the increased production and growth of normal cells in the 
liver; and/or hypertrophy -  an increase in the size of the liver brought about by the 
enlargement of its cells rather than by cell multiplication (Alison, 1986).
Hypertrophy of cells may be due to a number of factors. These include an increase in 
number of cytoplasmic components, such as the endoplasmic reticulum, lysosomes or 
peroxisomes; as well as the deposition of various substances such as glycogen (Reddy 
and Lalwani, 1983; Hers, 1985; McMahon et a l, 1988).
Compounds capable of directly causing liver cell hyperplasia are known as primary 
mitogens. Examples of such compounds include lead nitrate, the peroxisome 
proliferators and cyproterone acetate. There is increasing evidence that hepatocyte 
proliferation induced by some primary mitogens is mediated by patterns of growth 
factor modulation and signal transduction different from those of compensatory 
regeneration (Columbano and Shinozuka, 1996). Activation of transcription factors 
such as NF-kB, and increased expression of immediate early genes such as c-fos, c- 
jun, and c-myc, are not observed during hyperplasia induced by certain primary 
mitogens, such as cyproterone acetate and BR931 (4-chloro-6-(2,3-xylidino)-2- 
pyrimidinylthio-(N-P-hydroxyethyl)acetamide) (Coni et a l, 1990; Ohmura et a l,
1996). The mechanisms involved in transition through the GI phase of the cell cycle 
may therefore be quite different. In addition, there is doubt on the involvement of 
growth factors such as HGF and TGF-a in direct mitogen-induced hepatocyte 
proliferation (Shinozuka et a l, 1994; Ohmura et a l, 1996).
It has been hypothesised that there are two mechanisms through which primary 
mitogens may act. One, involving the activation of nuclear hormone receptors, the 
other involving the cytokine TNF-a (Columbano and Shinozuka, 1996). Peroxisome
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proliferators are a well-studied example of primary mitogens acting through a nuclear 
receptor as their effects have been shown to be dependent on the nuclear receptor 
PPARa (section 1.2.2.3.2) with hepatomegaly not observed following peroxisome 
proliferator administration to PPARa knockout mice (Lee et a l, 1995). An example 
of a primary mitogen whose mechanism of action involves TNFa is lead nitrate, a 
single dose of which has been reported to induce a rapid increase in 77VF-a messenger 
RNA in rat liver at times that preceed DNA synthesis (Shinozuka et a l, 1994). In 
addition, inhibition of TNF-a transcription by dexamethasone is associated with the 
inhibition of mitogen-induced cell proliferation (Ledda-Columbano et a l, 1994). 
Columbano and Shinozuka have termed these mitogens ‘non-parenchymal cell- 
mediated hepatocyte mitogens’, indicating that they stimulate non-parenchymal cells 
to release TNF-a that subsequently induces DNA synthesis in hepatocytes 
(Columbano and Shinozuka, 1996).
The characteristics of mitogen-induced direct hyperplasia appear to depend on the 
type of mitogen involved. However, once a hepatocyte has committed to replication, 
progression through the cell cycle appears to be the same regardless of the original 
initiator. Usually, as soon as the mitogenic stimulus is withdrawn, liver mass and 
DNA content return to their original values, regressing through what appears to be the 
well-controlled process of apoptosis (Columbano and Shinozuka, 1996).
1.2.2.2 Hepatocarcinogenesis
Augmentative growth such as that described above may ultimately result in the 
development of hepatocarcinogenesis. Hepatocarcinogenesis may be induced by a 
number of different classes of compounds, but they typically fall into two main 
classes - namely the genotoxic (DNA-reactive) and the non-genotoxic (epigenetic) 
carcinogens (Purchase, 1994).
Carcinogenesis is a multi-stage process resulting in the emergence of an abnormal 
population of cells which is capable of excessive growth and possible metastasis. 
There are three main stages in the development of any cancer namely initiation, 
promotion and progression (Purchase, 1994). Initiation is a 2-step process in which 
some change is induced in a rare hepatocyte by an activated carcinogen, typically by 
an interaction with DNA (Cohen and Ellwein, 1991). This change generates a new 
constitutive phenotype if a round of cell proliferation occurs. Initiation is therefore
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dependent on the occurrence of cell proliferation. This may be triggered by the 
induction of cell death by the carcinogen. If cell proliferation does not occur or is 
delayed for several days, the initial interaction may be repaired. Following this 
neoplastic conversion of a cell, further development and proliferation is required for 
the formation of a tumour. This stage is known as promotion, and results in the 
formation of focal proliferations (hepatocyte nodules). The hepatocytes in the 
nodules have a special resistance phenotype that enables them to grow and expand in 
an environment that is inhibitory to cell proliferation of the hepatocytes surrounding 
the nodules. Progression involves the change of one or more of these hepatocyte 
nodules from benign to malignant neoplasia. The mutated cells rapidly proliferate, 
without restraint and are over-responsive/unresponsive to the usual factors involved in 
growth control. As neoplasias become more malignant they become more prone to 
show invasion and then métastasés. (Johannessen and Lapis, 1979). Changes in 
release/expression of various growth factors, cytokines and genes has been reported to 
play a pivotal role in the development of hepatocarcinogenesis (Purchase, 1994). 
Both overexpression of mitogens and inhibition/loss of function of growth suppressor 
genes are known to occur (Purchase, 1994). Increases in the expression and activation 
of various protooncogenes such as c-ras and c-myc have been reported to take place 
during rat liver carcinogenesis (Fausto and Shank, 1983). It appears that specific 
changes in expression of transcription factors during liver growth in vivo are 
dependent on the growth inducer (Fausto and Shank, 1983).
1.2.2.2.1 Genotoxic carcinogens
Genotoxic carcinogens induce neoplastic conversion of the cell by damaging DNA 
through direct chemical interaction, resulting in alterations of gene expression 
(Purchase, 1994). If this DNA damage is not repaired, or the cells affected do not 
undergo apoptosis, mutations may develop in the form of base deletions, substitutions 
or additions; as well as rearrangements and translocations of segments of DNA, 
including oncogenes (Cohen and Ellwein, 1991). Typically, the action of genotoxic 
carcinogens involves activation of oncogenes, such as ras, through mutations at 
specific loci in the gene. Loss of function of tumour suppressor genes, such as p5S, 
also plays a key role.
Most genotoxic carcinogens are pro-carcinogens and require enzymatic activation to
generate the reactive species that produces their carcinogenic effects. The enzymes
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responsible are numerous, but one family commonly involved comprises the 
cytochrome P450 enzymes which are abundant in the liver (Gonzalez, 1989). For a 
number of the liver carcinogens, sex-dependent differences in susceptibility exist 
which are largely due to hormonally-determined differences in activation (Schulte- 
Hermann, 1980a; Gonzalez, 1989; Kasper and Mueller, 1999).
1.2.2.2.2 Non-genotoxic carcinogens
Non-genotoxic carcinogens do not interact with DNA directly, but produce some 
other biological effect that underlies their carcinogenicity. For many the mechanism 
of action has yet to be elucidated. Those for which a mechanism is already known 
may be divided into three main classes (Purchase, 1994). The first class is known to 
cause an excessive secretion of trophic hormones controlling endocrine organs. An 
example of this is the production of excess thyroid stimulating hormone by a variety 
of agents such as sulphamethazine and urea, resulting in hyperplasia of the thyroid 
which if chronically maintained leads to adenoma and carcinoma formation. Another 
class act via activation of specific receptors that are involved in growth and 
differentiation. An example of a compound of this type is dioxin, which acts through 
the Ah receptor (Lucier et at., 1993). The final class is known to cause chronic cell 
injury which results in cell proliferation and hyperplasia. The action of certain 
chemicals which bind to a2-microglobulin causing male rat kidney cancer is a clear 
example of this latter class (Swenberg et al, 1989).
There is no general hypothesis that explains all examples of non-genotoxic cancer
induction. The most likely unifying hypothesis is that such chemicals induce
mitogenesis allowing the fixing of DNA damage produced by oxygen free radicals
and other non-direct (epigenetic) mutagenic events (Purchase, 1994). One proposed
mechanism for non-genotoxic carcinogenesis is that such compounds increase cell
proliferation in conjunction with suppression of apoptosis. Apoptosis is the normal
mechanism by which physiologically unwanted cells are removed (Bursch et a l,
1992). Apoptosis has been shown to occur at different stages of carcinogenesis, in an
attempt to remove initiated cells, control growth at the promotion stage, and it even
occurs in malignant tumours (Bursch et a l, 1992). It also appears to be important in
regression of some tumours (Bursch et a l, 1992). Dysregulation of apoptosis may
result in the decreased ability of cells to undergo apoptosis and provide a selective
survival advantage for those cells, thus leading to altered growth, cellular
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transformation and tumour progression. Non-genotoxic carcinogens may initiate 
cellular processes leading to the production of reactive species such as activated 
oxygen or hydrogen peroxide which could in turn produce such genotoxicity (Reddy 
and Lalwani, 1983; Rao and Reddy, 1987). Non-genotoxic carcinogens may be 
capable of suppressing hepatocyte apoptosis that would normally act to remove such 
DNA-damaged, potentially initiated cells from the liver. Importantly, an enhanced 
rate of cell replication can increase the frequency of spontaneous mutations as well as 
the probability of converting DNA adducts from both endogenous and exogenous 
sources into mutations before they can be repaired (Grasl-Kraupp et a l, 1991; Lake, 
1995b). This clearly may aid and quicken the development of non-genotoxic 
hepatocarcinogenesis (Bayly et a l, 1994).
Although some possible contributory factors have been identified, often the precise 
molecular mechanisms involved in the development of hepatocarcinogenesis by non- 
genotoxic carcinogens is largely unknown, the peroxisome proliferators being a prime 
example of this (Reddy et a l, 1979; 1980).
As previously discussed, exposure of rodents (rats and mice) to various classes of 
xenobiotic compounds results in liver enlargement (Schulte-Hermann, 1974). 
Although an area of substantial research, precise mechanisms of action of growth 
caused by many of these compounds still remain unclear. My project is concerned 
with four such compounds -  namely Wy-14,643, cyproterone acetate, phénobarbital 
and dexamethasone, which will now be discussed in some detail.
1.2.2.3 Wy-14,643
Wy-14,643 is a classic example of a potent peroxisome proliferator (Rao and Reddy, 
1987). The term ‘peroxisome proliferator’ was introduced to designate a drug or 
xenobiotic that induces proliferation of peroxisomes in liver cells, and encompasses a 
wide range of compounds (Lake, 1995a) (see Table 1.3).
Many of the peroxisome proliferators are hypolipidemic drugs and such drugs have 
been shown to lower triglycerides and cholesterol concentrations in the plasma, 
proving to be beneficial in the prevention of ischaemic heart disease in people with 
elevated levels of cholesterol (Havel and Kane, 1973).
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Table 1.3 Classes of peroxisome proliferators
CHEMICAL CLASS EXAMPLES
Therapeutic agents Acetylsalicylic acid, benzaflbrate, bifonazole, ciprofibrate, 
clobuzarit, clofibrate, fenofrbrate, methylclofenapate, 
LY171883, nafenopin, tiadenol, Wy-14,643
Steroids Dehydroepiandrosterone
Herbicides 2,4-Dichlorophenoxyacetic acid, formesafen, lactofen, 2,4,5- 
trichlorophenoxyacetic acid
Plasticisers DEHA, DEHP, di-(2-ethylhexyl)terephthalate, di- 
(isodecyl)pthalate, di-(isononyl)phthalate, tri-(2- 
ethylhexyl)trimellitate
Solvents and 
industrial chemicals
Chlorinated paraffins, perchloroethylene perfluoro-M-octanoic 
acid, trichloroethylene
Food flavours and 
natural products
Cinnamyl anthranilate, citral, linalool
(Taken from Lake, 1995a)
1.2.2.3.1 Effects on the liver
Exposure of mice and rats to peroxisome proliferators results in a variety of 
biochemical and physiological changes, some or all of which are presumably 
responsible for the hepatomegalic and carcinogenic effects. These are listed below, 
all of which have been observed in in vitro and in vivo rat liver studies dependent on 
both the potency of the peroxisome proliferator and extent of exposure.
- Increase in the number and size of peroxisomes (Lalwani et a l, 1981; Rao and 
Reddy, 1987)
- Hepatomegaly, (hypertrophy -  characterised by proliferation of peroxisomes 
and smooth endoplasmic reticulum, and hyperplasia (Reddy et a l, 1979; 
Reddy and Lalwani, 1983; Rao et a l, 1984))
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Increased hepatocyte DNA synthesis and cell proliferation (Reddy et a l, 1979; 
Marsman et a l, 1988)
Suppression of apoptosis (Roberts et al 1995)
Increased numbers of smooth endoplasmic reticulum and mitochondria 
(Reddy and Lalwani, 1983)
Selective induction of peroxisomal enzymes (Reddy and Lalwani, 1983) 
Increase in microsomal fatty acid m-hydroxylase activity (Lake 1995a) 
Hepatocarcinogenesis (Reddy et a l, 1980)
A number of studies have been conducted on patients treated with hypolipidaemic 
agents for several months to several years, in an attempt to elucidate the effect of 
peroxisome proliferators in humans. In general, studies have failed to provide clear 
evidence of peroxisome proliferation (De La Iglesia, 1981; Blumcke et a l, 1983). 
Studies involving human hepatocytes in culture have also been carried out. For 
example, Blaauboer and co-workers monitored the effects of beclobric acid and 
clofibric acid on peroxisomal p-oxidation and peroxisome proliferation in primary 
cultures of hepatocytes derived from rat, monkey and human, and reported that rat 
hepatocytes responded to the compounds whereas monkey and human hepatocytes did 
not (Blaauboer et al, 1990). Similarly, Parzefall and colleagues demonstrated that 
human hepatocytes cultured in vitro do not increase in number following treatment 
with the peroxisome proliferator nafenopin, which clearly contrasts from findings 
with rat hepatocytes in culture (Parzefall et al, 1991). This notable species difference 
is thought to be due to variations in human PPARa (see 1.2.2.3.2 (d)) as compared to 
rat, including differences in sequence, expression, as well as susceptibility to 
peroxisome proliferator activation (Sher et a l, 1993; Mukherjee et a l, 1994; 
Tugwood et a l, 1996; Palmer et a l, 1998).
However, the knowledge that peroxisome proliferators are capable of causing 
hepatocarcinogenesis in rats and mice combined with the fact that this class of 
compounds is widely used (Table 1.3), has been an area of concern in terms of human 
exposure and risk assessment.
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1.2.2.3.2 Mechanisms of hepatomegaly and hepatocarcinogenic action
Hepatomegaly due to both hypertrophy and hyperplasia has been well-documented in 
rats and mice following treatment with peroxisome proliferators (Reddy et a l, 1979; 
Reddy and Lalwani, 1983; Rao et a l, 1984). Hypertrophy of hepatocytes occurs as a 
result of the ability of peroxisome proliferators to rapidly induce the proliferation of 
both peroxisomes (Lalwani et al, 1981; Rao and Reddy, 1987) and smooth 
endoplasmic reticulum (Reddy and Lalwani, 1983). In conjunction with this, 
proliferation of hepatocytes has been shown to be induced 12 hours following a single 
dose of Wy-14,643 peaking at 24 to 36 hours (Ohmura et a l, 1996). Peroxisome 
proliferators are also known to be non-genotoxic carcinogens, and the development of 
hepatocellular carcinomas in response to feeding of rats with a peroxisome 
proliferator was first reported in the 1970s (Reddy et a l, 1976). Rao and co-workers 
demonstrated that during Wy-14,643-induced hepatocarcinogenesis in rats, altered 
hepatocyte foci appear by 22 weeks and neoplastic liver nodules between 26 and 50 
weeks, subsequently followed by the emergence of hepatocellular carcinomas (Rao et 
al, 1984). More recently, Marsman and Popp demonstrated that Wy-14,643, fed to 
male rats at 0.1% in the diet, was highly hepatocarcinogenic, inducing in male rats a 
95% incidence of hepatocellular adenomas and a 38% incidence of hepatocellular 
carcinomas by 52 weeks (Marsman and Popp, 1994).
To date, numerous studies have been performed in an attempt to identify a mechanism 
of action underlying peroxisome proliferator effects, and various potential pathways 
have been outlined. Factors that may contribute to, or be responsible for, the 
development of hepatomegaly resulting in hepatocarcinogenesis are discussed below:-
(a) Increased cell proliferation
It has clearly been demonstrated that peroxisome proliferator-induced liver
enlargement in rodents involves both hepatocyte hypertrophy and hyperplasia (Reddy
and Lalwani, 1983; Lock et a l, 1989). Peroxisome proliferators produce a
pronounced mitogenic effect during the first several days of administration (Reddy et
al, 1979; Marsman et al, 1988; Eacho et a l, 1991; Wada et al, 1992), which may be
sufficient to allow replication of spontaneous mutations. It is possible that oxidative-
stress induced damage (see below (e)) may cause the transformation of hepatocytes
(Reddy et al, 1982; Reddy and Lalwani, 1983), as would a spontaneous mutation and
without apoptosis (see below (b)), such initiated cells could then be promoted into
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liver tumours by enhanced cell replication. Wy-14,643, like other peroxisome 
proliferators, not only causes an initial pronounced mitogenic effect which peaks 24 
hours following a single dose (Ohmura et a l, 1996), but in contrast with other 
compounds of its class, is able to sustain a smaller, yet persistant increase in cell 
replication up to 365 days of administration (Marsman et al, 1988; Eacho et a l, 
1991). This sustained mitogenic effect may account for the high potency of Wy- 
14,643 as a carcinogen, as prolonged cell replication would further increase the 
likelihood of the replication and fixation of spontaneous mutations, and additionally 
may be important in the promotion and progression phases of cancer development. 
Indeed, Lake and co-workers, reported a more rapid production of liver tumours in 
rats by peroxisome proliferators that produce a sustained stimulation of cell 
replication (Wy-14,643), compared to those that do not (nafenopin) (Lake et al
1993). Marsman and Popp have proposed a two-stage cancer model for Wy-14,643 in 
which it is thought that two critical events: mutation 1 (Ml) and mutation 2 (M2), 
must occur for Wy-14,643 to induce hepatocarcinogenesis (Marsmann and Popp,
1994). Peroxisome proliferation or enhanced cell replication, may indirectly or 
directly enhance the likelihood of Ml occurring. Despite phenotypic differences, no 
biological distinction exists between Wy-14,643-induced homogeneous basophilic 
foci and hepatic adenomas. The sustained presence of Wy-14,643 would continue 
this chronic cell proliferation (promotion) and so similarly increase the likelihood of 
M2 occurring, whereas removal of Wy-14,643 would diminish the size of the cellular 
population and decrease the likelihood of M2 occurring. Removal of the mitogenic 
stimulus (Wy-14,643) is known to result in regression and the liver returns to its 
normal size, due to an elevation of apoptosis (Roberts et al, 1995; Plant et a l, 1998).
(b) Suppression of apoptosis
Many studies have demonstrated apoptosis suppression by peroxisome proliferators.
Roberts and co-workers showed that nafenopin suppressed the basal level of rat liver
apoptosis in vivo', and withdrawal of this peroxisome proliferator resulted in a 100- to
200- fold elevation in apoptosis that was inhibited by the re-administration of the
compound (Roberts et a l, 1995). This suppression of apoptosis may contribute to the
hepatocarcinogenic effect of Wy-14,643, in that it may mean that damaged or altered
DNA is not efficiently removed. Apoptosis was also demonstrated to be suppressed
in a dose-dependent manner in a rat hepatocyte cell culture system using
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methylclofenopate (MCP) (Plant et a l, 1998). Again, the suppression of apoptosis by 
the peroxisome proliferator was reversible and withdrawal of MCP led to rapid 
induction of apoptosis. It appears that the majority of the hepatocytes generated 
during peroxisome proliferator-induced hyperplasia were protected from apoptosis 
during liver regression, apoptosis essentially occurring in ‘old’ hepatocytes (Roberts 
e ta l, 1995).
Much attention has recently been given to the identification of molecular targets that 
are involved in the regulation of apoptosis and that are altered in tumours. 
Components thought to be involved include: -
bcl-2 and BAG-1 -  anti-apoptotic proteins, levels of which have been demonstrated 
to increase following acute (1-30 days) treatment of mice with Wy-14,643 
(Christensen et al, 1999). Such proteins may therefore be involved in the observed 
apoptosis suppression.
TGF-Pi - it is possible that actions on TGF-Pi and one of its receptors, the mannose- 
6-phosphate / insulin-like growth factor II receptor (M6P/IGFII) may be responsible 
for the suppression of apoptosis seen following treatment with peroxisome 
proliferators (Jirtle et al, 1994). TGF-pi is an inhibitor of replication of hepatocytes 
in vitro and in vivo, and it also induces apoptosis in rat hepatocytes in vitro and in vivo 
(Bursch et al, 1992; Bayly et a l, 1994). Acute administration of various peroxisome 
proliferators to rats have all been shown to increase TGF-Pi mRNA and M6P/IGFII 
receptor levels (Rumsby et a l, 1994), which is thought to be an attempt to limit the 
hyperplastic response of these compounds. However, the growth inhibitory effect of 
TGF-pi in rat liver epithelial cells appears to be lost on malignant transformation 
(McMahon et al, 1986; Jirtle et a l, 1994). It has therefore been postulated that the 
decrease in apoptosis may be due to the loss of growth inhibitoiy effect of TGF-Pi.
PPARa (see below (d)) - PPARa itself may contribute to this suppression of 
apoptosis. Isolation of a ‘dominant negative’ form of human PPARa from a human 
liver sample and introduction of this into primary rat liver cell cultures; demonstrated 
that the suppression of hepatocyte apoptosis by peroxisome proliferators is mediated
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by activation of one or several isoforms of PPAR (Roberts et al, 1998). PPARa is 
likely to play the predominant role in this regulation.
TNFa - Rolfe and co-workers hypothesized that TNFa may mediate at least some of 
the effects of peroxisome proliferators (Rolfe et a l, 1997). They went on to 
demonstrate that the effects of the peroxisome proliferator, nafenopin, on hepatocyte 
apoptosis may be attenuated by neutralising anti-TNFa antibodies.
(c) Tumour promotion
It has been demonstrated that peroxisome proliferators are efficient promotors of 
certain genotoxic carcinogen-induced lesions such as those induced by aflatoxin B1 or 
diethylnitrosamine in rats (Grasl-Kraupp et al, 1990, 1991; Cattley et al, 1994). The 
incidence of tumour production by nafenopin was shown to be much higher in livers 
of aged as compared to young rats (Grasl-Kraupp et a l, 1991). The latter observation 
may be explained by the promotion of preneoplastic foci occurring spontaneously in 
livers of the rats during ageing.
It has been suggested that the ability for peroxisome proliferators to cause promotion 
depends on the nature of the initiating carcinogen. Cattley and co-workers 
administered Wy-14,643 and clofibrate to rats following initiation as achieved by 
either 2-acetyl-aminofluorene (2-AAF), or diethylnitrosamine (DEN) (Cattley et a l,
1994). No effect was seen following 2-AAF initiation, but following DEN initiation, 
both Wy-14,643 and clofibrate exhibited promoting activity (Cattley et al, 1994). It 
therefore appears that some fundamental aspect of 2-AAF initiation differs from 
initiation by DEN. 2-AAF, unlike DEN, has been associated with substantial 
inhibitory effects on hepatocyte replication and marked proliferation of oval and 
biliary epithelial cells, which may contribute to the reported differences in promoting 
activity (Cattley et al, 1994).
(d) Peroxisome Proliferator Activated Receptor Alpha (PPARa)-mediated effects
Peroxisome proliferators are known to interact with a nuclear receptor to increase 
transcription of peroxisome specific messenger RNAs and the first peroxisome 
proliferator activated receptor (PPAR) was cloned by Isseman and Green in mice 
(Isseman and Green, 1990). Subsequently it has been shown that PFARs are a small
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family of genes with reports of at least a, P (also known as Ô) and y isoforms in rats 
and mice (Lake et al, 1995b; Kliewer et al, 1994). Kliewer and co-workers 
demonstrated that tissues in mice which were most responsive to Wy-14,643 
expressed high amounts of PPARaPAAK and relatively low amounts of PPAR-ysnà - 
6 (Kliewer et a l, 1994). This, in conjunction with the demonstration that disruption 
of the ligand-binding domain of the a  isoform of mouse PPAR (mPPARa) following 
exposure to the classical peroxisome proliferators clofibrate and Wy-14,643, resulted 
in no classic peroxisome proliferator-mediated effects (hepatomegaly, peroxisome 
proliferation, and transcriptional activation of target genes) (Lee et a l, 1995), has lead 
to the deduction that the a-isoform of PPAR is required for the actions of peroxisome 
proliferators.
The mechanisms following receptor activation have been analysed and it has been 
discovered that following receptor activation by a peroxisome proliferator, the PPAR 
undergoes heterodimerisation with the retinoid X receptor (RXRa) (Green et al, 
1993). Following this heterodimerisation, PPAR-RXR interacts with DNA sequence 
elements known as peroxisome proliferator response elements (PPREs) within the 
regulatory regions of responsive genes (Isseman and Green, 1990; Kliewer et a l, 
1992; Marcus et a l, 1993, Waxman, 1999). PPREs are situated upstream of several 
genes and are constituted by two copies of the core motif, AGGTCA, separated by a 
single nucleotide, named DRl (Isseman and Green, 1990; Tugwood et a l, 1996; 
Columbano and Shinozuka, 1996). PPREs have been shown to exist within many 
genes encoding microsomal and fatty acid metabolising enzymes (Lake, 1995a), 
including those involved in the peroxisomal p-oxidation pathway such as 3-ketoacyl- 
CoA thiolase and acyl CoA oxidase (Kliewer et a l, 1992). The PPAR-RXR complex 
can be activated by peroxisome proliferators and/or 9-cis retinoic acid, which 
indicates that the retinoid and fatty acid signalling pathways converge in modulating 
lipid metabolism (Kliewer et al, 1992).
A classic example of a gene containing a PPRE, and standard marker for peroxisome 
proliferators is cytochrome P4504A1 (CYP4A1), mRNA levels of which have been 
shown to be induced up to 15-fold in rat liver following peroxisome proliferator 
administration (Bell et a l, 1991). Induction of CYP4A1 has been indicated in a 
potential mechanism of hepatocarcinogenic action of peroxisome proliferators, (Lake, 
1995b) (see below (e)).
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PPREs have also been shown to be present within the promotors of genes not 
primarily involved in the oxidation of fatty acids, indicating that peroxisome 
proliferator exposure could result in the interaction with many different pathways. 
The first gene of this type was that encoding the ‘malic’ enzyme, which is a lipogenic 
enzyme localised in the cytosol (Castelein et a l, 1994).
As discussed, most responses induced by peroxisome proliferators in rodent liver are 
dependent on PPARa (Lee et a l, 1995). Of great interest is how this PPARa 
activation ultimately leads to hepatocarcinogenesis. It is possible that the regulation 
of levels of specific genes may be altered that may contribute to the development of 
liver cancer. PPARa may mediate effects that may contribute to 
hepatocarcinogenesis such as ‘oxidative stress’ (see below (e)) -  due to increases in 
hepatic expression of acyl CoA oxidase; or alterations in hepatocellular 
replication/apoptosis (see above (a&b)). In support of this, Wy-14,643 has recently 
shown to cause discordant expression of a number of cell cycle regulatory/control 
proteins, these effects being dependent on PPARa (Peters et a l, 1998).
(e) Oxidative stress
One well-studied hypothesis regarding a mechanism of peroxisome proliferator- 
induced hepatomegaly and hepatocarcinogenicity involves observation of the 
presence of oxidative stress, with there being at least two possible sources of oxidants 
following administration of peroxisome proliferators. To date, two major oxidative 
stress-related hypotheses have been described, namely the hepatocyte hypothesis and 
the Kupffer cell hypothesis: -
The hepatocyte hypothesis
The first is based on the observation that chronic administration of peroxisome 
proliferators results in an imbalance in the production and degradation of hydrogen 
peroxide (H2O2) in rodent hepatocytes (Reddy and Lalwani, 1983; Rao and Reddy, 
1987). As discussed, peroxisome proliferators induce the enzymes of the peroxisomal 
fatty acid p-oxidation cycle (Reddy and Lalwani, 1983; Lock et a l, 1989), the first 
enzyme of which is acyl CoA oxidase (ACoX). ACoX may be increased by over one 
order of magnitude in rodent liver following treatment with peroxisome proliferators 
(Marsman et a l, 1988; Nemali et a l, 1988, 1989). This enzyme produces H2O2, a
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known genotoxic carcinogen (Reddy and Lalwani, 1983), and it has been proposed 
that an excess of H2O2 then diffuses out of the peroxisome and reacts with biological 
macromolecules such as DNA either directly or indirectly by generating several 
unstable oxygen species, such as the superoxide anion and the hydroxyl radical (Lake, 
1995a). Another possible source of reactive oxygen species is the CYP4A-dependent 
metabolism of fatty acids (Lake, 1995b). DNA damage may lead to altered gene 
expression which could result in tumour initiation (Figure 1.4).
Under normal circumstances, the cell is reasonably protected against active oxygen 
species due to the presence of both catalase and glutathione peroxidase (Gibson, 
1989). However, peroxisome proliferators do not readily induce catalase (catalase 
levels are never increased more than 2-fold (Conway et a l, 1989; Nemali et a l, 
1989)); and in addition, selenium-dependent glutathione peroxidase activity is 
approximately halved after treatment with hypolipidemic drugs such as clofibrate, 
DEHP, and Wy-14,643 (Cirioli et a l, 1982; Conway et al, 1989).
A number of studies have provided further supporting evidence regarding this 
hypothesis: -
(i) Peroxisome proliferators such as ciprofibrate have been shown to generate 8- 
hydroxy-deoxyguanosine (8-OH-dG), an adduct that results from damage of DNA 
caused by a hydroxyl radical attacking guanine residues in liver DNA (Kasai et al, 
1989; Kim, 1998).
(ii) A number of studies recorded excessive accumulation of lipofuscin in rat liver 
following exposure to a variety of peroxisome proliferators (Lalwani et a l, 1981; 
Reddy et a l, 1982; Conway et a l, 1989), indicative of an increase in lipid 
peroxidation and the presence o f ‘oxidative stress’ (Rao and Reddy, 1987).
(iii) H2O2 is a potent activator of the transcription factor nuclear factor kappa-B (NF- 
kB) (Schreck et a l, 1991), and Li and co-workers provided evidence indicating that 
rats fed diets containing the peroxisome proliferator ciprofibrate exhibited increased 
hepatic NF-kB DNA-binding activity (Li et al, 1996). As NF-kB is involved in the 
regulation of various genes (Fausto and Webber, 1993), it may contribute to changes 
in the transcription of genes following peroxisome proliferator treatment -  for 
example, the immediate early genes such as c-myc and c-jun may be activated in 
response to NF-kB activation (Fausto and Webber, 1993; Ruff-Jamison et a l, 1993).
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However, conflicting evidence has also accumulated: -
(i) In studies measuring 8-OH-dG levels (Kasai et a l, 1989 and Tagaki et a l, 1993), 
background levels of 8-OH-dG were found to be high, which made interpretation of 
results difficult and in addition, increases in 8-OH-dG adducts did not always 
correlate well with the potency of the drug administered. (Kasai et a l, 1989; Tagaki 
et a l, 1993)
(ii) Additionally Kasai and co-workers did not distinguish precisely where in the cell 
DNA damage occurred following long-term administration of ciprofibrate to rats 
(Kasai et a l, 1989). Richter and colleagues studied this damage in livers isolated 
from rats to find that production of excited oxygen species by radiation resulted in 
8-OH-dG being present at a level of 1 per 130,000 bases in nuclear DNA (nDNA), but 
at a much more frequent 1 per 8000 bases in mitochondrial DNA (mtDNA) (Richter 
et a l, 1988). It was suggested that this high level of 8-OH-dG in mtDNA may be 
caused by the immense oxygen metabolism, relatively inefficient DNA repair, and the 
absence of histones in mitochondria (Richter et a l, 1988). It was therefore concluded 
that although the incidence of oxidative damage to nDNA is relatively high, damage 
to mtDNA is much more likely to take place without affecting the magnitude of 
carcinogenic risk.
(iii) Disputes relating to the magnitude and therefore relevance of the increase in H2O2 
following peroxisome proliferator treatment have been presented. It has been 
demonstrated that administration of the hypolipidaemic agent benzafibrate to isolated 
perfused rat liver with added fatty acids, lead to only slightly increased yields of H2O2 
for most of the acids tested, and with oleate the yield was decreased to half the 
original (Foerster et a l, 1981). In addition Handler and Thurman found that treatment 
of rats with ciprofibrate increased hepatic activity of acyl-CoA oxidase by 400%, but 
did not increase fatty-acid-stimulated H2O2 generation (Handler and Thurman, 1988).
(iv) F2 -Isoprostanes are produced in vivo by free radical catalysed peroxidation of 
arachidonic acid, via a cyclooxygenase-independent reaction, and have been proposed 
as a valuable sensitive tool to assess oxidative stress in vivo (Morrow et a l, 1992; 
Morrow and Roberts, 1996). It has been demonstrated that in livers of mice, 
Wy-14,643 caused a 16-fold increase in hepatic peroxisomal p-oxidation and only a 
2-fold increase in catalase activity within 7 days (Soliman et a l, 1997). This 
remarkable imbalance between H2O2 production (peroxisomal P-oxidation) and its
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destruction (catalase) would be expected to lead to accumulation of H2O2 which has 
been shown to cause a rapid and substantial increase in levels of F2 -isoprostanes. 
However, hepatic concentrations of esterified F2 -isoprostanes were unaltered in those 
animals (Soliman et a l, 1997).
Due to the conflicting studies relating to the hepatocyte oxidative stress hypothesis, it 
may be concluded that the production of reactive oxygen species within hepatocytes 
may not be a sole cause for the development of peroxisome proliferator-induced 
hepatocarcinogenesis, but may instead contribute to the overall effect.
Figure 1.4 The hepatocyte oxidative stress cycle (Adapted from Lake, 1995b)
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Figure 1.4 Chronic peroxisome proliferator treatment results in an imbalance in the 
production and degradation of peroxisomal hydrogen peroxide, which, possibly in 
conjunction with CYP4A-mediated generation of other reactive oxygen species, results in 
DNA damage, ultimately leading to hepatocarcinogenesis.
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The Kupffer cell hypothesis
The second hypothesis is based on the observation that peroxisome proliferators 
stimulate the activation of NADPH oxidase in Kupffer cells (Figure 1.5). Kupffer 
cells are the resident hepatic macrophages, and are a rich source of mitogenic 
cytokines in the liver (Decker, 1990) (section 1.1.2.5). Kupffer cells were recently 
demonstrated to be causally responsible for Wy-14,643-induced increases in cell 
proliferation (Rose et a l, 1997a), and so great interest has arisen in determining a 
possible mechanism of action, as described below. This hypothesis suggests that 
Kupffer cell oxidant production is responsible for the observed increase in hepatocyte 
replication following treatment of rats with peroxisome proliferators. Indeed, it has 
been demonstrated that peroxisome proliferators are unable to increase DNA 
synthesis in isolated hepatocytes; but when incubated with conditioned medium from 
Kupffer cells incubated with Wy-14,643, DNA synthesis was increased (Parzefall et 
al, 2001).
Wy-14,643, by mechanisms that remain unknown, has been shown to activate protein 
kinase C (PKC) and in Kupffer cells, PKC has been shown to phosphorylate specific 
subunits of NADPH oxidase leading to its activation and the resultant production of 
superoxide (Dieter et a l, 1986; Mayer and Spitzer, 1994). It is thought that this 
superoxide production causes activation of NF-kB within Kupffer cells which results 
in increased TNFa production. Various studies have been performed which have 
demonstrated that TNFa plays a role in hepatocellular proliferation and liver mass 
homeostasis (Akerman et a l, 1992; Rolfe et a l, 1997), and it is thought that TNFa 
mediates the mitogenic response to peroxisome proliferators (Bojes et a l, 1997), with 
peroxisome proliferator-activated Kupffer cells being responsible for the synthesis 
and secretion of TNFa which stimulates neighbouring hepatocytes to proliferate. 
Rose and co-workers demonstrated that peroxisome proliferators can activate Kupffer 
cells in vivo and in vitro (Rose et a l, 1999a). TNFa mRNA has been observed to be 
increased 2-2.5-fold by Wy-14,643 treatment in rats (Bojes et al, 1997; Rose et a l, 
1997b). In addition to this, antibodies to TNF-a have been shown to prevent 
increased cell replication (Bojes et a l, 1997). It is thought that this TNFa then 
activates NF-kB in hepatocytes, which is known to increase hepatocyte proliferation 
(Cressman et al, 1994; Fausto et a l, 1995).
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However, a more recent study has indicated that TNFa is not required for Wy-14,643 
induced cell proliferation (Lawrence et a l, 2001). Induction of peroxisome and 
hepatocyte proliferation was compared in wild-type and TNFa knockout mice. 
Treatment with Wy-14,643 resulted in similar effects in both strains of mice. These 
included an increase in liver:brain ratios, an approximate 8-fold increase of fatty acyl- 
coA oxidase activity and 5-fold increase in mRNA content, an increased number of 
peroxisomes, as well as a 15-fold increase in hepatic cell proliferation. It was 
suggested that the contradictory data may be a result of the absence of TNFa during 
in utero and neonatal development in the knockout mice which lead to the 
development of compensatory pathways. It is therefore hypothesised that TNFa may 
not be solely responsible for the stimulation of hepatocyte DNA synthesis and cell 
proliferation, and a number of Kupffer cell-released cytokines may be involved. 
However, PPARa has also been shown to be required for the mediation of the 
increased hepatocyte proliferation and hepatomegaly (see above (d)) (Kliewer et a l, 
1994; Lee et a l, 1995). Indeed, an increase in DNA synthesis did not occur in 
PPARa knockout mice (Peters et a l, 1997). However, PPARa is not present in 
Kupffer cells and is restricted to hepatic parenchymal cells (Peters et a l, 2000). This 
indicates that Kupffer cells, whilst being required for stimulation of hepatocyte 
proliferation, are not solely responsible for the observed peroxisome proliferator 
effects.
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Figure 1.5 The Kupffer cell oxidative stress cycle
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Figure 1.5 Kupffer cell activation following treatment with Wy-14,643 results in the production of 
protein kinase C (PKC) which activates NADPH oxidase causing the release of superoxide (Oi*)- 
Superoxide activates NF-kB within Kupffer cells which results in increased TNFa production. This 
TNFa then activates NF-kB in hepatocytes, which is known to increase hepatocyte proliferation.
Summary
It appears that a number of peroxisome proliferator-mediated actions on rat liver may
act in conjunction with one another to result in the observed hepatomegaly and
hepatocarcinogenesis. Wy-14,643, being a non-genotoxic carcinogen, has been
demonstrated to induce hepatocyte DNA synthesis and cell proliferation and suppress
apoptosis in rats, which clearly would contribute to an increase in liver size. Both
parenchymal cell PPARa and Kupffer cell-released mitogenic cytokines have been
shown to be required for maximal peroxisome proliferator-stimulated DNA synthesis
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and cell proliferation. In conjunction with this, hypertrophy resulting from the 
proliferation of peroxisomes and smooth endoplasmic reticulum also contributes to 
the growth of the liver. It is hypothesised that the initiation of liver growth and the 
development of hepatocarcinogenesis is due to the release of mitogenic cytokines 
from activated Kupffer cells which, in conjunction with PPARa-mediated effects, 
results in an increased rate of hepatocyte cell proliferation and suppression of 
apoptosis. This may result in the replication of transformed hepatocytes ultimately 
leading to hepatocarcinogenesis. The transformed hepatocytes may be a result of 
spontaneous mutations that are enhanced by the excessive increased replication rate, 
or may be due to oxidative stress-induced damage as a result of hydrogen peroxide 
production in hepatocytes. Figure 1.6 incorporates all factors that may contribute to 
Wy-14,643-induced hepatocarcinogenesis.
Figure 1.6 Summary of possible mechanisms of peroxisome proliferator-induced 
hepatocarcinogenicity (Adapted from Lake 1995b)
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Possible mechanisms of peroxisome proliferator-induced hepatocarcinogenicity. Hepatocytes 
may become initiated by sustained hepatocyte oxidative stress-induced damage, by enhanced 
cell replication, or spontaneously. Growth selection of initiated cells and their promotion and 
progression to hepatocellular carcinoma may involve enhanced cell replication, effects on 
growth factors, and inhibition of apoptosis.
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1.2.2.4 Cyproterone acetate
Cyproterone acetate is a synthetic steroid hormone. It is a potent androgen antagonist, 
a property which is widely exploited in its therapeutic use. It therefore inhibits all 
functions and organs which are regulated by androgens. These include the accessory 
sex glands, libido, spermatogenesis and bone maturation as well as some less sex- 
specific systems and organs such as the skin. Its major clinical indications include 
prostatic carcinoma (main use) (Jacobi et a i, 1980), acne and seborrhea (Burton et a l,
1973), idiopathic hirsutism (Bardin and Lipsett, 1967), polycystic ovarian disease 
(Neumann, 1994), androgenic alopecia (Neumann, 1994), idiopathic precocious 
puberty (Girard et a l, 1978) as well as the treatment of sexual offenders (Laschet and 
Laschet, 1971). However, in addition to its anti-androgenic properties, it also 
possesses progestational activity and suppresses the secretion of gonadotrophins, so 
inhibiting ovulation. Another major use of this steroid has therefore been as an oral 
contraceptive, where it is often prescribed in a preparation also containing 
ethinylestradiol (Neumann, 1994).
The molecular mechanism of action of cyproterone acetate involves its binding to the 
nuclear androgen receptor, so blocking binding of the active form of testosterone 
(dihydrotestosterone), resulting in prevention of the synthesis of specific proteins and 
enzymes (Neumann, 1994).
1.2.2.4.1 Effects on the liver
Most effects on the liver have been observed in rats and mice. These include:
- Hepatomegaly thought to be primarily due to hyperplasia (Schulte-Hermann et 
al, 1980b)
- Increased hepatocyte DNA synthesis and cell proliferation (Roberts et al, 1995)
- Suppression of apoptosis (Roberts et a l, 1995)
- Induction of liver drug-metabolising enzymes including the monooxygenase and 
cytochrome P450 enzymes (more pronounced in females) (Schulte-Hermann et 
al, 1980a)
- Hepatocarcinogenesis (Schuppler and Gunzel, 1979; Schulte-Hermann et a l, 
1980b)
Concern has arisen in terms of human administration as serious and dose-related
hepatic toxicity has been shown to result from the prolonged use of cyproterone
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acetate in a minority of patients, including hepatitis, cholestatic jaundice and hepatic 
failure (Rabe et al, 1996). The majority of these patients had been treated with high 
doses (300mg/kg) for prostate cancer. However, no observations have been made 
which indicate a hazard regarding the compounds potential proliferative and 
carcinogenic activity, as observed in rats and mice. Whereas clear DNA synthesis and 
mitosis is seen following cyproterone acetate administration to rats, no such reaction 
has been observed in human hepatocytes (Parzefall et a l, 1991).
1.2.2.4.2 Mechanisms of hepatomegaly and hepatocarcinogenic action
Cyproterone acetate is an example of a non-genotoxic liver carcinogen and primary 
hepatomitogen causing liver hyperplasia. Daily treatment of rats with cyproterone 
acetate has been shown to result in liver enlargement of up to 40% within 3 days, 
(Schulte-Hermann et al, 1980b). Liver growth following cyproterone acetate 
treatment is thought to be due to cell replication as growth was not found to be 
associated with significant changes in size or ploidy of hepatocytes and can therefore 
not be due to hypertrophy (Schulte-Hermann et al, 1980c). Only minor hypertrophy 
has been observed in rats following treatment with cyproterone acetate due to 
proliferation of endoplasmic reticulum (Roberts et a l, 1995). This absence of 
hypertrophy is surprising as administration of many other enzyme inducers, such as 
phénobarbital, pregnenolone 16a-carbonitrile (PCN), or a-hexachlorocyclohexane 
(aHCH), characteristically result in an increase in liver cell size (Schulte-Hermann,
1974). Like many other non-genotoxic xenobiotics the hepatomegalic action of 
cyproterone acetate is thought to be due to a combination of inhibition of hepatocyte 
apoptosis in conjunction with an increase in DNA synthesis and mitotic activity 
(Roberts et a l, 1995). Therefore the effects of cyproterone acetate on these two 
processes are very similar to those observed following Wy-14,643 treatment. 
Numerous studies have been performed in rats and mice in order to investigate the 
carcinogenic potential of cyproterone acetate. Exhibiting no cytotoxic activity, it is 
not an initiating carcinogen and is thought to act as a tumour promotor (Schulte- 
Hermann et al, 1980b; Lang and Reimann, 1993). However, a potential 
hepatogenotoxic effect has been observed in female rats (see below (e)).
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(a) Increased cell proliferation
Administration of cyproterone acetate to rats and mice, even at very low doses has 
clearly been demonstrated to enhance DNA synthesis and induce cell proliferation 
(Roberts et a l, 1995). The induced liver enlargement in rats has reported to be 
accompanied by parallel increases in the RNA and DNA content of the organ 
(Schulte-Hermann et al., 1980b), which suggests that hyperplasia is the predominant 
cause of the growth process. The increase in hepatic DNA synthesis appears to be 
dose-dependent, beginning 12-14 hours after a single dose with a maximal effect 
being seen at 100 mg/kg. The effect is more pronounced in female as compared to 
male rats. Mitotic activity in parenchymal cells of cyproterone acetate-treated rat 
liver has been shown to increase with a similar time-course as DNA synthesis, the 
proliferating cells being predominantly found in the periportal regions (Roberts et a l,
1995). It is thought that the increase in hepatic DNA synthesis is almost entirely due 
to multiplication of parenchymal cells.
The direct hyperplasia mediated by cyproterone acetate appears to occur via different 
mechanisms than those seen during the process of liver regeneration, and this has 
been indicated by a number of studies. Hyperplasia in rats following cyproterone 
acetate administration occurs in the absence of the modification of various cytokines 
that are known to contribute to regeneration of the liver. These include NF-kB, AP-1 
(c-fos and c-jun), c-myc, TNFa (Menegazzi et a l, 1997) or C/EBPa and p (Skrtic et 
al, 1997).
Remarkably, once short-term cyproterone acetate treatment is withdrawn, partial 
regression of hyperplasia occurs in conjunction with a decrease in liver size, due to an 
elevation of apoptosis (see below (b)) (Roberts et a l, 1995). Following a single dose 
of cyproterone acetate, hepatic DNA synthesis has been shown to return to almost 
control levels within 36 hours (Schulte-Hermann et a l, 1980b).
(b) Effects on apoptosis
Cyproterone acetate has been shown to suppress the basal level of rat liver apoptosis 
in vivo (Roberts et al, 1995). This apoptosis suppression occurs in conjunction with 
the induction of DNA synthesis and cell proliferation discussed, and so is thought to 
contribute to the hepatomegaly observed.
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However, following withdrawal of cyproterone acetate, a dramatic increase (100-200 
fold) in the rate of apoptosis has been reported (Bursch et al, 1984, 1986; Roberts et 
al, 1995). Apoptotic bodies and S phase were observed to be predominantly in the 
periportal region. However, very few of the apoptotic bodies were labelled with 
bromodeoxyuridine (administered during the hyperplastic phase of cyproterone 
acetate administration in order to detect DNA synthesis). As observed following 
Wy-14,643 treatment, it appears that the majority of the hepatocytes generated during 
compound-induced hyperplasia were protected from apoptosis during liver regression, 
apoptosis essentially occurring in ‘old’ hepatocytes (Roberts et a l, 1995). In female 
rat hepatocytes, this stimulation of apoptosis induced following withdrawal of 
cyproterone acetate has been shown to be dependent on hydroxysteroid 
sulfotransferase (HST) activity (Kasper and Mueller, 1999). Addition of 
dehydroepiandrosterone (DHEA), a known inhibitor of hepatic HST to primary 
female rat hepatocytes, prior to treatment with cyproterone acetate, almost completely 
inhibited induction of apoptosis. DHEA also reduced cyproterone acetate-induced 
DNA excision repair, suggesting that apoptosis induction is indirectly related to DNA 
damage induced by (HST)-dependent cyproterone acetate metabolites (sse below (d)). 
In male hepatocytes only a very minor increase in apoptosis even at high exposure 
was observed (Kasper and Mueller, 1999).
Furthermore, if treatment with cyproterone acetate is resumed, the enhanced DNA 
content persists and the number of apoptotic bodies is greatly reduced.
(c) Tumour promotion
A lack of any significant signs of genotoxicity in the liver indicates that CPA is not an
initiating carcinogen (Lang and Reimann, 1993). However, long-term administration
(12-24 months) of cyproterone acetate to both male and female rats has shown to
induce nodular hyperplasia and hepatomas, depending on the dose (Schuppler and
Gunzel, 1979). These proliferative liver lesions are not unique to cyproterone acetate
and are well documented with a number of progestogens and estrogen/progestogen
combinations used in therapy and contraception. This increased incidence of
proliferative liver changes has been considered to be due to the growth-stimulatory
effect of steroid hormones on rat liver cells and thought to be confined to rats and
possibly mice (Geil and Lamar, 1977). It is therefore thought that tumour formation
in rat liver during long-term treatment with high doses of CPA, may result from a
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mitogenic effect on preexistent, dormant (pre-)neoplastic cells (Schulte-Hermann et 
al, 1980b).
(d) Enzyme induction
Rapid, reversible induction of various liver enzymes has been observed following 
treatment of rats with cyproterone acetate. In microsomes of female rat liver, a dose- 
dependent increase in monooxygenase activities reaching nearly a maximum within 
24 hours, and a 40 % increase in the specific content of cytochrome P450 enzymes 
was observed (Schulte-Hermann et a l, 1980a). In both cases, the inductions were 
reversible within 6 days of treatment. Effects on these enzymes in male rats were 
much less pronounced. Androgens have been shown to induce certain pathways of 
drug metabolism in rat liver (Neumann, 1994) and so the weak enzyme effects in 
males may be partly due to competition of the anti-androgen cyproterone acetate with 
physiological androgens. In addition, cyproterone acetate inhibits gonadotrophin 
secretion which results in decreased testicular androgen production (Neumann, 1994). 
Therefore, the stimulatory effect of cyproterone acetate may be masked by a reduction 
of effective androgen concentrations.
No correlation between induction of various liver enzymes and enlargement of the 
liver has been observed. This is surprising as hypertrophy is often recorded in 
conjunction with the induction of such enzymes, as exemplified by a number of 
compounds including a-hexachlorocyclohexane and phénobarbital (Schulte-Hermann, 
1974; 1980b).
Interestingly this enzyme effect is more pronounced in female rats than in males, as is 
the compounds effects on DNA synthesis, cell proliferation and DNA adduct 
formation (see below (e)). It is possible that there is an as yet unidentified link 
between the liver enzyme induction and hepatocarcinogenic effects of cyproterone 
acetate.
(e) Genotoxicity
Potential genotoxic effects have been recorded following administration of 
cyproterone acetate to female rats. However, although an interaction with DNA has 
been observed, no mutagenicity or initiation has yet been indicated (Lang and 
Reimann, 1993). The definite role of DNA adducts in tumorigenesis is not clear.
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Adducts are often observed but are not sufficient for the formation of tumours by 
chemical carcinogens. Cyproterone acetate is therefore still thought to be a non- 
genotoxic carcinogen as no correlation between DNA adduct formation and 
carcinogenic activity has been shown. In addition to this, the adduct formation is sex- 
specific (Topinka et a l, 1995) and so could not account for the prevalence of tumours 
observed in male individuals.
The observation that cyproterone acetate induces DNA repair synthesis in primary 
cultures of rat hepatocytes provided the first indication of potential genotoxic activity 
(Neumann et a l, 1992). Since then, cyproterone acetate has been shown to form 
DNA adducts in rat liver cells after in vitro incubation and in vivo exposure, with a 
maximum of 4 different adducts being identified (Topinka et a l, 1993, 1995, 1996; 
Werner et a l, 1995). Work is in progress to examine the structure of the DNA 
binding cyproterone acetate metabolite and adducts formed. The number of adducts 
produced is much greater in female hepatocytes than in males. The cyproterone 
acetate molecule seems to be incorporated directly into the adduct structure, which 
once formed is stable for several weeks in vivo in the rat. The sex-specificity of this 
adduct formation is thought to be due to the expression of HST which is involved in 
the bioactivation of cyproterone acetate to reactive metabolites (Kasper and Mueller,
1999). The major DNA reactive metabolite is 3a-hydroxy-cyproterone acetate, and 
this has been shown to form the same major adduct in vitro that has been observed 
previously in cyproterone acetate-treated rats in vivo and rat hepatocytes in vitro 
(Kerdar et a l, 1995). As indicated, evidence for this DNA adduct formation is 
provided by the fact that cyproterone acetate has been shown to initiate an increase in 
DNA repair in female rat hepatocytes; however, this is not seen in male hepatocytes 
(Neumann et al, 1992). Interestingly, studies on human hepatocytes in vitro 
demonstrate that cyproterone acetate also induces unscheduled DNA synthesis in 
human-derived cells (Martelli et al, 1995). The relatively high adduct rate for 
cyproterone acetate correlates positively with the unscheduled DNA synthesis 
response.
However, despite this clear indication of DNA-reactivity, cyproterone acetate has 
demonstrated a lack of mutagenicity in standard tests (Lang and Reimann, 1993; 
Reimann e ta l, 1993).
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Summary
Studies indicate that hyperplasia is responsible for hepatomegaly in rats following 
cyproterone acetate treatment, with no significant hypertrophy being observed. 
Interestingly, many of the liver effects, including enzyme induction and the 
stimulation of cell proliferation, recorded following cyproterone acetate treatment 
appear to be more prominent in female than in male rats. Cyproterone acetate is 
thought to be a non-genotoxic carcinogen, and has therefore demonstrated to stimulate 
hepatocyte proliferation and suppress apoptosis, which may result in the replication of 
transformed hepatocytes. Some evidence of a potential genotoxic effect has been 
observed in female rats, where the formation of 4 different DNA adducts has been 
recorded. However, although this interaction with DNA has been observed, no 
mutagenicity or cancer initiation has yet been indicated following treatment of rats 
with cyproterone acetate.
1.2.2.5 Phénobarbital
Phénobarbital (PB) is a barbiturate that has been used since 1912 as a sedative, 
hypnotic and anticonvulsant, which in treatment of epilepsy has been administered at 
relatively high dosages for up to lifetime exposure. The therapeutic actions of PB are 
primarily mediated through enhancement of the inhibitory effects of the 
neurotransmitter y-aminobutyric acid (GABA) by actions on the GABAa receptor, but 
PB may also act via the inhibition of excitatory synaptic responses (Rang, Dale and 
Ritter, 1987). These actions result in suppression of polysynaptic responses, 
especially in the mesencephalic reticular activating system (Whysner et a l, 1996).
1.2.2.5.1 Effects on the liver
Although widely used in humans for its beneficial effects in the treatment of epilepsy, 
PB does have a number of additional actions that have been observed in rats and mice:
- hepatomegaly -  predominantly by hepatocyte hypertrophy, although some 
initial, transient hyperplasia is observed (Jirtle, 1991; Tsai et a l, 1996; Sanders 
and Thorgeirsson, 1999)
- stimulation of cell proliferation (Furukawa et a l, 2000)
- suppression of apoptosis (Plant et al, 1998; Kolaja et a l, 2000)
- effects on cell-cell communication (Kolaja et a l, 2000)
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- alteration of cell cycle checkpoint controls (Gonzales et al, 1998)
‘ enzyme effects -  induction/repression of more than 50 different enzymes 
including various cytochrome P450 genes (Waxman and Azaroff, 1992; 
Whysner et a l , 1996)
- hepatocarcinogenesis (Schulte-Hermann et al,, 1983 ; Goldsworthy et a l , 1984)
1.2.2.5.2 Mechanisms of hepatomegaly and hepatocarcinogenic action
Studies first conducted 30 years ago suggested that phénobarbital produces liver 
enlargement in rodents due to both hyperplasia and hypertrophy of liver cells 
(Ruttiman, 1972). The observed hypertrophy is thought to be a result of the induction 
of various enzymes (Furukawa et a l, 2000). Many studies have been carried out in 
support of these observations, in addition to studies demonstrating hepatocarcinogenic 
action.
PB is thought to be non-genotoxic and so direct DNA damage does not contribute to 
its hepatocarcinogenic action (Purchase, 1994). A number of tests have been carried 
out in order to investigate this. Using an alkaline elution technique, no single strand 
breaks following PB treatment to rats were demonstrated (Kitchin and Brown, 1994). 
Likewise, no unscheduled DNA synthesis as assessed by tritiated thymidine 
incorporation using autoradiography has been observed (Williams et a l, 1985). In 
addition to this, PB treatment has demonstrated a reduction of 8-oxodeoxyguanosine 
adducts and spontaneous DNA adducts in rats (Donghui et a l, 1992; Li et a l, 1992; 
Randerath et a l, 1992; Cattley and Glover, 1993).
It appears that the hepatocarcinogenic effect of phénobarbital (PB) may be attributed 
to its ability to cause tumour promotion. PB is a classic example of a hepatic tumour 
promotor, with no evidence for initiating or DNA damaging activity in the liver. PB 
was the first tumour promotor for rodent liver to be associated with the 2-stage or 
initiation-promotion concept of carcinogenesis (Whysner et a l, 1996). Tumour 
promotors exert their effect on pre-existing preneoplastic lesions and tumour 
promotion may be defined as an enhanced growth of altered foci eventually leading to 
neoplasia.
Many of the various effects of PB on the liver have been implicated in its mechanism 
of hepatocarcinogenic action. The possible contributory factors in the development of 
hepatocarcinogenesis are discussed below.
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(a) Effects on cell proliferation
The effects of phénobarbital administration on DNA synthesis and cell proliferation 
have been widely studied in rats and mice when given alone as well as when 
proceeded by known initiators of carcinogenesis.
Exposure of rats to phénobarbital has been shown to increase the rate of DNA 
synthesis and stimulate cell proliferation in a time- (Klaunig, 1991) and dose- 
dependent manner (Busser and Lutz, 1987). The hyperplastic response observed 
appears to be rapid and transient. The increase in liver mass observed during PB 
treatment in rats has been shown to be initially due to a transient increase in mitoses 
within the first week (typically 3 days), which then falls to control levels, the increase 
in liver mass being maintained predominantly through extensive cellular hypertrophy 
(Berman et al, 1983; Jones and Clarke, 1993; Sanders and Thorgeirsson, 1999). 
Therefore, hepatomegaly observed in rats following PB treatment has been shown to 
be attributable to both hepatocyte proliferation and enzyme induction, and following 
withdrawal of PB, proliferation is reduced to less than confrol values (Furukawa et al, 
2000).
It has been proposed that the enhanced cell proliferation observed following PB 
administration to rats is mediated by an increase in plasma levels of hepatocyte 
growth factor (HGF) (Lindroos et a l, 1992). This increase in HGF occurs just prior 
to the transient wave of DNA synthesis caused by PB.
In order to further investigate the tumour-promoting effects of phénobarbital, its 
effects on DNA synthesis and cell proliferation following initiation have been studied. 
Phénobarbital has been shown to enhance DNA synthesis and cell proliferation in rat 
liver altered foci following initiation with 2-acetylaminofluorene (2-AAF) (Pugh and 
Goldfarb, 1978), N-Nitrosodiethylamine (NDEA) (Schulte-Hermann et a l, 1981), and 
N-nitrosomorpholine (NNM) (Schulte-Hermann et a l, 1990), as well as in ‘naturally 
occurring’, foci (Ward and Ohishima, 1985), in comparison with normal hepatocytes. 
The rate of DNA synthesis in foci has been shown to be approximately 10-fold higher 
than in surrounding liver tissue (Schulte-Hermann et a l, 1990).
(b) Effects on apoptosis
Phénobarbital administration has been shown to inhibit apoptosis in rat and mouse
livers, and this is thought to contribute to its hepatocarcinogenic action. An inhibition
of apoptosis has been observed in rats treated with a promoting dose of PB for seven
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days (Kolaja et al, 2000). Administration of PB to rats following chemical (NNM or 
2-AAF) or physical insult (UV radiation) has also demonstrated a reduction in 
apoptotic activity in altered foci, with the number of apoptotic bodies present 
increasing steeply once PB was withdrawn (Bursch et a l, 1984; Schulte-Hermann et 
al, 1990; Womer and Shrenk, 1996). In primary rat hepatocytes, PB has also 
demonstrated dose-dependent suppression of apoptosis (Plant et al, 1998).
It has been hypothesised that PB may act via the same autocrine growth pathway as 
TGF-a to promote hepatocarcinogenesis through inhibition of apoptosis (Smith et al, 
1995; Santoni-Rugui et a l, 1998), with TGFa demonstrating the ability to replace PB 
in PB-dependent rat liver cell culture (Kaufmann et a l, 1997). However, doubt has 
been cast on this hypothesis by work involving the use of a double transgenic mouse 
model carrying both the TGFa and c-myc transgenes (Sanders and Thorgeirsson,
1999). It was shown that treatment with PB caused an additive effect on liver size to 
c-myc/TGFa, even in mice already overexpressing c-myc and TGFa transgenes and 
in which the TGFa pathway was already maximally stimulated. This implies that PB 
effects may therefore be occurring through a separate pathway.
The suppression of apoptosis observed during PB treatment has been demonstrated to 
coincide with an elevation in the level of bcl-2 and concomitant depression of TGFPi. 
Withdrawal of PB resulted in a dramatic, brief increase in cell death, with a large 
rapid increase in TGFpi. TGFpi is known to inhibit growth and induce apoptosis in 
hepatocytes (Bursch et al, 1992; Bayly et a l, 1994), therefore the effects on TGFPi 
may explain the PB-induced suppression of apoptosis. Various tumour promotors, 
including PB, have been shown to inhibit TGFpi-induced apoptosis in rat hepatocytes 
(Chen et a l, 2000).
(c) Tumour promotion
PB, when given alone, has only very limited tumorigenic potential in rat liver and 
enhancement of tumour formation has only been observed in aged rats where 
considerable numbers of spontaneously occurring initiated cells are believed to be 
present (Schulte-Hermann et a l, 1983). However, continuous exposure of rats to PB, 
subsequent to a brief exposure of the animals to an initiating dose of a carcinogen has 
been repeatedly demonstrated to lead to an increase in preneoplastic and neoplastic 
responses in the liver (Goldsworthy et al, 1984). PB treatment results in increased
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incidence and size of altered foci, adenomas and hepatocellular carcinomas in rats and 
mice following initiation with a single dose of various carcinogens. These include 
2-AAF (Pugh and Goldfarb, 1978; Williams and Furuya, 1984); NDEA (Goldsworthy 
et a l, 1984; Diwan et a l, 1986; Maekawa et a l, 1992), or diethylnitrosamine (DEN) 
(Schulte-Hermann et a l, 1990; Pereira, 1993). Dose-dependency of PB promotion of 
hepatocarcinogenesis in rats has been reported (Maekawa et al, 1992). However, 
administration of different doses of PB to rats over varying lengths of time, indicated 
that the promoting effects of PB is dependent on the actual concentration of the 
compound and duration of treatment rather than on the total dose administered (Appel 
et a l, 1991). Williams and Furuya, 1984, demonstrated that PB only produced 
enhancement of liver carcinogenicity when given after 2-AAF, but not before, 
confirming that PB produces a promoting, but not syncarcinogenic effect. 
Discontinuation of such PB treatment has been shown to result in the reversal of 
PB-induced altered foci (Schulte-Hermann et a l, 1990; Appel et a l, 1991).
A correlation between the potency of tumour-promoting ability of various barbiturates 
and the induction of cytochrome P450 activity (see below (d)) has been indicated 
(Nims et a l, 1987; Rice et al, 1994). It also appears that those barbiturates that 
display the strongest liver tumour promoting effects also cause the longest duration of 
sedative action (Rice et a l, 1994).
d) Enzyme induction and gene expression
Phénobarbital increases the metabolic capability of hepatocytes by its ability to 
activate numerous genes encoding xenobiotic metabolising enzymes such as various 
cytochrome P450s and specific transferases.
The effects of PB on cytochrome P450 induction have been widely investigated, and 
PB is a classic example of a CYP2B inducer, demonstrating up to a 100-fold increase 
in the level of mRNA and protein in rats (Waxman, 1999). PB induces CYP2B1 and 
CYP2B2, as well as 2A1, 3A1, 2C6, 2C7, 2C11 and 3A2 in rat liver (Waxman and 
Azaroff, 1992). Other enzymes induced by PB include aldehyde dehydrogenase, 
epoxide hydrolase, NADPH:P450 reductase, UDP-glucuronyl transferase and several 
glutathione S-transferases (Whysner et a l, 1996). In addition, increased levels of 
y-glutamyltranspeptidase (GGT) and catalase, but not glutathione peroxidase, have 
been reported (Furukawa et al, 1985).
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PB induces/represses the transcription of various genes through the constitutive 
androsterone receptor (CAR) (Waxman, 1999; Zelko and Negishi, 2000). CAR is a 
member of the nuclear receptor family mostly expressed in the liver which, in 
response to PB exposure, translocates from the cytoplasm to the nucleus where it 
heterodimerizes with the retinoid X receptor (RXR), before binding to and activating 
a specific region known as the PB response element (PBRE) present within the 
promotor of CYP2B as well as numerous other genes (Waxman, 1999). It has been 
shown that the PBRE exclusively is the enhancer element that is required for PB 
induction. The PBRE consists of two nuclear receptor binding sites (NRl and NR2) 
and a central nuclear factor (NFl) binding site. The NRl and NR2 sites consist of 2 
imperfect direct repeats spaced by 4 bases (‘DR-4 motif) based on the half-site 
sequence AGGTCA. Only the NR sites are essential for the PB response, although 
the NFl site may be required to confer full PBRE activity. CAR has been shown to 
transactivate both the CYP2B and CYP3A genes (Xie et a l, 2000; Pascussi et al, 
2000b).
Links between prolonged elevation of P450s and related enzymes by PB and liver 
enlargement have been indicated, ranging from cell hypertrophy (Furukawa et a l,
2000), to the development of focal proliferative lesions (Collins et a l, 1984). 
Specifically, Schulte-Hermann and colleagues observed that in rats treated with 
phénobarbital, those cells that demonstrated an increase in DNA synthesis were 
confined to the CYP2B-containing cells in the pericentral lobular region 
(Shulte-Hermann et a l, 1986). Interestingly, rodent strains that develop liver tumours 
in response to PB exposure exhibit elevated P450 expression upon PB exposure; 
whereas hamsters, who do not develop liver tumours in response to PB, do not exhibit 
this elevated P450 expression upon PB exposure (Lubet et a l, 1989). In addition to 
this, the level of CYP2B induction in rat liver has been shown to correlate with the 
degree of tumorigenesis for a series of structurally-related compounds including 
barbiturates (Nims et al, 1987; Rice et a l, 1994).
(e) Effects on cell-cell communication
Alterations in the number of gap junctions or the level of gap-junctional intercellular
communication (GJIC) have been found in preneoplastic and neoplastic cells for
several rodent and human tissues. In rodent and human liver, the abundance of gap
junctions, the level of GJIC, and the expression of the major constituent protein of gap
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junctions, connexin 32, are all diminished in most preneoplastic altered foci and 
adenomas (Yamasaki, 1990; Klaunig, 1991). Furthermore, many tumour promotors, 
oncogenic proteins and growth factors modulate GJIC (Williams et a l, 1981; 
Yamasaki, 1990; Klaunig, 1991). Many nongenotoxic hepatocarcinogens are able to 
induce cell proliferation, and inhibit apoptosis and GJIC. Inhibition of GJIC can 
increase cell proliferation and possibly, inhibit apoptosis. Inhibition of intercellular 
communication has been proposed to be a primary mechanism of tumour promotion 
(Williams et a l, 1981; Klaunig, 1991).
Phénobarbital has been shown to decrease intercellular communication of
hepatocytes. Tumorigenic doses of PB administered to rats for seven days causes a
50 % decrease in GJIC, in conjunction with an increase in parenchymal cell
proliferation and inhibition of apoptosis (Kolaja et a l, 2000). Sugie et a l, 1987,
showed that PB administration diminished the total area and size of gap junctions.
The ratio of gap junction area per membrane area in hepatocytes of rats given PB was
also smaller than that in the hepatocytes of controls. It has previously been shown
that PB decreases the level of gap junction protein connexin 32 immunostaining in
centrilobular hepatocytes in both preneoplastic-altered hepatic foci and centrilobular
hepatocytes in rats, these alterations being rapidly reversed following PB withdrawal
(Neveu et a l, 1990). Double immunostaining has demonstrated that centrilobular
hepatocytes that exhibited a decrease in connexin 32 also expressed an increase in
CYP2B protein (Neveu et a l, 1994). Comparison with other structurally-related
barbiturates indicated that the extent of the alterations in connexin 32 and CYP2B
staining correlated with the ability of the compounds to promote liver oncogenesis. It
is hypothesised that PB induces alterations in connexin 32 conformation rather than a
change in abundance, as despite the decreased connexin 32 immunostaining, no
reduction in the level of connexin 32 steady-state mRNA transcripts or a change in
abundance of connexin 32 in total liver homogenates was observed (Neveu et a l,
1994). PB therefore may affect GJIC through posttranslational effects such as
changes in the transport, assembly, and/or turnover of gap junctions. It is thought that
oxidative stress may play a role in the PB effects on connexin 32 as many antioxidants
have been shown to prevent the PB-inhibitory effects on GJIC (Ruch and Klaunig,
1986). Interestingly, the P450 inhibitor SKF-525A (Klaunig et a l, 1990) has also
been shown to prevent the PB effects on GJIC, and an increase in the production of
reactive oxygen species was found to associate with CYP2B induction in
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centrolobular hepatocytes and neoplastic nodules (Scholz et a l, 1990). Cyclic AMP 
(cAMP) may also be responsible for the changes in connexin 32 following PB 
treatment. Treatment of primary hepatocytes with PB has shown a transient decrease 
in cAMP levels, and an increase in cAMP levels in hepatocytes has been shown to 
reverse PB-inhibitory effects on GJIC (Klaunig and Ruch, 1987; Klaunig e ta l, 1990).
(f) Alteration of cell cycle checkpoint controls
It has been hypothesised that mitogenic, non-genotoxic chemicals may exert their 
carcinogenic effect partly by alteration of cell cycle checkpoint controls as cell cycle 
checkpoints function to maintain genomic integrity (Hartwell and Weinhert, 1989). If 
checkpoint function is lost, DNA repair systems may not have time to remove 
potentially mutagenic DNA damage before they are fixed during DNA replication and 
mitosis, which may lead to neoplastic transformation (Hartwell, 1992; Kaufmaim and 
Wilson, 1994). Several genes have been shown to be involved in cell-cycle 
checkpoint responses to DNA damage, the most commonly known being the p53- 
dependent G1 checkpoint, which possesses the ability to prevent S-phase progression 
(Sherr, 1994). Gonzales et a l, 1998, investigated whether PB could alter checkpoint 
responses to DNA damage in mouse hepatocytes. It was shown that in response to 
bleomycin-induced DNA damage, the cells arrested in G1 and G2. PB was shown to 
delay and attenuate the G1 checkpoint function without affecting the G2 checkpoint 
response. PB also delayed and attenuated p53 protein induction during DNA damage, 
indicating that changes in p53 protein may contribute to the effects PB exerted on the 
G1 checkpoint.
Summary
Hepatomegaly observed in rats following treatment with phénobarbital has been
shown to be attributable to both hepatocyte proliferation and hypertrophy. A
significant amount of evidence has accumulated supporting a non-genotoxic
mechanism of hepatocarcinogenesis by phénobarbital, with the compound exerting
the characteristic stimulation of cell proliferation and suppression of apoptosis. PB
has demonstrated delay and attenuation of G1 checkpoint function within the cell
cycle which may mean that DNA repair systems may not have time to remove
spontaneous potentially mutagenic DNA damage before they are fixed during DNA
replication and mitosis, which may lead to neoplastic transformation. Links between
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prolonged elevation of cytochrome P450s and related enzymes by PB and liver 
enlargement have been indicated, ranging from cell hypertrophy to the development 
of focal proliferative lesions. It appears that the hepatocarcinogenic effect of 
phénobarbital (PB) may be attributed to its ability to cause tumour promotion, 
treatment of rats and mice with this compound resulting in an increased incidence and 
size of altered foci, adenomas and hepatocellular carcinomas following initiation with 
a single dose of various carcinogens. Phénobarbital has also been demonstrated to 
decrease intercellular communication of hepatocytes which has been proposed to be a 
primary mechanism of tumour promotion.
1.2.2.6 Dexamethasone
Dexamethasone is a synthetic glucocorticoid. The potential uses of such a compound 
may be illustrated by the necessity and varied roles of naturally occurring 
corticosteroids in the body.
The adrenal cortex synthesises two classes of steroids: the corticosteroids 
(glucocorticoids and mineralocorticoids) and the androgens (Moffett, Moffett and 
Schauf, 1993). The effects of the corticosteroids are numerous and widespread. They 
are known to influence carbohydrate, protein and lipid metabolism, electrolyte and 
water balance, and the functions of the cardiovascular system, the kidney, skeletal 
muscle, the nervous system, as well as other organs and tissues. Importantly, they 
also provide the organism with the ability to resist many types of noxious stimuli. (Di 
Rosa et al, 1985; Funder, 1987; McMahon et a l, 1988).
Like other steroid hormones, corticosteroids act by controlling the rate of synthesis of 
proteins. They react with receptor proteins in the cytoplasm of sensitive cells in many 
tissues to form a steroid-receptor complex which undergoes a modification and then 
translocates into the nucleus, where it binds to chromatin and regulates transcription 
of specific genes (Buller and O’Malley, 1976). Glucocorticoids have been shown 
both to increase and decrease the transcription of some genes (Gonzalez, 1989).
Due to the wide range of effects corticosteroids have on the body, it follows that the 
synthetic analogues share a vast array of clinical indications. These include adrenal 
insufficiency, arthritis, renal diuresis, collagen diseases, allergic diseases, bronchial 
asthma, ocular diseases, skin diseases, as well as malignancies (chemotherapy of 
acute lymphocytic leukemia and lymphomas by induction of apoptosis) (Hofmann et 
al, 1998; Moffet, Moffet and Shauf, 1993).
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Glucocorticoids are widely known and widely exploited for their immunosuppressive 
and anti-inflammatory effects, both of which involve interference of macrophage 
function (Newton, 2000). Their immunosuppressive effects involve inhibition of the 
action of macrophage inhibitory factor (MF) promoting the egress of macrophages 
from affected areas, inhibition of antigen processing and display, inhibition of 
synthesis and release of ILl which suppresses the action of T cells, as well as 
suppression of the amplification of cell-mediated immunity by interfering with IL2 
expression and actions. There are a number of mechanisms responsible for their anti­
inflammatory effects. These include the inhibition of the recruitment of leukocytes 
and monocyte-macrophages into affected areas, inhibition of the ability of these cells 
to elaborate a variety of chemotactic substances as well as factors that mediate 
increased capillary permeability, vasodilation, and contraction of various nonvascular 
smooth muscles (Di Rosa et a l, 1985; Newton, 2000). Glucocorticoids affect the 
synthesis/release of various substances including arachidonic acid and its metabolites 
(prostaglandins and leukotrienes) (Peters et al, 1990), platelet activating factor (PAF) 
(Parente and Flower, 1985), TNFa (Peters et a l, 1990; Chensue et a l, 1991), as well 
as ILl (Chensue et a l, 1991).
1.2.2.6.1 Effects on the liver
Dexamethasone has demonstrated a number of effects on the liver, most of which 
have been observed in studies using rats and mice.
- Hepatomegaly -  an increase in liver weight and size thought to be due to 
hypertrophy (Nagy et a l, 2001)
- Inhibition of apoptosis (Buenemann et a l , 2001 )
- Glycogen deposition (McMahon et a l, 1988)
- Water retention (Thatcher and Caldwell, 1994)
- Induction of various cytochrome P450 enzymes (Waxman, 1999)
1.2.2.6.2 Mechanisms of hepatomegaly
Growth of the liver following dexamethasone treatment is thought to be largely due to 
the enlargement of liver cells. The occurrence of increased weight and hypertrophy 
has been widely demonstrated in rat liver, the hypertrophy of hepatocytes essentially 
occurring in the periportal region (Thottassary and Yarborough, 1991; Goodlad and
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Clark, 1994; Nagy et al. 2001). Hepatocellular enlargement and significantly 
increased liver weight has been recorded following treatment of rats with 
dexamethasone, but no parallel increase in cell proliferation has been observed 
(Thatcher and Caldwell 1994; Lake et a l, 1998). DNA synthesis and cell 
proliferation have actually been shown to be inhibited following dexamethasone 
treatment (Nagy et al, 1998; 2001). It is thought that inhibition of various cytokines, 
such as IL6 and TNFa, may be involved in this inhibition of proliferation (Nagy et 
al, 1998). Inhibition of growth by cell division is actually a rather widespread effect 
of glucocorticoids on tissues of laboratory animals. Following dexamethasone 
treatment, tissues affected include the thymus, spleen, liver, skeletal muscle and 
lumbar vertebrae (Hinton et a l, 1998; Rooman et a l, 1999; Orzechowski et a l,
2000). Inhibition of mitogenesis indicates that dexamethasone is unlikely to 
predispose to hepatocellular carcinoma, and indeed no data exists indicating 
carcinogenic activity in rats or mice.
(a) Inhibition of apoptosis
Glucocorticoids are widely known for their ability to induce apoptosis in 
lymphocytes, which is thought to account for their therapeutic effects in various 
diseases including leukaemia (Helmberg et a l, 1995; Hofmann et a l, 1998). This 
induction of apoptosis is dependent on the glucocorticoid receptor (see below (b)). 
However, even though glucocorticoid receptors are present in many cells and tissues, 
only certain lymphoid cells are susceptible to glucocorticoid-induced apoptosis. 
Studies have indicated that dexamethasone actually inhibits apoptosis in the liver. 
TGFpi is involved in the regulation of liver cell proliferation and apoptosis, and 
escape of hepatoma cells from the growth restraining signals of TGFPi has been 
suggested to contribute to tumour development (Buenemann et al, 2001). TGFpi- 
induced apoptosis has been shown to be inhibited by pretreatment with 
dexamethasone in rat liver derived epithelial cells (Teramoto et a l, 1998), primary 
hepatocyte cultures (Qiao and Farrell, 1999), as well as hepatoma cells (Buchmann et 
al, 1999; Buenemann et a l, 2001). Corticosteroids appear to suppress apoptosis of 
cultured hepatocytes in a non-dose-dependent manner (Qiao and Farrell, 1999). In 
addition, dexamethasone mediated inhibition of TGFPi-induced apoptosis is strongly 
correlated with a decrease in CPP32-like caspase activity in hepatoma cells
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(Buchmann et a l, 1999), as well as prevention of expression of the apoptotic gene, 
Bax, in rat liver derived epithelial cells (Teramoto et al, 1998).
(b) Enzyme induction and gene expression
Dexamethasone is a known inducer of cytochrome P450 enzymes, specifically the 
CYP3A family (Waxman, 1999). This induction occurs in conjunction with the 
observed liver enlargement, although it is not thought to contribute to the recorded 
hypertrophy.
Dexamethasone was initially thought to mediate all of its effects through binding to 
the glucocorticoid receptor (GR), which results in translocation of this complex into 
the nucleus, interaction with glucocorticoid response elements (GREs) with 
subsequent effects on gene expression (Buller and O’Malley, 1976). However, 
evidence has accumulated which indicates that the induction of CYP3A in rat and 
human liver observed following dexamethasone treatment could not be fully 
accounted for through activation of GR (Pascussi, 2000a). More recently the orphan 
nuclear receptor pregnane X receptor (PXR) was cloned in mice (Kliewer et al, 
1998), humans (Lehmann et al, 1998) and rats (Zhang et a l, 1999) and was identified 
as being responsible for CYP3A induction. Dexamethasone has been shown to bind 
to PXR, which then forms a heterodimer with the retinoid X receptor (RXRa), before 
binding to conserved motifs within the promotor regions of CYPSA genes (Waxman et 
al, 1999). More recently it has been indicated that dexamethasone induces the 
expression of PXR and RXRa through interaction with GR (Pascussi et a/., 2000a). 
Potential cross-regulation between PXR and CAR has also been demonstrated, 
indicating further potential effects of dexamethasone on gene expression (Xie et al., 
2000, Pascussi et a l, 2000b, Gerbal-Chaloin et a l, 2001). This has been illustrated 
by a further enhancement of phenobarbital-induced CYP2B expression following 
dexamethasone treatment, in conjunction with an increase in expression of mRNA 
and protein levels of CAR. Conversely, CAR has been indicated in the regulation of 
CYP3A (Moore et al, 2000). It has been shown that PXR and CAR possess the 
ability to recognise each other’s response elements (Xie et a l, 2000). It is thought 
that GR might control the expression of nuclear receptor transcription factors, such as 
RXR, PXR and CAR (Pascussi et a l, 2000a, b).
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Interestingly, dexamethasone has been shown to affect expression of some genes that 
lack GREs or the required conserved motifs within their promotor regions. This may 
be explained by functional interactions of the GR with other transcription factors 
including AP-1, C/EBP, and NF-kB (Hofmann et a l, 1998).
Through interaction with these nuclear hormone receptors, dexamethasone may 
therefore have the potential to affect expression of a variety of genes, some of which 
may be involved in a mechanism of growth.
(c) Glycogen deposition
Deposition of glycogen in the livers of dexamethasone-treated rats is thought to be the 
most likely reason for the observed hypertrophy. The property of glucocorticoids to 
greatly increase the glycogen content of the liver becomes apparent in rats and mice 
within approximately 3 hours (DeWulf and Hers, 1967; Hers, 1985). The rates of 
glycogen synthesis and degradation in the liver depend on the activities of glycogen 
synthase and glycogen phosphorylase, respectively. It appears that the property of 
glucocorticoids to greatly increase the content of glycogen in the liver is due to the 
synthesis of a protein factor which has the ability to dissociate synthase phosphatase 
from the inhibition normally exerted by phosphorylase a. Glycogen synthase may be 
activated by synthase phosphatase. Glucocorticoids therefore act to increase the 
activity rather than the total amount of glycogen synthase (Hers, 1985; McMahon et 
aA, 1988).
(d) Water retention
Water retention is also thought to be another possible contributor to the enlargement 
of liver cells. Thatcher and Caldwell, demonstrated hepatocellular enlargement in the 
livers of dexamethasone treated rats which was accompanied by a significant increase 
in water content, with no increase in cell number (Thatcher and Caldwell, 1994).
Summary
Hepatocellular enlargement and significantly increased liver weight has been recorded 
following treatment of rats with dexamethasone. Hepatomegaly is thought to be due 
to the vast hypertrophy of hepatocytes which is a result of the deposition of glycogen 
and possible retention of water. Dexamethasone has been shown to suppress
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apoptosis, but no parallel increase in cell proliferation has been observed with DNA 
synthesis and cell proliferation actually being inhibited following dexamethasone 
treatment. As a result, although treatment of rats with dexamethasone has been 
widely demonstrated to cause hepatomegaly, no studies have been performed 
indicating the development of hepatocarcinogenesis.
1.3 Investigation of molecular mechanisms of action of xenobiotics
As discussed (section 1.2.2), numerous compounds are capable of causing liver 
enlargement, often resulting in hepatocarcinogenesis following their administration to 
rats. Many such compounds have been demonstrated to be non-genotoxic, their 
precise mechanisms of action remaining far from being totally understood. Although, 
typically for these compounds, no evidence has been provided to indicate any 
carcinogenic potential in humans, it is still potentially concerning that many of them 
are in wide everyday use. Examples of such compounds include various drug 
treatments as well as pesticides. Elucidation of the precise molecular mechanisms 
involved in such compound-induced rodent carcinogenesis may help to determine 
whether similar molecular and cellular changes exist in human tumours, and so aid in 
human risk assessment. Such investigations may also identify specific early 
biomarkers of carcinogenic potential of new chemicals.
1.3.1 Gene Expression
Altered gene expression occurs in affected cells compared to their normal state in
response to xenobiotic exposure. There are enormous potential medical and
therapeutic benefits in the understanding of the precise molecular changes that occur
in such cells in response to specific xenobiotics. Numerous studies have been
performed involving many different compounds, the non-genotoxic carcinogens
attracting extensive interest. Such studies often allow the identification of specific
biomarkers of a specific class of compound. For example, the up-regulation of
CYP4A1 (Bell et a l, 1991; Rockett et al, 2000) and peroxisomal enoyl-
CoA:hydratase-3-hydroxyacyl-CoA bifunctional enzyme (Chen and Crane, 1992;
Rockett et a l, 2000), following treatment of rats with a peroxisome proliferator, or the
induction of CYP2B (Waxman and Azaroff, 1992), glutathione S-transferase (Pinkus
et a l, 1993), and UDF glucoronosyltransferase (Lechner et a l, 1987), following
administration of phénobarbital to rats. It is hoped that characterisation of the genetic
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changes that occur in a cell in response to chemical exposure will ultimately provide a 
fingerprint for specific compound classes. This will enable not only the screening of 
new compounds for specific activities and carcinogenic potential, but also indicates 
therapeutic potential following exposure to such compounds. It may enable the 
provision of the most effective treatment as such fingerprints could indicate the type 
of chemical, even the dose and length of exposure, to which an individual has come 
into contact.
1.3.2 Methods used for identification of differentially expressed genes 
To date, a variety of methods have been developed and successfully utilised in the 
identification of differentially expressed sequences. They may be divided into two 
main classes, ‘open’ and ‘closed’. An ‘open’ system refers to one that does not 
require knowledge of gene sequences and is therefore useful when little is known 
about the xenobiotic in question. This type of system may be used to isolate unknown 
genes and potentially identify new pathways that may be involved in the mechanism 
of action of a particular xenobiotic. A ‘closed’ system utilises previously identified 
gene sequences. This type of system is useful for investigating the effects of a 
xenobiotic on genes linked to known pathways that are likely to be involved in the 
mechanism of action of the compound.
1.3.2.1 Differential plaque filter hybridisation
Attempts to characterise differentially expressed genes were first reported more than 
20 years ago by St. John and Davis (1979). The method used was termed ‘differential 
plaque filter hybridisation’, and was used to isolate galactose-inducible DNA 
sequences in yeast. This was achieved by the differential screening of a genomic 
DNA library prepared from normal, unstimulated cells, with radioactively-labelled 
cDNA probes prepared from the control and test cell mRNA populations.
This procedure was successful, but is now considered insensitive (as most cellular 
mRNAs are not sufficiently abundant to be detected by this approach) and time- 
consuming, and so has led to the development of more convenient methods of 
analysis.
More recently, methods that enrich differentially expressed gene sequences by 
removing mRNA common to both populations have been developed. This process is 
known as subtractive hybridisation.
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1.3.2.2 Subtractive Hybridisation
Subtractive hybridisation is an integral method allowing one to obtain small cDNA 
libraries enriched with transcripts which are present only in one of the samples 
compared. It generally involves hybridisation of mRNA/cDNA from one population 
(tester) to excess mRNA/cDNA from another (driver), followed by separation of the 
unhybridised tester fraction (differentially expressed) from the hybridised common 
sequences.
There are various methods available which incorporate this basic idea.
1.3.2.2.1 Physical Separation 
Hydroxyapatite chromatography
This technique involves the removal of common mRNA species by 
cDNA (from test cells)-mRNA (from control cells) subtractive hybridisation, 
followed by hydroxyapatite chromatography. Hydroxyapatite specifically adsorbs 
cDNA-mRNA hybrids. The unhybridised test cDNA is not absorbed and can be used 
to construct a cDNA library of differentially expressed genes (Sargent and David, 
1983; Schneider et a l, 1988), or used directly as a probe to screen a pre-selected 
library (Zimmerman et al, 1980; Hedrick et al, 1984).
Avidin-biotin technology
Biotin-affinity systems may be utilised as a means to remove common hybridised 
sequences (Duguid and Dinauer, 1990; Straus and Ausubel, 1990). The polymerase 
chain reaction (PCR) may be used to further enrich those species differentially 
expressed in the tester cDNA.
Oligo-dT-latex separation
01igo-(dT3o) primers attached to a latex substrate are used to first capture mRNA 
extracted from a control population. Following first strand cDNA synthesis, the RNA 
strand is removed by heat dénaturation and centrifugation. A quantity of tester 
mRNA is then repeatedly hybridised to the immobilised control (driver) cDNA. Brief 
centrifugation allows the separation of unhybridised tester specific mRNA species 
(supernatant) from the hybridised mRNA. The unhybridised mRNA species are then 
converted to cDNA and amplified by PCR. (Hara et a/., 1991)
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1.3.2.2.2 Chemical cross-linking subtraction (CCLS)
This technique was originally described by Hampson et al. (1992) and basically 
involves the formation of tester cDNA.driver mRNA hybrids, which are separated 
from the unhybridised tester cDNA by chemical inactivation via
2,5 diaziridinyl-1,4-benzoquinone (DZQ). DZQ acts by causing cross-linking of all 
GC pairs of the RNA-cDNA hybrids. Radiolabelled probes are synthesised from the 
remaining single-stranded cDNA species, which are then used to screen a cDNA 
library made from the tester cell population.
1.3.2.2.3 Representational Difference Analysis (RDA)
This technique was described by Lisitsyn et al (1993) and Hubank and Schatz (1994). 
RDA is a process of subtraction and hybridisation followed by amplification. 
Sequences in the tester that have homologues in the driver are rendered unamplifiable, 
whilst those genes expressed only in the tester retain the ability to be amplified by 
PCR.
A number of stages are involved in this technique:-
- The driver and tester mRNA populations are first converted to cDNA and amplified 
by PCR following ligation of an adaptor.
- The adaptors are then removed from both populations and a new (different) adaptor 
ligated to the amplified tester population only.
- Driver and tester populations are next melted and hybridised together in a ratio of 
100:1.
- PCR - Following hybridisation, only tester:tester homohybrids have 5' adaptors at 
each end of the DNA duplex and can thus be filled in at both 3' ends -  only these 
molecules are amplified exponentially during the subsequent PCR step. Tester-driver 
heterohybrids are present, but they only amplify in a linear fashion since the strand 
derived from the driver has no adaptor to which the primer can bind. Driver-driver 
homohybrids have no adaptors and therefore are not amplified. Single-stranded 
molecules are digested before a further PCR-enrichment of the tester-tester 
homohybrids. The adaptors (different) on the amplified tester population are then 
replaced and the whole process repeated a further two or three times using an 
increasing excess of driver.
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The final display is a series of differentially expressed gene products easily 
observable on an ethidium bromide gel.
This method is sensitive and easily reproducible. However, it does have the 
disadvantage of presenting difficulties in the isolation of rare transcripts.
1.3.2.2.4 Suppression PCR Subtractive Hybridisation (SSH)
As indicated the major drawback of subtractive cDNA libraries it that the original 
disproportion in concentrations of different types of transcripts is preserved, resulting 
in the isolation of specific rare transcripts being extremely difficult. This may be a 
problem, as this minor fraction is likely to be of particular interest, since transcripts 
for many regulatory proteins fall into this category.
Gurskaya and colleagues performed one of the most recent adaptations of the 
subtractive hybridisation approach to differential gene expression studies, in which a 
high enrichment of rare cDNAs is obtained without the need for multiple 
hybridisations/subtractions (Gurskaya et al, 1996). This process is termed 
suppression subtractive hybridisation (SSH). SSH involves the enrichment of target 
molecules while actively preventing the amplification of the undesirable sequences. 
To do this, a PCR-based suppression system is used, instead of physical or chemical 
removal of the common sequences. This technique is described in depth in section 
2.2 .2.
1.3.2.3 Differential Display (DD)
This method was originally described by Liang and Pardee and the general strategy is 
to amplify partial cDNA sequences from subsets of mRNAs from the control and 
treated cell populations by reverse transcription and the polymerase chain reaction 
(PCR) (Liang and Pardee, 1992). These short sequences are then displayed on a 
sequencing gel. Those bands that are present in one display only, or are more intense 
in one display compared to the other, are differentially expressed and may be 
recovered for further characterisation.
Variations of this method differ in priming the reverse transcription step. The method 
described by Liang and Pardee (1992) selected 3' primers to take advantage of the 
polyadenylate [poly(A)] tail present on most eukaryotic mRNAs to anchor the primer 
at the 3' end of the mRNA, plus two additional 3' bases. An example of this would be
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5'-TiiCA which would allow anchored annealing to mRNAs containing TG located 
just upstream of their poly(A) tails. Pairs of primers are selected so that each will 
amplify DNA from about 50-100 mRNAs because this number is optimal for display 
on the gel. In contrast, the method utilised by Welsh et al (1992) involves an 
arbitrary primer (has a single base at each position, compared to random primers, 
which contain a mixture of all four bases at each position) for first strand synthesis. 
This allows PCR products to be derived from anywhere in the RNA, including open 
reading frames, and additionally may be used in mRNAs that are not polyadenylated. 
Following reverse transcription and dénaturation, second strand cDNA synthesis in 
both methods involves an arbitrary primer. When a combination of different 
dT-anchors and arbitrary primers are used, almost all mRNA species from a cell can 
be amplified.
1.3.2.4 Restriction Endonuclease-Facilitated Analysis of Gene Expression
1.3.2.4.1 Serial Analysis of Gene Expression (SAGE)
The process of SAGE involves a number of steps and is based on the principles that 
typically, short nucleotide sequences (‘tags’) of around 10 base pairs provide 
sufficient information to identify their gene of origin, and the serial linking of such 
tags allows sequencing of multiple cDNAs within a single clone. Firstly, double­
stranded cDNA from the test cells is synthesised with a biotinylated poly-dT primer. 
This is followed by digestion with a common-cutter (4 base pair recognition 
sequence) restriction enzyme (‘anchoring enzyme’), with the 3’ ends of the cDNA 
population being captured with streptavidin beads. The captured population is then 
divided in half and different adaptors ligated to the 5' ends of each group to form a 
Tag. Incorporated into the adaptors is a recognition sequence for a type IIS restriction 
enzyme -  one which cuts DNA at a defined distance (less than 20 base pairs) from its 
recognition sequence. Therefore, following digestion of each captured cDNA 
population with the IIS enzyme, the adaptors plus a short piece of the captured cDNA 
are released. The two populations are then ligated to form a DiTag and the products 
amplified. These products are cleaved with the original anchoring enzyme, religated 
and may be cloned into a vector of choice for sequencing. (Velculescu et a l, 1995)
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The number of times a given transcript is identified is a quantitative measurement of 
that gene’s abundance in the original population. This allows the identification of 
differentially expressed genes in different cell populations.
1.3.2.4.2 Gene Expression Fingerprinting (GEF)
This method is based on the consecutive restriction digestions of 3' terminal cDNA 
fragments to produce a fingerprint of gene expression.
RNA is first reverse-transcribed to cDNA using biotinylated oligo-dT primers and this 
cDNA population is then digested with a specific endonuclease and captured with 
magnetic streptavidin microbeads to facilitate removal of the unwanted 5' digestion 
products. The use of restricted 3'-ends alone results in a reduction of the complexity 
of the cDNA fragment pool and helps to ensure that each RNA species is represented 
by only one restriction product. Following this, an adaptor is ligated to allow the 
amplification of the captured population and then PCR is performed with one adaptor- 
specific and one biotinylated poly-dT primer. The reamplified population is 
recaptured and the non-biotinylated strand is then resynthesised using a different 
adaptor-specific primer in the presence of a radiolabelled dNTP. The labelled 
immobilised 3' cDNA ends are next sequentially treated with a series of different 
restriction endonucleases and the products from each digestion analyzed by 
polyacrylamide gel electrophoresis (PAGE). This provides a ‘fingerprint’ composed 
of a number of ladders which is equal to the number of sequential digests used. 
(Ivanova and Belyavsky, 1995). By the comparison of test and control fingerprints, 
differentially expressed products may be identified which can then be isolated from 
the gel and cloned into a suitable vector for sequencing.
1.3.2.5 Expressed Sequence Tag (EST) Databases
These were first described by Adams et al. (1991) who conducted automated partial 
DNA sequencing on more than 600 randomly selected human brain complementary 
DNA (cDNA) clones to generate expressed sequence tags (ESTs).
An EST is therefore simply a segment of a sequence from a cDNA clone that 
corresponds to a mRNA. ESTs represent uniquely identified map positions and can 
point directly to an expressed gene. They have applications in the discovery of new 
genes, gene mapping of the human genome, and identification of coding regions in
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genomic sequences. There are just 30,000-40,000 protein coding genes within the 
human genome (Lander et a l, 2001), although hundreds of thousands of human ESTs 
have been generated (Hillier et a l, 1996; Vasmatzis et a l, 1998). Although still 
incomplete, this large database can now be used to obtain valuable genetic 
information. The ESTs belong to different cDNA libraries, each of which was 
prepared from one particular cell type, organ, or tumour. Therefore the presence or 
absence of ESTs in different libraries provides information about the organ, cell type, 
or tumour specificity of expressed genes. A gene is also often represented by many 
ESTs and generally, the more a gene is expressed in a given tissue, the more ESTs for 
that gene will be found in the library. Therefore, the number of ESTs that represent 
the same gene in a given library is a rough indication of the expression level of the 
gene in the tissue from which the library was derived (Vasmatzis et a l, 1998). 
Vasmatzis and colleagues used these characteristics of the EST database to identify 
genes that are specifically expressed in the human prostate, incorporating the theme of 
differential gene expression analysis. In theory, the approach is simple. EST 
databases are first searched for genes that have a number of related EST sequences 
from the target tissue of choice, but none or few from non-target tissue libraries. 
Candidate EST clones representing different genes are then analysed using RNA blot 
methods. However, many problems may be encountered. For example, because EST 
sequences are rather short DNA fragments, when used as probes they may not be 
specific to the target sequence, and indeed, may not be of sufficient length to bind to 
the target sequence. In contrast, there may be problems in separation of highly 
homologous sequences that are derived from different genes (Vasmatzis et a l, 1998), 
which may lead to a false impression that particular genes are highly expressed.
1.3.2.6 DNA Arrays
This approach, as utilised by Zhao et al (1995) and Schena et al (1996), attempts to
speed up analysis of gene expression. It is a clear example of a closed system.
DNA arrays consist of a gridded membrane or a glass ‘chip’ containing hundreds of
blots, each blot comprising a specific cDNA clone to be investigated. The availability
of large numbers of ESTs provides a rich resource of human cDNA clones for micro-
arraying computer programmes. The genes are often selected based on previously
proven involvement in oncogenesis, cell cycling, DNA repair, development and other
cellular processes, and are usually chosen to be as specific as possible for each gene
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and animal species. Hundreds or thousands of genes may be spotted on a single array 
and cDNA from the test populations can be labelled and used directly as a probe. The 
arrays are then analysed utilising appropriate computer programmes to assess 
differences in gene expression between two cell populations. This technique enables 
the quantitation of any changes.
1.3.2.7 Quantitation
Most of the techniques used for isolating differentially expressed genes do not allow 
accurate quantitation of the changes observed. Subsequent experiments must then be 
carried out in order to accomplish this. This is not only used as confirmation of the 
change but also helps to determine its significance. Typically, methods utilised 
include northern blotting, RT-PCR, or the increasingly popular real-time PCR 
(Taqman), (section 2.2).
1.3.3 Problems and considerations in the identification of differential gene 
expression
For some years now, the identification of specific differentially regulated mRNA 
sequences following compound treatments has been used in attempts to assemble 
pathways that may be involved in mechanisms of action. This has provided useful 
information in a number of studies involving various compounds, but there are a 
number of caveats to bear in mind.
Before commencing such studies, care must be taken in experimental design. This 
includes selection of a suitable species (susceptible to the compound effects) as well 
as of an appropriate dose (sufficient to cause the effect) and importantly the 
determination of a suitable time-point(s). If inappropriate or insufficient time-points 
are selected vital evidence may be missed, as different genes will be affected at 
different times following compound administration. A suitable number of subjects 
must also be selected in order to consider the incidence and implications of 
interindividual biological variation.
Following such studies obvious questions are raised regarding the
functional/biological significance of the changes in the identified genes. This is not
always easy to deduce, as for many sequences specific functions are not yet known. It
is then essential to consider whether or not this alteration in mRNA levels is a cause
or consequence of the compound treatment - does the change actually contribute to
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the compound’s mechanism of action? The magnitude and significance of the change 
in expression must also be considered. What level of change may be accepted as 
true? This may depend on the sensitivity of the technique being used. For example, 
using SSH, isolation of genes whose expression is changed as little as 1.5-fold has 
been reported (Groenink and Leegwater, 1996). However, such small changes may be 
Tost’ between experiments or due to interindividual variation. If a change indicates 
statistical significance, the biological significance of the change as related to the 
function of the gene in question must also be considered. In addition to this, it is 
important to determine if the identified change in mRNA level is reflected in the 
subsequent protein levels of that specific gene, and indeed protein studies may reveal 
changes in gene expression that do not involve changes in mRNA levels. It may be 
that an observation of a difference in mRNA levels may be caused by differences in 
transcription rate and/or in mRNA stability, which may result in no change in the final 
protein levels. It is therefore ideal, where possible, to utilise a combination of 
genomics and proteomics techniques when performing this type of study.
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1.4 Aims of the present study
Many xenobiotics are known to cause liver growth in rats by mechanisms that remain 
mostly undefined. Several of these compounds have significant human exposure, yet 
their potential hazards, with regard to effects on the liver, are largely unknown.
The objective of this study was to characterise the effect of four compounds well- 
documented to cause liver enlargement, namely phénobarbital, Wy-14,643, 
dexamethasone and cyproterone acetate, on cell proliferation, apoptosis and 
differential gene expression in rats. This project, using the gene-hunting technique, 
suppression subtractive hybridisation and quantitative RT-PCR methods, was 
designed to investigate the molecular mechanism of liver enlargement with the aim of 
identifying molecular markers for the prediction of compound-induced hepatomegaly 
and hepatocarcinogenesis in vivo.
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Chapter 2
Materials and Methods
2.1 Materials
2.1.1 Chemicals and other laboratory items
All general chemicals and solvents were of the highest possible quality and were 
obtained from Sigma or Fisher unless otherwise stated. The suppliers of all additional 
materials are detailed below.
Item Supplier
Acetic anhydride Sigma
Acetylated bovine albumin serum Promega
Agar, bacteriological, No. 1 Oxoid
Agarose, standard FMC Bioproducts
Agarose, MetaPhor FMC Bioproducts
Ampicillin Sigma
Com oil Tesco
Cyproterone acetate Sigma
Dexamethasone Sigma
Dextran sulphate Sigma
Diethylpyrocarbonate Sigma
Dithiothreitol Sigma
DPX mounting media Fisher
Ethidium bromide Sigma
Ficoll Pharmacia
Formamide Sigma
Hybond N+ membranes Amersham Biosciences
Hydrogen peroxide VWR
Isopropylthio-P-D-galactoside (IPT G) Promega
Nuclease-free water Promega
N,N,N-trimethylglycine (betaine) Sigma
Orange G Roche
Phénobarbital Sigma
Phenol xhloroform Sigma
Polaroid film (type 677) Sigma
Poly-L-lysine microscope slides VWR
Polyvinylpyrrolidone Sigma
Proteinase K Roche
Ribonuclease A Sigma
Triethanolamine Lancaster
tRNA Sigma
Tryptone Oxoid
Wy-14,643 Chemsyn Science Labs
5-bromo-4-chloro-3-indoyl-p-D-galactoside (X-gal) Promega
Yeast Extract Oxoid
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2.1.2 Plasmids
Figure 2.1 pCR® 2.1-TOPO vector map
Ml.% mfT%e
primlnt
pCR 2.1 - 
lOFO
3.9 kb
pCR®2.1-TOPO vector reference points:
Lac Za fragment; bases 1-571 
M13 reverse priming site: bases 205-221 
Multiple cloning site: bases 234-357 
T7 promotor/priming site: bases 364-383 
M13 Forward (-20) priming site: bases 391-406 
M l3 Forward (-40) priming site: bases 411-426 
fl origin: bases 548-962 
Kanamycin Resistance ORF: bases 1296-2090 
Ampicillin resistance ORF: bases 2108-2968 
pUC origin: bases 3113-3786
75
Figure 2.2 pGEM®-T Easy Vector map
I 2009
Seal 1890
pGEM®-T Easy 
Vector
(3015bp) Sac il£TcoR. i
î  SP6
pGEM®-T Easy Vector reference points:
T7 RNA Polymerase transcription initiation site: base 1
SP6 RNA Polymerase transcription initiation site: base 141
T7 RNA Polymerase promoter: bases 3002-6
SP6 RNA Polymerase promoter: bases 136-158
Multiple cloning site: bases 10-128
LacZ start codon: base 180
lac operon sequences: bases 2839-2999, 166-395
lac operator: bases 100-216
p-lactamase coding region: bases 1337-2197
phage fl region: bases 2383-2838
binding site of pUC/M13 Forward sequencing primer: bases 2959-2975 
binding site of pUC/M13 Reverse sequencing primer: bases 176-192
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2.2 Methods
2.2.1 Animals and treatment
2 animal studies were carried out in this project. Study 1 was performed in order to 
characterise the effects of 4 different compounds known to cause hepatomegaly in the 
rat on cell proliferation, apoptosis and differential gene expression in the liver. Using 
the data obtained in study 1, study 2 was subsequently designed to both confirm and 
further investigate the effects of some of these compounds on expression of 4 
identified differentially expressed genes in other organs, in order to determine 
liver-specificity of the identified gene changes.
2.2.1.1 Study 1
Animal study 1 was carried out at GlaxoSmithKline Pharmaceuticals, Welwyn, 
Hertfordshire, U.K. and was undertaken in accordance with Her Majesty’s Home 
Office Department guidelines under the auspices of approved personal and project 
licences. Male Sprague Dawley rats (290-340 g) were obtained from Charles River 
(Portage, MI and Raleigh, NC). Upon receipt, animals were randomly assigned into 
groups of five. They were maintained on SQC Rat & Mouse maintenance Diet No. 1 
(Special Diet Services Ltd), and a daily cycle of alternating 12-hour periods of dark 
and light. The room temperature was maintained at 21 °C and 55 % relative 
humidity. The animals were acclimatised to this environment for seven days before 
treatment commenced. Groups of 5 rats were administered intra-peritoneally (i.p.) 
one of the following 4 compounds in com oil or saline vehicle: phénobarbital 
(50 mg/kg), Wy-14,643 (50 mg/kg), dexamethasone (100 mg/kg) or cyproterone 
acetate (60 mg/kg), whilst control groups received an equal volume of com oil or 
saline, daily for 3 days. Injections were administered at 9 am each day. During this 
time, all animals had free access to food and water. Animals were killed by cervical 
dislocation at 6 different time-points: la, lb, Ic -  2, 12, 24 hours respectively after 1 
dose; 2 - 2 4  hours after 2 consecutive daily doses (48 hours); and 3a, 3b -  24 and 48 
hours respectively after 3 consecutive daily doses (72 and 96 hours respectively). 
Livers were immediately excised, weighed, sliced into approximately 0.5 cm cubes, 
snap frozen in liquid nitrogen and stored at -  80 °C.
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2.2.1.2 Study 2
Animal study 2 was carried out at University of Surrey, Guildford, Surrey, U.K. and 
was undertaken in accordance with Her Majesty’s Home Office Department 
guidelines under the auspices of approved personal and project licences. Male 
Sprague Dawley rats (270-340 g) were obtained from Charles River (Portage, MI and 
Raleigh, NC). Upon receipt, animals were randomly assigned into groups of five and 
housed under controlled conditions. They were exposed to a daily cycle of alternating 
12-periods of dark and light, and allowed free access to food (Rat and Mouse 
Expanded Diet (B and K Universal)) and water. The room temperature was 
maintained at 21 ± 1 °C. The animals were acclimatised to this environment for seven 
days before treatment commenced. Groups of 5 rats were administered (i.p.) one of 
the following 3 compounds in com oil vehicle: Wy-14,643 (50 mg/kg), 
dexamethasone (100 mg/kg) or cyproterone acetate (60 mg/kg), whilst the control 
group received an equal volume of com oil daily for 3 days. Injections were 
administered at 9 am each day. Animals were killed by cervical dislocation at 3 
different time-points: Ic -  24 hours after 1 dose; 2 - 2 4  hours after 2 consecutive 
daily doses (48 hours); 3a -  24 hours after 3 consecutive daily doses (72 hours). 
Livers, spleens, testes, kidneys, hearts, lungs, and brains were immediately excised, 
weighed, snap frozen in liquid nitrogen and stored at -80 °C.
2.2.2 Identification of differentially expressed genes
The method of identification of differentially expressed genes that has been optimised 
and utilised successfully in the molecular toxicology laboratory at the University of 
Surrey and is used in this project is Suppression Subtractive Hybridisation (SSH). 
SSH requires the initial isolation of mRNA and its conversion to cDNA before 
utilising a method of subtraction of one cDNA population from another in order to 
identify genes that are differentially expressed.
Typically, the major drawback of subtractive cDNA libraries it that the original 
disproportion in concentrations of different types of transcripts is preserved -  this 
usually makes isolation of specific rare transcripts extremely difficult. This may be a 
problem, as this minor fraction is likely to be of particular interest, since transcripts 
for many regulatory proteins fall into this category. However, Diatchenko et a l, 
1996, performed one of the most recent adaptations of the subtractive hybridisation
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approach to differential display, in which a high enrichment of rare cDNAs is 
obtained without the need for multiple hybridisations/subtractions. Populations are 
‘normalised’ in that concentrations of rare and abundant transcripts are equalised. In 
conjunction with this, target differentially expressed molecules are enriched while the 
amplification of undesirable sequences is actively prevented. This occurs by the use 
of a Polymerase Chain Reaction (PCR)-based suppression system instead of physical 
or chemical removal of the common sequences.
Livers from animals killed 12 and 24 hours following one dose of Wy-14,643 in study 
1 were used in the initial identification of differentially expressed genes, and the 
various stages of the procedure are described below.
2.2.2.1 mRNA extraction
Approximately 100 mg of each frozen liver sample (animals killed 12 and 24 hours 
following 1 dose of Wy-14,643) was ground under dry ice using a mortar and pestle. 
Messenger RNA was extracted from the ground liver using the PolyATract® System 
1000 kit (Promega). The method involved hybridisation of a biotinylated oligo-dT 
probe to the poly-A tail of mRNA in homogenised liver. The hybridised mRNA 
particles were then captured with streptavidin paramagnetic beads (SA-PMPs). The 
mRNA was eluted from the beads using nuclease-ffee water. The concentration of 
mRNA was measured using a Genequant^^ II spectrophotometer (Pharmacia Biotech), 
and was found to range between 20 and 60 pg/ml.
10 p.1 of each sample was run on a 1.5 % agarose gel containing 0.5 pg/ml ethidium 
bromide. Quality of the mRNA was assessed by analysis of the size of the smear 
obtained (typically 1-3 kb).
Ethanol precipitation (section 2.2.6.6) was then carried out on the remaining mRNA 
and concentrated mRNA was resuspended in 4 p.1 nuclease-free water.
2.2.2.2 cDNA subtraction
Subtractions were carried out with 2.5 pg mRNA derived from single animals.
The extracted, concentrated mRNA (section 2.2.2.1) was first converted to double­
stranded cDNA, which was then taken through the stages of SSH. cDNA subtraction 
was carried out using the PCR-Selecf^’^  cDNA Subtraction Kit (Clontech). The 
procedure is described below and is illustrated in Figure 2.3.
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Figure 2.3 Schematic diagram of equalising cDNA subtraction procedure with 
the use of PCR suppression effect (Adapted from Gurskaya et a l, 1996)
Tester A cDNA with adaptor 1 Driver cDNA 
(in excess)
Tester B cDNA with adaptor 2
First hybridisation
Second hybridisation 
mix samples, add fresh denatured driver, and anneaL
a, b, c, d,
Fill in ends
I  Add primers and amplify by PCR
a, d no amplification (missing primer annealing sites) 
b no amplification (suppressed due to formation of pan-like structure)
c linear amplification (only one primer annealing site)
e Exponential amplification (two different primer annealing sites)
Figure 2.3 In the primary hybridisation, an excess of driver cDNA is added to each tester cDNA 
population, the samples heat denatured and allowed to hybridise. This serves two purposes (1) 
equalises rare and abundant molecules; and (2) enriches for differentially expressed sequences -  
cDNAs that are not differentially expressed form type c molecules with the driver. In the secondary 
hybridisation, the 2 primary hybridisations are mixed together without denaturing. Fresh denatured 
driver is also added to allow further enrichment of differentially expressed sequences. Type e 
molecules are formed in this secondary hybridisation which are subsequently amplified using 2 rounds 
of PCR. g g  represent adaptor 1; n  represent adaptor 2.
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The process of SSH may be divided into 2 main stages. ‘Driver’ refers to ‘control’, 
and ‘tester’ to ‘treated’ samples.
Stage 1 :
Excess driver cDNA (from control samples) was added to 2 portions (A and B) of 
tester cDNA (from treated samples) which had been ligated with double-stranded 
adaptors, 1: H  and 2: CZl at their 5' ends. The samples were melted and left to 
anneal. This first round of hybridisation serves to enrich differentially expressed 
genes and equalise rare and abundant messages. During hybridisation, tester 
molecules that have a complement in the driver (known as ‘redundant molecules’) 
mostly form driver-tester heterohybrids and are removed from the single-stranded 
fraction. This is much more likely to occur for the more abundant redundant 
molecules due to the second-order kinetics of hybridisation, and leads to the 
approximate equalisation of concentrations of various types of single-stranded 
redundant molecules, (the concentrations of highly abundant molecules drop to the 
level of low-abundance molecules).
Stage 2:
Without denaturing, the two primary hybridisation mixes were then mixed together in 
the presence of excess driver and allowed to hybridise further. This step allows the 
annealing of single-stranded complementary sequences that did not hybridise in the 
primary hybridisation, and in doing so generates templates for PCR amplification. 
Two PCR reactions were then carried out to amplify the desired differentially 
expressed sequences. The first involved the addition of primers identical to the most 
5’ sequences (outer edge) of the adaptors 1 and 2. Although there are several possible 
combinations of the single-stranded molecules present in the secondary hybridisation 
mix, only one particular combination (differentially expressed in the tester cDNA 
composed of complimentary strands having different adaptors) can amplify 
exponentially. Once the suppression PCR had been carried out (Figure 2.3), a second 
PCR was performed using nested primers. These primers have an identical sequence 
to the inner sequences of both adaptors 1 and 2. This results in further enrichment of 
the differentially expressed sequences, and reduces any background PCR products. 
(Diatchenko et aL, 1996; Gurskaya et al., 1996, Rockett et a l, 1999)
All primers used in SSH were those provided with the PCR-Select™ cDNA 
Subtraction Kit, the sequences of which are in Table 2.1.
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Table 2.1 Sequences of adaptors and primers used in SSH
Sequence (5'-3')
Adaptor 1 g g GTATACGACTCACTATAGGGCTCGAGCGGCCGCCCGGGCAGGT
Adaptor 2 q TGTAGCGTGAAGACGACAGAAAGGGCGTGGTGCGGAGGGCGGTG
CCTCCCGCCA
Primer 1 GTATACGACTCACTATAGGGC
Primer 2 TGTAGCGTGAAGACGACAGAA
Nested primer 1 TCGAGCGGCCGCCCGGGCAGGT
Nested primer 2 AGGGCGTGGTGCGGAGGGCGGT
2.2.2.3 Band extraction and cloning
Solutions:
Luria-Bertani agar (LB agar): 
10 g Tryptone 
5 g Yeast Extract 
10 g Sodium chloride 
IL Milli-Q water
Divided into 500 ml Durans
7.5 g Bacto-Agar added to each, autoclaved
Secondary PCR reactions from the cDNA subtraction procedure were run on a 2 % 
MetaPhor agarose gel containing 0.5 pg/ml ethidium bromide. Gels were run for 1.5- 
2 hr at 3 V/cm. DNA from each differentially expressed band was stabbed out of the 
gel and individually re-amplified by repetition of the secondary PCR reaction using 
the original nested PCR primers supplied with the PCR-Select™ cDNA Subtraction 
kit. 8 pi of each PCR product was then run on a 2 % standard agarose gel to ensure 
an individual band had been amplified in each reaction. 1 pi of each PCR product 
was immediately ligated into a pCR®2.1-T0P0 vector (Figure 2.1) (Invitrogen) 
before transformation in Escherichia coli TOPI OF' One Shot™ cells (Invitrogen) 
according to the manufacturer’s instructions. Colonies were grown up overnight at 
37 °C on LB-Agar plates containing ampicillin (100 pg/ml), X-gal (15 mg/ml), and 
IPTG(0.1 pg/ml).
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2.2.Z.4 Colony screening
Solutions:
Luria Broth (LB medium): 
10 g Tryptone 
5 g Yeast Extract 
10 g Sodium chloride 
1 L MilliQ water
 ^ Divided into 500 ml Durans, autoclaved
Five white transformed colonies (each theoretically containing an insert) derived from 
each differentially expressed band were grown up overnight in 5 ml LB medium 
containing 50 pg/ml ampicillin. Purified plasmid was prepared from 1.5 ml of each, 
using Wizard Plus SV Minipreps DNA Purification System (Promega).
2.2.2.5 Restriction digest
Restriction digest analysis was then carried out on each of the minipreps to confirm 
presence of an insert. For each miniprep, a 20 pi reaction was set up:
Volume (uB
lOx enzyme buffer (Promega) 2
Bovine serum albumin (Acetylated) (1 mg/ml) 2
Plasmid DNA (0.2-1.0 pg) 5
Restriction enzyme EcoRl (10 u/pl) (Promega) 1
nuclease-free water up to a total reaction volume of 20 pi
Reactions were incubated at 37 °C for 2 h. The digested products were analysed by 
electrophoresis on 1 % agarose gels containing 0.5 pg/ml ethidium bromide.
Those samples shown to contain inserts were quantified using a Genequanf^” II 
RNA/DNA calculator.
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2.2.2.6 Dot blots
Solutions:
Dénaturation solution: Neutralisation solution (pH 7.5):
1.5MNaCl 1.5MNaCl
0.5 M NaOH 0.5 M Tris HCl
Each plasmid miniprep containing an insert was used to prepare duplicate dot blots on 
Hybond N+ membranes.
An equal volume of 0.4 M NaOH was added to 500 ng of each of the plasmid DNA 
clones, which were then denatured by heating at 95 °C for 10 min and placed on ice. 
Each sample was then blotted in duplicate. After blotting, dénaturation and 
neutralisation steps were carried out. This involved placing the blot on top of 3 MM 
Whatman filter paper (Amersham) soaked in dénaturation solution for 10 mins, then 
on more filter paper soaked in neutralisation solution for 5 mins. The blot was then 
sandwiched between 2 fresh pieces of filter paper, placed in a 37 °C incubator to dry, 
followed by baking at 80 °C for 2 hours in a vacuum oven.
The duplicate dot blots were then probed with 500 ng of (a) the final differential 
display reaction and (b) the ‘reverse-subtracted’ differential display reaction (see 
section 2.2.2.2). To make the ‘reverse-subtracted’ probe, the subtractive hybridisation 
step of the SSH procedure was carried out using the original tester (treated) mRNA as 
the driver and the original driver (control) mRNA as the tester. Probing and 
visualisation were carried out using the ECL Direct Nucleic Acid Labelling and 
Detection System (Amersham) according to the manufacturer’s instructions. Those 
clones that were positive for (a) but negative for (b), or showed a larger positive 
signal with (a) compared to (b), were considered to be differentially expressed and so 
were selected for DNA sequence analysis.
2,2.3 Gene identification
2.2.3.1 DNA sequencing
The cloned inserts (differentially expressed sequences) were sequenced using the M l3 
Reverse Primer (AACAGCTATGACCATG). Sequencing was carried out at the core 
sequencing facility, GlaxoSmithkline, using the ABI Prism® BigDye Terminators 
cycle sequencing kit (version 3.0) (Applied Biosystems) and an ABI3700 capillary
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autosequencer. The method is based on the Sanger method of sequencing (Sanger et 
al, 1977) involving the attachment of base-specific fluorescent terminator-dyes to the 
end of each DNA fragment, which are then detected by laser activation.
2.2.3.2 Identification of differentially expressed genes
Insert sequences were identified and isolated from the vector, so that they could then 
be matched against the EMBASE database using the BLAST algorithm 
(http://www.ncbi.nlm.nih.gov/) (Altschul e ta l, 1997).
The sequence match of the highest ‘score’ (greatest similarity and length) was 
recorded as the sequence identification.
2.2.4 Quantitation
2.2.4.1 Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of 
selected candidate genes
Although time-consuming, semi-quantitative RT-PCR is a reliable method that may 
be used for confirmation of differential expression. It is ‘ semi’-quantitative in that it 
does not provide actual values for the amount of target sequence present in the 
mRNA, it simply provides a comparison of relative levels between samples. 
mRNA, PCR reagents and reverse transcriptase are initially incubated at a 
temperature optimal for reverse transcription (41 °C -  48 °C), immediately followed 
by incubation at 95 °C to inactivate the reverse transcriptase. This is then followed by 
a standard PCR reaction to amplify the required product.
The time-consuming part includes design of suitable primers and optimisation of 
reaction conditions for each individual gene species. Usually, both annealing 
temperature and number of cycles are altered a number of times before optimum 
results are achieved.
For RT-PCR assays, the use of a ‘house-keeping’ gene as an internal control can be 
used as an active reference to normahse experimental results. It is essential that this 
internal standard does not change its level of expression in the cell regardless of cell 
age, stage in the cell cycle, or through effects of external stimuli (Rockett et a l, 
1999). Numerous reference genes have been utilised in previous experiments which 
include interferon-gamma (IFN-y) (Frye et a l, 1989), fFactin (Heuval et a l, 1994),
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glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Wong et a l, 1994) and 
albumin (Rockett et al, 2000), to name but a few.
2.2.4.1.1 Primer design
oDNA sequences of the target genes (sequence matches obtained following BLAST 
searches) were obtained from the NIH gene database (http:/www.ncbi.nlm.nih.gov/) 
and the computer programme Vector NTI 4.0 (InforMax, Inc) used to select primer 
pairs from these sequences. Primer parameters were set at 15-30 base pairs in length, 
% GC content ranging between 45-60, and primeritarget annealing temperature (Tm) 
between 45 °C -  75 °C. Primers (MWG-Biotech U.K. Ltd.) were reconstituted at a 
concentration of 50 pmoles/pl in nuclease-free water and stored at -20 °C. All primer 
sequences are listed in Table 2.2.
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2.2.4.1.2 Primer optimisation
Optimisation of the reaction conditions was necessary in order to obtain a clear PCR 
product of the correct size. Optimisation was achieved by altering the number of PCR 
cycles and/or annealing temperature. If optimisation proved difficult 2 M N,N,N- 
trimethylglycine (Betaine) was added (Mytelka and Chamberlin, 1996; Henke et al, 
1997). Kinetic analysis (10-40 cycles) was then performed in each case to determine 
the location of the mid-exponential phase (Figure 2.4). The optimised RT-PCR 
conditions and mid-exponential phase cycle number for each target gene are given in 
Table 2.3. RT-PCR was attempted for transcription factor IID and glutathione 
peroxidase with a number of different sets of primers over a range of conditions, but 
no product of the correct size could be obtained for either of the two genes.
Figure 2.4 Determination of mid-exponential phase for PCR amplification of 
transferrin (using densitometry)
2000
3 1000
20 25
Cycle num ber
__ __ _ Transferrin PCR 
product formation
Cycle number for RT-PCR analysis was chosen within this region (cycle 17) as the level o f  
product is rapidly increasing and production is clearly within the exponential phase. After 
cycle 19, the rate o f production o f the required PCR product declines as it approaches a 
maximum level.
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Table 2.3 Optimised RT-PCR conditions for the target genes
Target gene Annealing temperature 
("C)
Cycle
number
2M Betaine
+/-
Albumin 60 15 -
Apolipoprotein E 60 30 +
Arginine vasopressin receptor (Via) 55 31 -
Carboxylesterase 60 24 +
Cathepsin H 60 28 +
D-dopachrome tautomerase 55 22 -
Fetuin (pp63) 60 26 +
Kupffer cell receptor 60 21 +
Metallopanstimulin 55 26 -
Preproalbumin 60 13 -
Selenoprotein P 60 24 -
Slow myosin binding protein C 55 30 -
Superoxide dismutase 55 30 +
Transferrin 60 17 -
tRNAs 60 18 -
Ubiquitin activating enzyme E l 60 32 -
2.2.4.1.3 Semi-quantitative RT-PCR analysis
mRNA was extracted as described (section 2.2.2.1) from livers from all animals killed 
12 and 24 hours after 1 dose of Wy-14,643 (study 1), and the concentration measured 
using a Genequant^^ II spectrophotometer. RT-PCR was carried out for each mRNA 
sample individually in a single tube (50 pi) reaction using Ready-To-Go^"  ^RT-PCR 
beads (Amersham Pharmacia Biotech) according to the manufacturer’s instructions. 
100 ng of mRNA was used in each reaction.
Albumin was selected as the reference gene as it has previously shown to be 
unchanged in rat liver following treatment with Wy-14,643 (Rockett et a i, 1999).
For the semi-quantitative analysis of each target gene, RT-PCR reactions for all 
samples were repeated in triplicate. Amplification of albumin (the reference gene) 
was carried out for each sample, but in separate tubes, as due to its high abundance
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the mid-exponential phase of this gene is at a much lower cycle number than the 
target genes.
For each reaction, nuclease-free water was added to each bead to give a final total 
volume of 50 pi, once primers, RNA and betaine (where necessary) had been added, 
and the bead allowed to dissolve on ice. 100 ng of mRNA was then added along with 
2 pi of primer from a previously made master mix of up- and down-stream primers 
(50 pmol of each primer per reaction). All RT-PCR reactions were carried out in a 
Peltier Thermal Cycler (MJ-Research PTC-200, DNA-engine), and cycled as shown 
in Figure 2.5.
Figure 2.5 RT-PCR Cycling
mRNA: First-strand synthesis 
Reverse transcription (RT): 
Inactivation of 
reverse transcriptase:
cDNA: PCR Amplification
Dénaturation
Annealing
Extension
48 °C for 45 mins
95 °C for 1 min
I
95 °C for 30 sec 
55-60 °C for 1 min 
68 °C for 1 min
15-32 cycles
8 pi of each RT-PCR product was analysed on a 2 % agarose gel containing 0.5 pg/ml 
ethidium bromide.
Quantitation of band intensity was carried out using an Imagemaster® YDS and 
Imagemaster® version ID software (Amersham Pharmacia Biotech).
Band intensity of target mRNA in control and treated samples were measured, 
normalised to albumin, and fold changes in target mRNA levels following treatments 
as compared to control were calculated. Statistical analysis of results was carried out 
using the Student’s t-test (section 2.2.6). Values were considered statistically 
significant at p < 0.05.
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2.2.4.2 Real-time PCR analysis (Taqman™) of selected candidate genes 
This is an example of quantitative PCR that measures product accumulation in real 
time. The system differs from a standard PCR procedure only in the addition to the 
reagent mix of a single agent, namely the fluorogenic probe designed to anneal to the 
target sequence. The probe is designed to hybridise within the target sequence and to 
generate a signal that accumulates during PCR cycling in a manner proportional to the 
concentration of amplification products. (Holland et al, 1991; Lee et a l, 1993). By 
this principle, the measurement of fluorescence in each sample provides a 
homogenous signal that is specifically associated with the amplified target and 
quantitatively related to the amount of PCR products. (Orlando et a l, 1998)
Principle
This 5' nuclease assay for detecting PCR products uses a non-extendable 
oligonucleotide hybridisation probe. The probe contains F AM (6-carboxy- 
fluorescein) as a fluorescent reporter dye covalently linked to the 5' end. The 
quencher dye TAMRA (6-carboxy-tetramethyl-rhodamine) is usually covalently 
linked to the 3' end. Because of the closeness of quencher to the reporter emitter, the 
reporter fluorescence is suppressed, mainly by energy transfer of Forster-type (Livak 
e ta l, 1995).
During PCR cycling, the primers and probe first specifically hybridise to the 
corresponding template. The probe is then cleaved via the 5' to 3' exonuclease 
activity of Taq DNA polymerase (Holland et a l, 1991). This cleavage results in an 
increase of fluorescence emission of the F AM reporter, without affecting the emission 
of quencher dye (since the emission intensity of the quencher dye varies only 
minimally during PCR, it is used to normalise variations in reporter dye emission 
intensities (Lie and Petropoulos, 1998)). This sequence of events occurs in each PCR 
cycle, without interference in the enzymatic reaction and PCR product accumulation. 
Since the exonuclease activity of Taq polymerase acts only if the fluorogenic probe is 
annealed to the target and the enzyme cannot hydrolyse the probe when it is free in 
solution, the increase of fluorescence is proportional to the amount of specific PCR 
product.
The steps of a typical Taqman reaction may be seen in Figure 2.6.
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Figure 2.6 Diagrammatic representation of the steps of a typical TaqMan 
reaction.
DNA dénaturation
I
Probe and primer annealing
5' Forward p i^ er
3 ' ---------------------
5' ______________
R = Reporter 
Q = Quencher
3'
5'
3'
5'
Reverse primer
Primer extension and 
strand displacement
5' ^
y  -  
y  _
î.
5'
3'
5'
5 ' exonuclease cleavage _
5' 
3' ■ 
5' .
?
S'
3'
5'
Continuing polymerisation 
5'
3 ' ---------
S' ______
S'
3'
5 '
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2.2.4.2.1 Total RNA extraction
Total RNA was extracted from all liver samples from study 1, and from five of the 
tissues removed from all of the animals from study 2. These five tissues were liver, 
spleen, testis, kidney and heart.
Approximately 80 mg of each frozen tissue sample was ground under dry ice using a 
mortar and pestle. Total RNA was extracted from the ground liver using the 
Bio/RNA-XCell™Xotàl RNA isolation system (Bio/Gene Ltd.). This method is based 
on the principle of a 14 M solution of guanidine salts and urea that act as denaturing 
agents and on the use of a specific RNA binding resin to purify total RNA from 
homogenised tissue. Bio/RNA-XCell ^ purifies the RNA by mixing the aqueous phase 
with RNA Binding Resin. The resin binds only the total RNA while other impurities 
are removed with 75 % ethanol. The pure RNA is eluted from the resin with 
nuclease-free water. The concentration of total RNA was measured using a 
Genequant^" II spectrophotometer (Pharmacia Biotech), and was found to range 
between 300 and 3500 pg/ml depending on the tissue.
5 pi of each extracted total RNA sample was run on a 1.5 % agarose gel, where RNA 
quality was assessed by analysis of the intensity of the 28S and 18S ribosomal RNA 
bands (Figure 4.4).
2.2.4.2.2 First-strand cDNA synthesis
cDNA synthesis was carried out on each total RNA sample (2.2.4.2.1). Where 
possible, 3 pg total RNA was used for each reaction. (As total RNA yields obtained 
from the heart samples were particularly low, only 1.5 pg of total RNA could be used 
for these samples). First-strand cDNA was synthesised using Superscript^^ First- 
Strand Synthesis System for RT-PCR (Life Technologies Ltd). The first-strand 
cDNA synthesis reaction was primed using random hexamers which means that all 
RNAs in a population are templates for first-strand cDNA synthesis, and the PCR 
primers confer specificity during PCR. For each sample, in addition to the standard 
reaction (RT+), a reaction containing no reverse transcriptase enzyme was also carried 
out (RT-). This was used to identify any genomic DNA contamination that may be 
present within the RNA samples. The system procedure is summarised in Figure 2.7.
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Figure 2.7 Superscript cDNA synthesis
RNA
Primer
First-strand synthesis
:
Removal of RNA
First-strand cDNA ready for PCR
Before Taqman experiments were performed, the prepared cDNA samples were first 
diluted in DEPC-treated water. For low abundance genes, cDNA was diluted 1:5 
{Kupffer cell receptor only) and for the higher abundance genes a 1:15 dilution was 
carried out. Heart cDNA was diluted appropriately as only half the amount of total 
RNA was used in the cDNA synthesis (section 2.2.4.2.2)
2.2.4.2.3 Primer and probe design
cDNA sequences of the target genes were obtained from the NIH gene database 
(http./www.ncbi.nim.nih.gov/). Primers were designed against those gene sequences 
previously selected for RT-PCR. For p21 the rat sequence was used, but for nekl no 
rat sequence was available therefore the mouse sequence was selected. Matching 
primers and fluorescence probes were designed for each of the genes according to the 
Primer Express™ version 1 software (Applied Biosystems). Probes were obtained 
from Applied Biosystems and primers from Sigma-Genoys Ltd. The guidelines used 
in primer and probe design are shown in Table 2.4. Sequences of primers and probes 
used are shown in Table 2.5.
94
2
0:m1
I
O
I
I
I
0JQ
1
-S
e
93I
Tf
N
I
H
0  
00
ô
m
1
s
Io
Ü
1
<2
I
I
I
1§%
C
I
»h
g
Ü
§
I
rh
93
I
I
I
IX>
u
Î
0
(N
1
I
§
!
I%
I
II
Uo
0  
<U 
T3
1 
Itw
01
0  :
1
Ü
'B
u0
I
i
I
1
1
.S
1
I
1
I
I
o
%a
%
I
«J
1
1)
.o
2
3
. §
O h
I
1%
I
s
93a
O '
H
I
Ir
aI
-og
«IP4
V)
ri
I
H
i
i a .
ÎC.
113
O
Ü;
I I %
Ov
II
§
I
I
}
I
i
15
2.2.4.2.4 Primer and probe optimisation
Both primer and probe concentrations were optimised in order to determine the 
minimum concentrations that give the highest ARn (instrument software provides this 
value representing the amount of annealed probe cleaved by the 5'-3' exonuclease 
activity of Taq polymerase during amplification), with the lowest Ct (threshold cycle - 
where the sequence detection application begins to detect the increase in signal 
associated with exponential growth of PCR product). This is performed in order to 
achieve optimum efficiency of the PCR reaction, and to ensure that the 3 phases of the 
reaction may be seen over the 40 cycles of the reaction (Figure 2.8).
Figure 2.8 Typical Taqman amplification plot illustrating ARn and Ct, and the 
phases of a PCR reaction
2.0 Phase 3  -  linear
1.5
R n
Phase 2  -  exponential1.0
Phase 10.5
Q
Cycle number
each illustrates a different sample
Optimisation was performed using 5 pi diluted cDNA obtained from control liver 
(section 2.2.4.2.2) in a 25 pi reaction total.
First, the primer concentrations were optimised, keeping the probe concentration 
constant at 200 nM.
The primer concentration combinations used in optimisation are shown in Table 2.6.
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Table 2.6 Primer combinations used in optimisation
Forward primer (nM)
Reverse primer (nM) 50 200 800
50 50/50 200/50 800/50
200 50/200 200/200 800/200
800 50/800 200/800 800/800
Having selected the optimum forward and reverse primer concentrations, the optimum 
probe concentrations were then determined. The optimised primer concentrations 
were kept constant and the effect of changing probe concentration was then 
investigated. Probe concentrations ranged between 25-225 nM, increasing by 
increments of 25 nM.
Optimised primer and probe concentrations are shown in Table 2.7.
Table 2.7 Optimum primer and probe concentrations
GENE
Concentration (nM)
Forward primer Reverse primer Probe
Carboxylesterase 200 200 200
Cathepsin H 200 800 225
Kupffer cell receptor 200 200 200
Ubiquitin activating enzyme E l 200 200 200
p21 200 200 200
nek 2 200 800 200
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2.2.4,2.5 Taqman analysis
Samples were prepared as for a standard PCR reaction as shown below:
Volume (pi)
Taqman Universal PCR mix (Applied Biosystems) 12.5
cDNA 5
Optimised concentrations of primer and probe 
DEPC-treated water to a final total volume of 25
Samples were set-up in 96-well plates, each of which were prepared in duplicate. A 
master-mix of reaction mix was prepared for each duplicate set of plates. Each plate 
included a standard curve, buffer blanks (containing no DNA), and RT+ and RT- 
cDNA for each sample (section 2.2.4.2.2). For the standard curve, sample cDNA was 
substituted with 5 pi rat genomic DNA (Promega), dilutions ranging from 
0.2 X 10^  copies/pl to 0.2 x 10^  copies/pl.
All real-time PCR (Taqman) analysis was performed in an ABI PRISM® 7700 
Sequence Detector (Applied Biosystems), and cycled as shown in Figure 2.9.
Using the standard curve, the ABI PRISM® 7700 instrument determines the initial 
copy number of the target template by analysing the cycle-to-cycle change in 
fluorescence signal as a result of the amplification of template during PCR. The
fewer cycles it takes to reach a detectable level of fluorescence, the greater the initial
copy number. Copy numbers of target mRNA in both control and treated samples 
were obtained and fold changes of target mRNA levels in treated samples as 
compared to control calculated. Statistical analysis of results was carried out using 
the Student’s t-test (section 2.2.6). Values were considered statistically significant at 
p<0.05.
Figure 2.9 Taqman PCR cycling
Stage 1: 50 ®C for 2 min
Stage 2: 95 °C for 10 min
Stage 3: 95 °C for 0.1 min (dénaturation)
60 ®C for 1 min (annealing) J  40 cycles 
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2.2.4.3 RT-PCR v Taqman
As the gene expression quantitation achieved by RT-PCR for Wy-14,643 samples (12 
and 24 hours after 1 dose) was repeated in the Taqman studies, the data were 
compared. It was observed that the RT-PCR and Taqman data obtained did not 
correspond for all of the genes. Therefore experiments were designed in order to 
determine the reason for this difference and to confirm which data were true.
2.2.4.3.1 RT-PCR and Taqman product confirmation
All RT-PCR products were sequenced and their identities as well as those of products 
obtained following Taqman experiments confirmed via BLAST searches as described 
previously (section 2.2.3.2).
2.2.4.3.2 Semi-quantitative RT-PCR using Taqman components
Components of the RT-PCR and Taqman reactions differ, this is shown in Table 2.8.
Table 2,8 RT-PCR and Taqman components
RT-PCR Taqman
RNA mRNA total RNA
RT-step gene-specific primers random hexamers
RT-PCR reactions were therefore performed as follows in an attempt to replicate 
conditions used for Taqman experiments:-
a) Using total RNA and gene-specific primers for the reverse transcriptase step 
Reactions were set-up substituting mRNA with total RNA and cycled as previously 
(section 2.2.4.1.3). 0.5 pg of total RNA per reaction was used in initial experiments, 
which was later reduced to 0.05 pg. This was because the greater amount of RNA 
produced bands of high intensity making analysis difficult.
b) Using total RNA and random hexamers for the reverse transcriptase step 
Reactions were set-up substituting mRNA with 0.05 pg total RNA, and replacing 
gene-specific primers with 2.5 pg random hexamers supplied with the Ready-To-Go 
RT-PCR kit used previously (section 2.2.4.1.3). Following the 45 min RT-step and
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2 min RT deactivation step, the reaction was paused briefly while the gene-specific 
primers were added to the tube. Reactions were then cycled as previously (section 
2.2.4.1.3).
8 pi of each RT-PCR product was analysed on a 2 % agarose gel containing 0.5 pg/ml 
ethidium bromide.
Quantitation of band intensity was carried out using an Imagemaster® VDS and 
Imagemaster® version ID software (Amersham Pharmacia Biotech).
Band intensities of target mRNA in control and treated samples were measured, and 
fold changes in target mRNA levels following treatments as compared to control were 
calculated. Statistical analysis of results was carried out using the Student’s t-test 
(section 2.2.6). Values were considered statistically significant at p < 0.05.
2.2.5 Kupffer cell receptor quantitation
2.2.5.1 Immunocytochemistry
This was carried out using a mouse monoclonal antibody to human CD68 
(Biogenesis), an antigen found specifically on macrophages (Lapis et a l, 1995).
2.2.5.1.1 Preparation of slides
Control rat and human liver that had been previously formalin fixed and wax 
embedded (archived stocks of University of Surrey) were used for initial experiments. 
5 pm sections were cut using a microtome (LKB Historange). Sections were cut as a 
ribbon and floated out onto distilled water at 50 °C in a water bath. Mounted needles 
were used to separate sections and remove any creases if necessary. Once all wrinkles 
had disappeared from the tissue, each individual section was picked up onto a clean 
poly-L-lysine microscope slide by half submerging the slide in water, positioning it 
near the section and withdrawing it, so bringing the section with it. Slides were 
placed overnight on a slide-drying hot plate.
2.2.5.1.2 Antibody staining
Sections were first de-waxed by submerging the slides in xylene for 3 mins and then 
rehydrated by passing slides through decreasing concentrations of alcohol (100 %, 
70 % and 50 %, each for 1 min). Slides were then immersed for 10 mins in blocking
1 0 0
reagent (1/3 hydrogen peroxide, 2/3 methanol), followed by washing for 10 mins in 
running water. Slides were then incubated for 30 mins in 1% BSA in 25 mM Tris 
saline buffer pH 7.5, before incubation overnight in primary antibody (CD68 
(Biogenesis)) (at the optimised working dilution *) at 4 °C in a humidity chamber. 
The next day, slides were rinsed for 2 x 10 mins in 25 mM Tris saline buffer pH 7.5, 
and then incubated for 40 mins in secondary antibody (compatible horseradish 
peroxidase-conjugated anti-mouse IgG (Santa Cruz)). Slides were again rinsed for 2 x 
10 mins in 25 mM Tris Saline buffer pH 7.5. Antibody binding was detected using 
Sigma Fast™ 3, 3 ’-diaminobenzidine (DAB) peroxidase substrate tablet set (Sigma). 
This involved dissolving one DAB and one H2O2 tablet in 15 ml of distilled water, 
and covering the tissue section with 0.2 to 0.5 ml of this solution. Antibody binding 
was monitored by light microscopy for the fast development of a brown-black 
precipitate. The formation of this precipitate indicates the position of target antigen 
sites.
The reaction that takes place is shown below: -
Peroxidase + 2 H2O2 ->02 + 2 H2O2
O2 + DAB insoluble, brown-black precipitate
* Optimisation of working dilution of primary antibody
Primary antibody was tested over a range of dilutions (in 25 mM Tris Saline buffer 
pH 7.5) -  1:500, 1:1000, 1:2000, 1:4000 while keeping the concentration of the 
secondary antibody constant -  1:4000 dilution.
2.2.S.2 In situ hybridisation
In situ hybridisation involves the localisation of specific mRNA species using an 
antisense radiolabelled RNA probe.
This was carried out on rat liver sections from study 2 (section 2.2.1.2) using a probe 
specific for the Kupffer cell receptor, and one specific for the positive control 
cytochrome P450 4A1 (CYF4A1).
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2.2.5.2.1 Preparation of slides
10 pm sections of frozen rat liver were cut using a cryostat and placed onto poly-L- 
lysine slides using forceps. Sections were fixed by immersing slides in 4 % 
formaldehyde for 1 hour at room temperature.
2.2.5.2.2 Probe preparation
a). Preparation of cDNA template
A standard RT-PCR reaction was performed using mRNA extracted previously 
(section 2.2.2.1) and primers to the gene of interest. Primer details may be seen in 
Table 2.2 and 2.9 for the Kupffer cell receptor and CYP4A1 respectively. All RT- 
PCR reactions were performed under the optimised conditions (Table 2.3 for Kupffer 
cell receptor). For the amplification of CYP4A1, reactions were cycled 22 times at an 
annealing temperature of 57 °C in the absence of betaine, as previously optimised 
(K. Swales, personal communication)). This provided the cDNA template encoding 
the gene of interest.
Table 2.9 Primer sequences for CYP4A1
GENE Accession
number
Primer sequences (5'-3') 
Upstream Downstream
Amplicon size 
(no. of base pairs)
CYP4A1 M14972 GATGGCTGCACCATGAG GGCCTTTGGATCTGATC 357
b). Ligation and cloning
2 pi of each RT-PCR product was immediately ligated into pGEM®-T Easy vector 
(Promega) (Figure 2.2) and left overnight at 4 ®C. Components of the ligation 
reaction are shown below:
T4 DNA Ligase lOx Buffer (Promega) 
pGEM®-T Easy vector (50 ng)
RT-PCR product
T4 DNA Ligase (3 Weiss units/ul) (Promega) 
Nuclease-free water to a final volume of
Volume (ul) 
1 
1 
2 
1
10 pi
1 0 2
Plasmid vectors were then transformed into Escherichia coli TOPI OF' One Shot™ 
cells (Invitrogen) according to the manufacturer’s instructions.
Colonies were grown up, plasmid minipreps carried out and insert presence confirmed 
as previously described (section 2.2.2.S -  2.2.2.5). In order to confirm insert 
identification, plasmids were sequenced and insert sequences matched against the 
EMBASE database using the BLAST algorithm as previously described (section 
2.2.3.1-2.2.3.2).
pGEM®-T Easy was selected as the vector as it contains both T7 and SP6 RNA 
polymerase transcription initiation sites, each one side of the insert (Figure 2.2). 
These are utilised during the transcription of RNA for use as the probe (step (e)).
c). Determination of insert orientation
Before the probe could be made, the orientation of the insert was first identified. This 
was essential in order to determine which RNA polymerase could be used in the later 
transcription reaction in order to synthesise antisense/sense RNA. Orientation was 
determined by restriction digestion (as previously described, section 222.5) with 
Sad  (Promega), and analysis of product size. Restriction enzyme selection was made 
on the basis that it would cut the vector a minimum number of times with the products 
obtained clearly distinguishing orientation of the insert. This procedure allowed 
selection of the appropriate RNA polymerase to be made.
d). Plasmid linearisation
This was performed by restriction digestion as previously described, this time using 
the restriction enzymes Sail or Ncol (Promega). These enzymes were selected as 
they cut at only one side of the insert and not elsewhere within the plasmid or insert 
(Figure 2.2). Once linearised (determined by gel electrophoresis), the plasmid was 
extracted twice with phenol:chloroform (v/v 1:1) (section 2.2.6.5), and then 
precipitated from the aqueous phase by ethanol precipitation (2.2.6.6).
The pellet was resuspended in 10 pi nuclease-ffee water.
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e) Transcription
Transcription was carried out using the Riboprobe in vitro Transcription System 
(Promega) and was assembled at room temperature in the order as shown below.
Volume (ul)
Transcription Optimised 5x Buffer 4
DTT, 100 mM 2
Recombinant RNasin Ribonuclease Inhibitor (20 u) 1 
A, G, CTP mix (2.5 mM each) 3
Water 6
lOOmMUTP 1
[a-^^S]UTP (Amersham Pharmacia Biotech) 5 (2-6 MBq)
DNA 2 (0.5-1.0 pg)
RNA polymerase (SP6/T7) 1
Two transcription reactions were performed, one for synthesis of antisense RNA 
(probe for target), the other for synthesis of sense RNA (probe for background). 
Transcription was allowed to occur for 1 hour at 37 °C for T7 RNA polymerase or at 
42 °C for SP6 RNA polymerase.
f)DE-81 test
Efficiency of [a-^^S]UTP incorporation was tested using DE-81 ion-exchange filters. 
One filter was cut in half and 1 pi of probe solution dotted on each side and allowed 
to evaporate. One half of the filter was then washed 4 times for 2 mins in Na2HP0 4 , 
rinsed briefly in ethanol and allowed to dry. Counts per second (cps) on washed and 
unwashed filters were then compared.
Percent [a-^^S]UTP incorporated = cps washed filter x 100
cps unwashed filter
Incorporation had to be greater than 60 % for use in in situ hybridisation.
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2.2.S.2.3 In situ hybridisation
For each experiment, one liver section was probed with the antisense radiolabelled 
RNA probe, another with the sense radiolabelled RNA probe, in order to distinguish 
target binding from background.
a) Prehybridisation 
Solutions:
Proteinase K solution: 
0.1 M Tris pH 8.0 
50mMEDTApH8.0 
1 pg/ml proteinase K
Acétylation mix:
0.1 M triethanolamine (TEA) pH 8.0 
0.25 % (v/v) acetic anhydride
20 X SSC (pH 7.3):
88.23 g sodium citrate 
175.32 g sodium chloride 
ILMilliQ-Water
Slides were first incubated in Proteinase K solution for 10 mins (to permeabilise the 
tissue and increase probe accessibility), rinsed briefly in water, then rinsed for 2 mins 
in 0.1 M TEA, pH 8.0. Following this, slides were incubated for 10 mins in 
acétylation mix to remove positive charges left by the proteinase K treatment (to 
prevent non-specific binding of the probe to positively charged amino groups), then 
rinsed 2 x 2  mins in 2 x SSC. Sections were then dehydrated in ascending 
concentrations of ethanol (50, 70, 95, 100, 100 % ethanol for 3 mins each). Slides 
were drained well and allowed to dry for 2 hours in a fume-hood.
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b) Hybridisation 
Solutions:
Hybridisation solution: 1 x Denhardt’s:
50 % (v/v) formamide 0.2 % bovine serum albumin
10 % dextran sulphate 0.2 % Ficoll
300 mM NaCl 0.2 % Polyvinylpyrollidone
1 X Denhardt’s solution
10 mM Tris pH 8.0
lmM EDTApH8.0
10 mM Dithiothreitol (DTT)
0.5 mg/ml tRNA
3 pl of previously synthesised probe (section 2.2.5.2.2) was added to 80 pi of 
hybridisation solution which was then heated at 65 °C for 10 mins using a heat block. 
The solution was then centrifuged at 5,000 g for 10 mins to remove any dextran 
sulphate precipitates that may have formed. 80 pi of hybridisation solution was then 
applied in a semicircle to a 50 x 22 mm coverslip. The microscope slide was then 
rolled over the coverslip, in order to pick up the coverslip without producing any air 
bubbles. The edges of the coverslip were sealed with DPX mountant and left to diy 
for 30 mins. Slides were then incubated overnight (16 hours) at the desired 
temperature (see calculation of Th below) on a foil-covered slide-warming tray.
Calculation of hybridisation temperature (Th):
Th = Tm (melting temperature of whole probe:target hybrid) -  18 °C 
(for RNA:RNA hybrids)
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c) Post-hybridisation 
Solutions:
RNase digestion solution:
20 pg/ml RNase A 
ImMEDTApHS.O 
10 mM Tris pH 8.0 
O.SMNaCl
Slides were removed from the slide-warming tray and allowed to cool to room 
temperature. Forceps were used to remove dried DPX mountant. Slides were then 
immersed in 4 x SSC for 30 mins with gentle agitation, after which the coverslips 
easily detached from the slides. Slides were then rinsed 4 x 5  mins in 4 x SSC 
followed by incubation in RNase digestion solution at 37 °C for 30 mins.
Slides were then taken through a series of washes at room temperature as shown 
below: -
2 x 5  mins in 2 x SSC, 1 mM dithiothreitol (DTT)
1 X 10 mins in 1 x  SSC, 1 mM DTT 
1x10 mins in 0.5 x SSC, 1 mM DTT
1 X 30 mins in 0.1 x SSC, 1 mM DTT at elevated temperature (initial Tm -  5 °C)
Slides were then rinsed in 0.1 x SSC, 1 mM DTT to return them to room temperature, 
and then sections dehydrated in ascending concentrations of ethanol (50, 70, 95, 100, 
100 % ethanol for 3 mins in each; including 0.1 x SSC, 1 mM DTT in the 50 and 
70 % ethanol steps). Slides were drained well and allowed to dry in a fume hood for
2 hours. Slides were then opposed to film for 1-3 days.
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Figure 2.10 Summary of steps involved in in situ hybridisation
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2.2.5.3 Kupffer cell quantitation
Experiments were designed to determine whether the changes in Kupffer cell receptor 
mRNA observed following the various compound treatments were due to a true effect 
on the actual receptor number, or were a consequence of an effect on the absolute 
number of Kupffer cells. For all Kupffer cell quantitation, study 1 samples were used.
2.2.5.3.1 Slide preparation
Slides were prepared by the Molecular and Immunological Toxicology group at 
GlaxoSmithKline, Welwyn.
On removal of the livers, a sample of left lateral lobe was retained and fixed in 10 % 
buffered formal saline for 6 days. Samples were then processed through to paraffin 
wax, sectioned and stained with haematoxylin and eosin. This was performed using 
tissues from all treated and control animals.
Compounds and time-points that had been included in both study 1 and study 2 were 
selected for analysis, as for those samples significant differential gene expression of 
the Kupffer cell receptor had been observed. Therefore, all com oil, Wy-14,643, 
dexamethasone and cyproterone acetate samples from the 24, 48 and 72 hour 
time-points (24 hours after 1, 2, and 3 daily doses respectively) from study 1 were 
analysed. Photographs were taken at a magnification of x400 using a Wild MPS 12 
camera (Wild Heerbmgg Ltd.) and a Laborlux D light microscope (Leitz).
2.2.5.3.2 Cell counting
All samples from control and the 3 treatments listed above at the 3 time-points were 
analysed.
Hepatocyte numbers were obtained by counting the number of nuclei.
A positive identification of a Kupffer cell was made by analysis of the location and 
characteristics of the nucleus according to the following criteria:
- dark-staining nucleus
- located inside sinusoid
- triangular nucleus (generally)
- granular nucleus
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All slides were ‘blinded’ so that there was no knowledge of animal identification and 
fields were randomly selected. Counting was performed at x400 magnification using 
a light microscope (Carl Zeiss).
10 fields per slide were randomly selected and both the number of hepatocytes and 
number of Kupffer cells counted per field. Mean numbers of Kupffer cells and 
hepatocytes per field for each animal were determined. In addition, the mean ratio of 
hepatocyte number to Kupffer cell number per field for each animal was calculated. 
Cell numbers and ratios obtained for treated animals were compared to those obtained 
for control. Statistical analysis of results was carried out using an ANOVA (section
2.2.6) and values were considered statistically significant at p < 0.05.
2.2.6 Statitical Tests
2.2.6.1 Student’s t-test
A student’s t-test may be used to determine if the mean of one particular variable 
differs between two groups. This test was therefore utilised to determine statistical 
significance of the observed fold changes in mean gene transcript levels between each 
treated and control group at each time-point. In each case a paired test was used, as 
each experiment included control and treated animals studied in parallel. A two-tailed 
test was carried out as it was not known which group would be expected to have the 
larger mean. Values were considered statistically significant where p-values were less 
than 0.05. A low p-value for the statistical test points to rejection of the null 
hypothesis (that states that the mean of two groups are equal), because it indicates 
how unlikely it is that a test statistic as extreme or more extreme than the one given by 
this data will be observed from this population if the null hypothesis is true. Since the 
p-value selected is 0.05, this means that if the population means were equal as 
hypothesised (under the null), there is a 5 % chance that a more extreme test statistic 
would be obtained using data from this population.
2.2.6.2 ANOVA (Analysis of Variance between groups)
An ANOVA may be used to test whether the mean of one particular variable differs
among three or more groups. This test was therefore utilised to compare all treatment
groups (including control) with one another. An ANOVA was used to determine
statistical significance in the cell proliferation, apoptosis and liver cell number studies.
A one-way ANOVA was used as groups were defined by a single factor -
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their compound treatment. An ANOVA simply determines whether there are 
significant differences between the groups being analysed, but does not provide 
information as to which group is significantly different from which. Following an 
ANOVA, post-hoc tests, such as the Bonferroni test as used in these investigations, 
are therefore carried out. This provides a p-value for all comparisons made. Values 
were considered statistically significant where p-values were less than 0.05. All 
results are presented as those treated groups that are statistically significantly different 
as compared to control.
2.2.7 General methods
2.2.7.1 Sterilisation procedures
All solutions (where possible), glassware and plastic-ware for nucleic acid work and 
bacterial cell culture were sterilised using a RSI series 32 automatic autoclave, at 
121 °C for 20 minutes at a pressure of 15 Ib/in .^
2.2.7.2 DEPC-treatment of solutions for RNA work
All solutions used for RNA work were treated with diethylpyrocarbonate (DEPC). 
Treatment involved addition of 1 pi of DEPC per ml of solution, incubation at room
temperature overnight, followed by autoclaving as described above. If it was not
possible for some solutions to be autoclaved they were made with DEPC-treated 
MilliQ-water.
2.2.1.3 Agarose gel electrophoresis of RNA and DNA
Solutions:
1 X Tris-acetate (TAE) buffer: 5 x Orange G loading dye:
40 mM Tris-acetate 10 ml formamide
1 mM EDTA 0.5 M EDTA (pH 8.0)
0.02 g Orange G
The gel electrophoresis in this project utilised 1-2 % agarose gels (as stated) 
containing ethidium bromide. Gels were prepared by dissolving agarose in 1 x TAE 
by heating. Depending on the size of gel required, 50-100 ml was prepared. 
Ethidium bromide was then added to a final concentration of 0.5 pg/ml.
I l l
Samples were prepared by the addition of 5 x orange G loading dye to give a final 
concentration of 1 x and were run alongside a 1 kb DNA ladder (Promega) at 
approximately 3 V/cm. 1 x TAE was used as the running buffer. All gels were 
photographed using an Imagemaster® VDS (Amersham Pharmacia Biotech).
2.2.7.4 Spectrophotometric quantitation of RNA and DNA
Throughout, RNA and DNA concentration and purity was determined 
spectrophotometrically at 260 nm and 280 nm by use of a Genequant^*  ^ RNA/DNA 
calculator (Pharmacia Biotech). 2 pi of each sample was diluted by a factor of 35 in 
nuclease-free water and quantified in a 70 pi quartz cuvette against a nuclease-fi'ee 
water reference. All Genequant’’^  measurements were confirmed by agarose gel 
electrophoresis.
2.2.7.5 Phenolichloroform extraction for RNA/DNA purification
An equal volume of phenokchloroform (1:1 v/v) was added to each sample and mixed 
thoroughly by brief vortexing. The upper aqueous layer was removed from each 
sample and the lower organic layer disposed of appropriately.
1.2.1.6 Ethanol precipitation
2 volumes of absolute ethanol and 1/10 volume 4 M ammonium acetate was added to 
the samples to be precipitated, which were then kept at -20 °C for 30 min. Samples 
were then spun at 12,000 g for 25 min. 90 % of the liquid was removed and then 
200 pi of 80 % ethanol added to the pellet. Samples were again spun at 12,000 g, this 
time for 10 min. As much ethanol was removed as possible and the sample allowed to 
air dry for 10 min. Samples were resuspended as described, depending on the 
application.
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Chapter 3 
Results 1
Study 1 - Effects of phénobarbital, Wy-14,643, dexamethasone and cyproterone 
acetate on rat liver weight, cell proliferation, apoptosis and differential gene
expression
Study I and subsequent proliferation and apoptosis studies were performed by the 
Molecular and Immunological Toxicology group at GlaxoSmithKline, Welwyn.
All differential gene expression studies were performed by me at the University o f  
Surrey.
3.1 Liver weights (study 1)
Livers were weighed immediately upon removal before being frozen in liquid 
nitrogen. Liver weights were calculated as the percentage of the total body weight. 
Weights are represented in Table 3.1 as % change as compared to control.
Table 3.1 Percentage change in liver weights following compound 
administration as compared with control
Time-point Phénobarbital
(50 mg/kg/day)
Wy-14,643
(50 mg/kg/day)
Dexamethasone
(100 mg/kg/day)
Cyproterone
acetate
(60 mg/kg/day)
la  (2h) +11±4 -4±2 +3+4 +2 ±5
lb (12h) +7±2 -5±2 +26 ± 6** +22 + 4***
Ic(24h) +6 ± 3 +2 + 5 +53 ± 6*** +29 ± 8***
2 (48h) +15±3* +17 ±3** +70 ±8*** +62 ± 10***
3a (72h) +15 ±4* +37 + 9*** +70 ±11*** +49 ± 9***
3b (96h) +13 ±6 +32 ± 8*** +68 ± 9*** +49 ± 10***
Table 3.1: Data represents mean percentage change in liver weights as compared to control ± SD, 
derived from 5 animals per treatment group.
Time-points defined as:
la, lb, Ic -  2, 12, 24 hours respectively after 1 dose; 2 -  24 h after 2 consecutive daily doses;
3 a, 3b -  24h, 48h respectively after 3 consecutive daily doses
Statistical analysis was performed using an ANOVA, where asterisks represent P-values of:
* = P < 0.05; *» = P < 0.01; *** = P < 0.001.
Mean absolute liver weights (g) ± SD are shown below for control groups:
Control 2h 12h 24h 48h 72h 96h
Saline 
Corn oil
14.110.3
13.810.4
13.910.6
14.010.6
14.510.3
14.510.4
14.010.8 
14.811.0
14.310.4 
14.410.6
14.810.6 
15.011.1
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3.2 Proliferation studies
Following removal and weighing of each liver, a sample of right lateral lobe was 
retained in 10 % buffered formal saline for 6 days. Following this fixation, each liver 
sample was processed through to paraffin wax and sectioned. Sections were then 
stained by immunocytochemical techniques, for the demonstration of 5-bromo-2- 
deoxyuridine (BrdU) using a monoclonal antibody to BrdU (DAKO Ltd, UK). Note 
that in this study BrdU was administered via osmotic minipumps over the whole time 
course of the experiment and is therefore a cumulative measurement. All sections 
were “blinded” so that the investigator had no knowledge of animal identification. 
Counts were carried out using a x40 objective in fields randomly selected using a 
battlement technique. Fields that included the edge of the section were excluded from 
the analysis.
The percentage of BrdU positive nuclei relative to the total (positive + negative) were 
calculated and defined as the Labelling Index (LI): -
LI = 100 X (N.Pos.)/(N.Pos +N.Neg)
(N.Pos: number of positive nuclei; N.Neg: number of negative nuclei)
Where the value for LI is greater in the treated group than the control indicates 
increased hepatocyte proliferation.
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Figure 3.1 (a&b) Hepatocyte proliferation following compound treatment
Figure 3.1(a) Phénobarbital
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Figure 3.1(a) Each data point represents the mean percentage of 5-bromo-2-deoxyuiidine 
positive nuclei relative to the total (positive + negative) identified in each liver section 
defined as the Labelling Index (LI), derived from 5 animals per treatment group. 
50 mg/kg/day phénobarbital:® was administered i.p for 3 days in saline vehicle: O . 
Statistical analysis was performed using an ANOVA, where an asterisk (*) represents 
P<0.05.
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Figure 3.1(b) Wy-14,643, dexamethasone, and cyproterone acetate
30-1
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1 0 -
48 72 9624
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Figure 3.1(b) Each data point represents the mean percentage of 5-bromo-2-deoxymidine 
positive nuclei relative to the total (positive + negative) identified in each liver section 
defined as the Labelling Index (LI), derived from 5 annuals per treatment group. 
50 mg/kg/day Wy-14,643: q  ; 100 mg/kg/day dexamethasone: ^  ; or 60 mg/kg/day 
cyproterone acetate (CPA): O was administered i.p for 3 days in com oil vehicle: ® . 
Statistical analysis was performed using an ANOVA, where an asterisk (*) represents 
P<0.05.
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3.3 Apoptosis studies
Right lateral lobe samples were fixed and sectioned as for proliferation studies. 
Sections were stained by immunocytochemistry techniques by the TUNEL method 
(Gavrieli et a l, 1992), using the Apoptag staining kit (Appligene Oncor), for the 
demonstration of apoptotic bodies (AB). The total number of apoptotic bodies (AB) 
identified by TUNEL in each liver section was counted. For each animal, a count of 
the number of hepatocyte nuclei (N) was made in each of 15 randomly selected fixed 
field areas (regions of interest, ROI) using a x40 objective. In each case 5 fields were 
centrilobular, 5 mid-zonal and 5 periportal. Using a xl objective, the total section 
area (As) and the summed area of central veins (Acv) were measured, and the area of 
parenchyma (Ap) was calculated:
Ap(mm^)= As -Acv
The apoptotic index (AI) was defined as the number of apoptotic bodies (AB) per 100 
hepatocytes and was calculated as follows:-
AI = 100 X AB / (the sum o fNx  Ap/  (15 xROI))
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Figure 3.2(a&b) Influence of xenobiotics on apoptosis
Figure 3.2(a) Phénobarbital
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Figure 3.2(a) Each data point represents the number of apoptotic bodies (AB) per 100 
hepatocytes (apoptotic index (AI)) identified in each liver section using the TUNEL method 
and Apoptag staining kit, derived from 5 animals per treatment group. 50 mg/kg/day 
phénobarbital: H ; was administered i.p for 3 days in saline vehicle: □  . Statistical analysis 
was performed using an ANOVA, where an asterisk (*) represents P < 0.05.
119
Figure 3.2(b) Wy-14,643, Dexamethasone and Cyproterone acetate
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Figure 3.2(b) Each data point represents the number of apoptotic bodies (AB) per 100 
hepatocytes (apoptotic index (AI)) identified in each liver section using the TUNEL method 
and Apoptag staining kit, derived from 5 animals per treatment gioup.
50 mg/kg/day Wy-14,643; O ; 100 mg/kg/day dexamethasone: ^  ; or 60 mg/kg/day 
cyproterone acetate (CPA): □  was administered i.p for 3 days in a com oil vehicle: ■  . 
Statistical analysis was performed using an ANOVA, where an asterisk (*) represents 
P<0.05.
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3.4 mRNA extraction
mRNA was extracted from 100 mg of each control and treated liver of rats 12 and 24 
hours following 1 dose of Wy-14,643, using the PolyATract 1000 kit as described. 
RNA was analysed by spectrophotometry to determine the quantity obtained. 10 pi of 
each sample of RNA was separated on a 1 % agarose gel where mRNA was observed 
as a smear, indicating mRNA species in the range 1-3 kb.
3.5 Suppression subtractive hybridisation
For both groups (12 and 24 hours), cDNA subtraction was carried out in the forward 
(control driving tester) and reverse (tester driving control) directions to isolate both 
up- and down-regulated species respectively.
cDNA obtained from 2.5 pg of previously isolated mRNA from both a control and a 
treated liver from each group was subjected to SSH using the PCR-Select cDNA 
subtraction kit. mRNA from a single animal from each group was used as it was 
thought that pooling of mRNA samples from a number of animals may result in the 
apparent Toss’ of minor gene changes due to inter-animal variation.
The products of the SSH procedure were examined on a 2 % Metaphor agarose gel, 
where they appeared as a ladder. The majority of these gene fragments fell within the 
150 to 2000 bp range, with bands up to 5 kbp occasionally being observed. Figure 3.3 
is an example of a final display of differentially expressed genes obtained using a 
control and treated sample of rat liver 12 hours after 1 dose of Wy-14,643.
Bands present in t and 4- but not in Tc and >lc respectively, are indicative of 
differentially expressed genes.
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Figure 3.3 Differential expression of cDNA species 12 hours following one
50 mg/kg dose Wy-14,643
L Î Tc i
1kb
L
t/4
Tc/4c
X
Ikb DNA ladder
up-/down regulated cDNA species
unsubtracted control cDNA
Example o f a differentially expressed band
3.6 Screening
Following cloning of every possible differentially expressed gene isolated from the 
SSH gel, screening steps were then carried out.
3.6.1 Restriction digest
The first screening test involved a simple restriction digest (Figure 3.4) to confirm 
those clones that contained an insert - those samples for which a successful ligation of 
a potential differentially expressed sequence and subsequent cloning reaction had 
been achieved.
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Figure 3.4 Example of a restriction digestion of clones to determine presence of 
an insert
1kb
_ Plasmid 
DNA
Insert
DNA
A B C  D E  F G  H I  J
A-D, F-H: inserts present
E : restriction enzyme cutting site may lie within insert region
(2 ‘insert’ bands visible)
I-J : no inserts present
3.6.2 Dot blots
As no subtraction technique will be 100 % efficient, it is necessary to screen every 
clone to confirm those that represent true differentially expressed genes.
The approach used in this study is termed PCR-Select differential screening (as 
recommended in Clontech’s PCR-Select cDNA subtraction kit protocol). Every 
plasmid miniprep clone isolated from each display that was shown to successfully 
contain an insert (section 3.6.1) was blotted in duplicate on Hybond-N+ membranes 
(Amersham). The forward and reverse subtractions obtained from the SSH procedure 
were used as probes to screen these blots. Because these probes have already 
undergone subtraction, they have been enriched for differentially expressed genes and 
are therefore much more sensitive than unsubtracted driver/tester cDNA probes for 
detecting true differential expression (CLONTECHniques, 1997). Therefore all 
clones were probed with the display from which they are obtained, plus the 
corresponding reverse-subtracted display. The probed blots were then compared. 
Genuine differentially expressed mRNAs were taken as those that hybridised with the 
subtracted cDNA probe, but not the reverse-subtracted probe; and those clones that 
gave a greater signal with the subtracted probe compared to the reverse-subtracted 
probe. Those that were rejected as false positives were those that gave an equal signal 
or no signal at all with both probes. An example of such a blot may be seen in 
Figure 3.5.
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Figure 3.5 Dot blot used to confirm down-regulated gene species isolated from 
livers of rats 12h following one dose of Wy-14,643.
All clones were blotted and probed with: -
(A) the differential display from which they originated (treated driving control) and
(B) the reverse subtraction (control driving treated)
White arrows highlight some of the true differentially expressed genes, black arrows 
indicate ‘false positives’.
3.7 Identification of clones
All clones were sequenced at GlaxoSmithKline, Harlow, using an ABI3700 capillary 
sequencer and M l3 Reverse primer. The method is based on the Sanger method of 
sequencing (Sanger et a i, 1977) involving the attachment of base-specific fluorescent 
terminator-dyes to the end of each DNA fragment, which are then detected by laser 
activation. Gene sequences were obtained via BLAST searches, the results of which 
are listed in Tables 3.2-3.3.
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Table 3.2 BLAST search results for differentially expressed sequences identified 24 hours
after one 50 mg/kg dose of Wy-14,643
Table 3.2( a) Up-regulated sequences
Identity Accession
number
Score
1
Length Homology Insert length
Cathepsin H Y00708 307 337/399 84% >400
Kupffer cell receptor J03734 577 402/449 89% >400
Preproalbumin V01222 582 329/345 95% 414
Selenoprotein P D25221 268 141/144 97% >200
Slow myosin binding protein C (human) X73114 383 193/193 100% >200
TFIID (mouse) DO1034 120 76/81 93% 156
Transferrin D38380 888 451/452 99% 492
Ubiquitin activating enzyme E l (mouse) D10576 165 108/115 93% 213
Mitochondrial genes for several tRNAs 
(human)
V00710 56 50/61 81% >400
Metallopanstimulin (human) L19739 109 68/72 94% >400
DNA sequence from clone 1183121 (human) AL035447.3 242 122/122 100% 438
No match (Nl) 440
No match (N2) 421
No match (N3) >400
No match (N4) >200
No match (N5) 46
Table 3.2(b) Down-regulated sequences
Identity Accession
number
Score
1
Length Homology Insert length
Apolipoprotein E J02582 428 216/216 100% >200
Via arginine vasopressin receptor (mouse) D49729 89.7 45/45 100% >400
No match (N6) 45
Table 3.2: All sequences are from the rat unless otherwise stated.
 ^ Is a measure provided by the BLAST programme that gives an indication of how accurate the match is. 
 ^ Indicates the length of the sequence homology between the cloned band isolated from the differential display 
and the corresponding gene identified from the BLAST search.
 ^ Refers to the nucleotide sequence homology between the cloned band isolated from the differential display and 
the corresponding gene identified from the BLAST search. Individual accession numbers were often identified 
more than once -  in each case details of the largest clone for each accession number is provided.
See appendix for sequences o f  N I-6.
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Table 3.3 BLAST search results for differentially expressed sequences identified 12 hours 
after one 50 mg/kg dose of Wy-14,643
Table 3.3(a) Up-regulated sequences
Identity Accession
number
Score1 ^Length Homology Insert length
D-dopachrome tautomerase Z36980 815 425/427 99% >500
Copper/zinc superoxide dismutase X55397 264 147/154 95% >400
RN protein U93197 242 125/126 99% 214
No match (N7) 781
No match (N8) 764
Table 3.3(b) Down-regulated sequences
Identity Accession
number
Score
1
Length Homology Insert length
Carboxylesterase M20629 811 421/424 99% 691
Fetuin (pp63) X63446 722 367/368 99% 483
Glutathione peroxidase I X12367 301 208/225 92% >250
Regulator o f  G protein signalling 10 (human) AF045229 81.8 50/52 96% >400
Chromosome 11Q13 BAG clone B79G17 
(human)
AC000159 192 228/268 85% 701
SAP 130 spliceosomal protein (human) AJOO 1443.1 44.1 22/22 100% 103
DNA sequence from clone RP11-163M1 on 
chromosome 22 (human)
AL109802.6 40.1 23/24 95% 690
No match (N9) 737
No match (NIO) 708
Table 3.3: All sequences are from the rat unless otherwise stated.
 ^ Is a measure provided by the BLAST programme that gives an indication of how accurate the match is. 
 ^ Indicates the length of the sequence homology between the cloned band isolated from the differential display 
and the corresponding gene identified from the BLAST search.
 ^ Refers to the nucleotide sequence homology between the cloned band isolated from the differential display and 
the corresponding gene identified from the BLAST search. Individual accession numbers were often identified 
more than once -  in each case details of the largest clone for each accession number is provided.
See appendix for sequences of N7-10.
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3.8 Discussion
3.8.1 Liver weight, cell proliferation and apoptosis
As expected, administration of each of the 4 compound treatments, Wy-14,643, 
dexamethasone (DEX), cyproterone acetate (CPA), and phénobarbital (PB), resulted 
in characteristic, significant increases in rat liver weight, observed over at least two of 
the time-points (Table 3.1). Both DEX and CPA were shown to increase the weight 
of the liver by around a quarter that of control after as little as 12 hours compound 
administration. For these 2 compounds, maximum liver weights appeared to have 
been achieved by 48 hours, further dosing resulting in no further increases in weight. 
In contrast, significant Wy-14,643-induced increases in liver weight were not 
observed until 48 hours with further increases in weight recorded up to 72 hours. 
Only relatively minor significant increases in liver weight were observed following 
PB treatment, which was maximal at 48 hours.
In accordance with the literature (Busser and Lutz, 1987; Marsmann et a l, 1988; 
Schulte-Hermann et a l, 1988), treatment of rats with all of the compounds except 
DEX resulted in increased hepatocyte proliferation as demonstrated by increased 
BrdU LI (Figure 3,1 (a&b)). In CPA treated animals the maximum increase of BrdU 
LI occurred between 24 and 48 hours (Figure 3.1b); whereas in PB and Wy-14,643 
treated animals the maximum increase of BrdU LI was observed at around 72 hours 
(Figures 3.1 (a&b)). It may be noted that for PB, Wy-14,643 and CPA, the peak of 
hepatocyte proliferation (LI) appeared to coincide with the peak of the increases in 
liver weight observed (Table 3.1), indicating that for each of these compounds 
hepatocyte proliferation is a major contributor towards the observed liver growth. 
Although all 4 compounds have been recorded in the literature to suppress apoptosis 
(Roberts et a l, 1995; Evans-Storms & Cidlowski, 2000; Kolaja et a l, 2000), 
statistically significant apoptosis suppression was only recorded following DEX 
treatment in this study. The timing of this inhibition of apoptosis appeared to 
correlate with the observed DEX-induced increases in liver weights (Table 3.1), so 
peaking at 48 hours. However, although not statistically significant, percentage 
apoptotic indices were observed to be reduced at 72 and 96 hours of Wy-14,643, CPA 
and PB treatment as compared to control (Figure 3.2(a&b)). Statistical significance 
was probably not observed due to it being a relatively subtle effect and a decrease on 
an already low level of apoptosis seen in the liver (Roberts et al, 1995; Kolaja et al, 
2000).
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Using the liver weight, cell proliferation and apoptosis data, it was therefore 
concluded that the increases in rat liver weight observed following Wy-14,643, PB 
and CPA may be partly attributed to an increase in cell proliferation in conjunction 
vrith only a slight suppression of apoptosis; whilst it is likely that DEX-induced 
increases in liver weight may be partly due to the marked suppression of apoptosis 
recorded. For these compounds, hypertrophy of hepatocytes may also contribute to 
the observed liver weight increases, this being particularly so with regard to 
Wy-14,643 and dexamethasone (Reddy and Lalwani, 1983; Nagy et al., 2001).
3,8.2 Differential gene expression
Using the organs and data obtained from the study, it was decided to investigate 
changes in gene expression that may occur in conjunction with the increases in liver 
weight observed, in an attempt to formulate potential pathways and possible 
mechanisms of liver growth action of these compounds.
Suppression subtractive hybridisation (SSH) was selected as the method of gene 
isolation, as not only is it a relatively short, straight-forward and efficient differential 
display technique, it is also capable of isolating extremely rare messages. Diatchenko 
et a l, 1996, and Gurskaya et a l, 1996, reported that a 1000-5000 fold enrichment of 
rare cDNAs (equivalent to isolating mRNAs present at only a few copies per cell) can 
be obtained without the need for multiple hybridisations or subtractions 
(sections 1.3.2; 2.2.2.2). This may be highly beneficial as this minor fraction is likely 
to be of particular interest, since transcripts for many regulatory proteins fall into this 
category (Diatchenko et al, 1996).
Wy-14,643 was selected as the compound to be used for the initial gene-hunting
investigations. This is because peroxisome proliferators have recently aroused much
interest regarding their mechanisms of action (section 1.2.2.3). Peroxisome
proliferators are known to be potentially hepatocarcinogenic in rats and mice, but their
mechanisms of carcinogenic action remain undefined (Reddy et a l, 1980). Causing
both hypertrophy and hyperplasia, Wy-14,643 is also thought to be a classic non-
genotoxic liver carcinogen (Reddy et a l, 1979; Reddy and Lalwani, 1983). This has
been cause for concern as human exposure is substantial with peroxisome
proliferators being used in a wide variety of applications including hypolipidemic
drugs, herbicides, and solvents (Lake, 1995a). It was reasoned that if specific genes
affected by Wy-14,643 treatment could be isolated, this may potentially provide a
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‘standard’ for other compounds of this class, and possibly identify mechanisms 
involved in xenobiotic-induced liver growth.
The original time-point selected for examination using SSH, was that for those liver 
samples removed from rats killed 24 hours after one dose of Wy-14,643. This was 
chosen on the basis that a single dose of Wy-14,643 has previously been shown to be 
sufficient to induce classic peroxisome proliferator effects including increased 
hepatocyte proliferation and induction of peroxisomal enzymes (Ohmura et a l, 1996). 
Following a 250 mg/kg dose of Wy-14,643 to Wistar rats, Ohmura and co-workers 
demonstrated a wave of hepatocyte DNA synthesis to begin after 12 hours, peaking at 
24 to 36 hours. However, in study 1, proliferation studies later indicated that the 
onset of increased hepatocyte DNA synthesis in Wy- 14,643-treated rats occurred 
much later, between 24 and 48 hours (Figure 3. lb). This delay may have been due to 
experimental variation, including factors such as compound preparations (different 
dose and route of administration) and housing conditions; as well as animal variation 
including differences in strain as well as in age. However, following SSH 
examination of the 24-hour time-point, it was still noted that some of the genes 
isolated were indicative of replicative DNA synthesis taking place (such as 
metallopanstimulin -  see below). It was therefore decided to also study the earlier 
12-hour time-point as it was thought that this may provide information regarding the 
molecular changes underlying the increase in DNA synthesis. However, the 
identification of any differentially expressed transcripts at this 12-hour time-point 
must be interpreted with caution, as it is possible that differences observed between 
0 and 12 hours may be due to circadian variation. Indeed, a recent study has 
identified the expression levels of 597 genes, including several key metabolic 
pathways, to be significantly affected by the time of day, in the liver and kidney of 
rats (Kita et a l, 2002). The expression levels of some of these genes were further 
modified by feeding state.
Many potential up- and down-regulated gene species were isolated from both time-
points, but before these changes were accepted, confirmatory experiments were
carried out. Although it has been reported that SSH is highly efficient at producing
differentially expressed gene species (Diatchenko et a l, 1996), it has previously been
demonstrated that various screening steps are valuable in the confirmation that clones
isolated via SSH are truly differentially expressed (Rockett et a l, 1999). A dotblot
screening technique (Figure 3.5) was therefore utilised which did indeed isolate a
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number of false positives (approximately 40 % at 24 hours and 5 % at 12 hours). This 
was felt to be acceptable and highlighted the need for such screening methods, as no 
gene hunting technique is 100 % efficient.
3.8.3 Identification and confirmation of differentially expressed sequences 
Following the elimination of false positives, sequencing and BLAST searches of 
identified clones provided interesting results from both time-points (Table 3.2-3.3). 
Obviously those clones that gave good matches to specific rat genes are of most 
interest as a function may be assigned to them, but the others must not be neglected. 
Some clones gave matches to sequences of unknovm function (for example, human 
DNA sequence from clone 1182121). Experiments are currently underway at the 
University of Surrey to attempt to identify such clones with bioinformatics. Those 
sequences where a BLAST search provided ‘no match’ were classed as ‘novel’ 
sequences as they appeared to be, as yet, ‘unknown’. The matches that appeared in 
both up- and down-regulated lists (such as a-2u globulin) were dismissed as false 
positives. They may have been identified in both lists simply because they are of such 
high abundance in the original sample.
An important consideration when matching sequences to known genes is determining 
how ‘good’ the match must be to ensure that it is correct. The BLAST programme 
matches entered sequences to all likely candidate genes and ranks them in order 
beginning with the closest match first. In conjunction with this, the BLAST 
programme indicates the accuracy of possible matches by giving each a score - the 
higher the score, the closer the match to the identified gene, (close matches typically 
have scores within the hundreds). The database also provides the exact length of the 
sequence homology between the cloned band isolated from the differential display 
and the corresponding gene identified from the BLAST search, which aids in positive 
gene identification. For each sequence isolated via SSH the highest ranked gene 
match was accepted as true, as in each case this match was by far the closest. All 
these matches came with sequence similarities ranging between 80-100 %, and most 
of lengths between 200 and 700 base pairs. However, sequences that gave a 100 % 
match to human sequences must be interpreted with caution, as it is possible that they 
may be the result of contamination. Where sequence similarities were less than 
100 %, this was typically observed to correlate with sequencing errors.
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One point that may be raised from the lists of isolated genes, is that none of the 
typical genes known as ‘markers’ for peroxisome proliferation have been identified as 
being differentially expressed. Such markers include CYP4AJ (Gibson, 1989; Bell et 
ai., 1991; Makowska and Gibson, 1992; Rockett et a l, 2000), and the peroxisomal 
enoyl-CoA:hydratase-3-hydroxyacyl-CoA bifunctional enzyme (Chen and Crane, 
1992; Rockett et al, 2000). This is not so much of a surprise, as due to the 
characteristics of the SSH technique (in particular the fact that it allows the 
normalisation of rare and abundant transcripts (Diatchenko et a l, 1996; Gurskaya et 
al, 1996)), rare, and only mildly affected transcripts are just as likely to be isolated as 
abundant or highly affected transcripts. It has been claimed by the manufacturers that 
this technique is able to identify changes as small as 1.5 fold between the driver and 
tester populations. This is probably of advantage regarding this project, as although 
identification of known markers such as CYP4A1 would provide confidence in the 
results obtained, little would be gained in terms of elucidation of a mechanism of 
action responsible for the observed liver growth from the repeated isolation of these 
known markers. It may be that the small changes in levels of these previously 
unidentified transcripts may actually be of greater significance with regard to the aim 
of this project.
It may also be noted that it is in no way possible for all potentially ‘changed’ genes to 
be isolated via gene identification methods such as SSH, as it is not an exhaustive 
technique. SSH is performed in this investigation simply to provide clues regarding 
possible mechanisms of action of compound-induced liver growth. Only a handful of 
the differentially expressed genes will be isolated as a result of each experiment, and 
in the case of this investigation only one ‘round’ of SSH was performed per time- 
point.
It must also be considered that differences in RNA levels may be caused by
differences in mRNA stability and/or in transcription rate. Once mRNA has been
translated it is rapidly degraded, allowing the purine and pyrimidine bases to be
recycled. A large number of intra- and extra-cellular exonucleases and endonucleases
are present which are involved in both the processing and degradation of RNA
(Zubay, 1993). Many of these enzymes are sequence or base-specific which may
contribute to differences in stability of particular mRNA sequences. Transcription
rate may also differ between genes, which may be the result of additional promotor
regions or the presence of enhancer elements. These additional regions tend to be
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gene-specific and bind additional transcription activation factors. It is therefore 
important to determine if the identified change in mRNA level is reflected in the 
subsequent protein levels of that specific gene, as mRNA is known to undergo many 
changes before it is finally translated into the corresponding protein.
However, many of the genes identified have functions that are not inconsistent with 
peroxisome proliferation (Figure 3.6 and below).
3.8.4 Functions of identified differentially expressed genes
Once specific genes have been identified and their differential expression confirmed, 
it is valuable to attempt to link some of them together in terms of function, as 
eventually it may be possible to identify specific pathways involved in the mechanism 
of action of these compounds. One such assignment has been outlined below (Figure
3.6) which incorporates many of the up- and down-regulated sequences that matched 
to specific genes of known function isolated from both time-points. Many of these 
genes may be placed into 4 main categories that may be related to liver growth, 
namely protein degradation, cell growth and development, cell proliferation and 
oxidative stress.
Figure 3.6 Possible functions of identified differentially expressed genes
PROTEIN DEGRADATION 
UbEI (t24hr)
Cathepsin H (t 24hr)
OXIDATIVE STRESS
Selenoprotein P (t24hr)
Superoxide dismutase (tl2hr)
Glutathione peroxidase (4<12hr)
-  .. .............................- ---------  ----------------------
KUPFFER CELLS 
Kupffer cell 
receptor (t24hr)
CELL GROWTH & CEL.. PROLIFERATION
DEVELOPMENT Metallopanstimulin (t24hr)
Cathepsin H (t24hr) Arginine vasopressin
Fetuin (4 12hr) receptor (4 24hr)
(Timepoint of initial identification and direction of change are shown in brackets)
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3.8.4.1 Protein degradation
There are many pathways of intracellular protein breakdown. Most proteins with 
short half-lives are degraded by cytosolic, ATP-dependent pathways that do or do not 
require ubiquitin conjugation (Dice, 1990). The bulk of cellular proteins, however, 
are long-lived, and both cytosolic and lysosomal pathways contribute to their 
degradation (Dice, 1990). A number of classes of proteases or proteinases are known 
to exist and these are responsible for the breakdown of proteins into peptides or amino 
acids (Barret, 1977).
Cathepsin H  was shown to be up-regulated 24 hours after one dose of Wy-14,643. 
Cathepsin His a member of the lysosomal cysteine proteinases which may well be the 
most active group of proteinases in the body (Barret, 1977). The cysteine proteinases 
participate in various cellular functions such as intracellular protein breakdown, cell 
growth, biosynthesis of peptide hormones and tumour metastasis. Cathepsin B, H, L 
and S are involved in the lysosomal degradation of mammalian tissues and rat liver 
cathepsin H has been demonstrated to act as both an endopeptidase and an 
aminopeptidase (Kirschke et a l, 1977; Rothe and Dodt, 1992).
Ubiquitin activating enzyme E l was found to be up-regulated 24 hours after one dose 
ofWy-14,643.
The selective degradation of many proteins in eukaryotic cells is carried out by the 
ubiquitin-mediated pathway (Finlay and Chau, 1991; Hershko and Ciechanover, 
1992). Ubiquitination is used in a wide variety of processes such as DNA repair, cell 
cycle progression, the heat shock response, the modification of histones and receptors, 
and the possible pathogenesis of some neurodegenerative diseases (Finlay and Chau, 
1991; Hershko and Ciechanover, 1992).
The major action of ubiquitin is conjugation to proteins signalling them for 
degradation by a 26S protease complex (Figure 3.7).
The first reaction in the ubiquitin conjugation system is the activation of ubiquitin to a
high-energy intermediate. This reaction is catalysed by ubiquitin activating enzyme
El, and takes place in 2 steps during which ubiquitin first forms an adenylate
intermediate before being transferred to a thiol site. El therefore plays a key
regulatory role in the process and is thought of as the rate-limiting enzyme in the
reaction. (Finley and Chau, 1991; Hershko and Ciechanover, 1992)
Ubiquitin is then transferred to one of the ubiquitin carrier proteins (E2s) to generate a
similar thioester linkage. At this point, ubiquitin can either be linked directly to a
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target protein or conjugated to proteins destined for degradation via the ubiquitin 
protein ligases (E3s). The 26S ubiquitin-conjugate-degrading complex can then carry 
out its function. This complex consists of 3 separate factors, namely CF-1, CF-2 and 
CF-3 for conjugate depending factors 1-3. (Hershko and Ciechanover, 1992)
Figure 3.7 Role of ubiquitin in protein catabolism
Ub
Peptides
SHUbn-PROTEIN
8-U b
Es * Protein
PROTEIN
Ub ; Ubiquitin; El : Ubiquitin activating enzyme E l;
E2 : Ubiquitin carrier protein; E3 ; Ubiquitin protein Hgase
Numerous studies have been performed in which components of the ubiquitin 
pathway have been shown to be affected.
The activity of the ubiquitin-dependent pathway has been demonstrated to increase 
during recovery from oxidative stress (Shang et a l, 1997). El has been shown to be 
the rate-limiting enzyme for ubiquitinylation and the oxidation and recovery-induced
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increases in ubiquitin conjugation were primarily due to the increase in El activity 
(Shang et a l, 1997). This may be of interest as oxidative stress underlies one of the 
proposed mechanisms of action of peroxisome proliferators (section 1.2.2.3.2). It 
may therefore be possible that peroxisome proliferator-induced oxidative stress leads 
to increased activity of the ubiquitin-dependent pathway.
The ubiquitin pathway has previously indicated roles in carcinogenicity. Multiple 
genes make up the ubiquitin family, 3 of which have been shown to be over-expressed 
in mouse epidermal tumours associated with enhanced cellular proliferation and stress 
(Finch et a l, 1992). In addition, the role ubiquitin plays in the degradation of the 
tumour suppressor protein p53 may be of significance, with regard to a carcinogenic 
role of the ubiquitin pathway. The nuclear phosphoprotein p53 is a negative regulator 
of cell proliferation and transformation. Blockage of degradation of p53 as well as its 
increased degradation may have oncogenic consequences. Chowdary and colleagues, 
reported the accumulation of p53 in a mutant cell line defective in the ubiquitin 
pathway (Chowdary et a l, 1994). Ciechanover and co-workers, also demonstrated 
degradation of p53 by the ubiquitin-mediated proteolytic system and postulated that 
this required a ‘novel’ species of ubiquitin-carrier protein, E2 (Ciechanover et al, 
1994).
The ubiquitin pathway has also been shown to be involved in regulation of the cell 
cycle. For example, the cyclin-dependent kinase inhibitor p27, which serves as a 
brake to cell division, is often deficient in tumour cells, where it is ubiquitinated and 
degraded, resulting in uncontrolled cell division (Pagano, 1995). In addition, Cdc 34, 
which is required for Gi to S phase progression, has been identified as ubc3, an E2 
enzyme (Goebl, 1988).
Accordingly there are a number of roles the up-regulation of the ubiquitin pathway 
may play in peroxisome proliferator-induced liver growth and hepatocarcinogenesis. 
Peroxisome proliferator-induced oxidative stress may be the underlying cause of this 
up-regulation; possible effects of which appear to involve the degradation of essential 
regulatory proteins, which may result in abnormal cellular regulation. This may 
explain the increase in hepatocyte cell proliferation observed following the treatment 
of rats with peroxisome proliferators (Reddy and Lalwani, 1983; Lock et a l, 1989).
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Intracellular protein degradation plays an important role in the modulation of the 
levels of specific proteins and the elimination of damaged proteins. The process is 
highly selective with some proteins being degraded within minutes, while others are 
essentially stable. Usually, regulatory proteins/enzymes have rapid turnover rates so 
that their levels can be rapidly changed in response to appropriate stimuli. In some 
cases, rates of degradation of regulatory proteins are controlled with high precision, 
such as with cyclins whose levels oscillate at certain stages of the cell cycle and thus 
control cell cycle progression (Hershko and Ciechanover, 1992). It is possible that the 
ubiquitin pathway and cathepsin H together affect the degradation of essential cell 
regulatory proteins, possibly resulting in abnormal or uncontrolled cell cycle 
progression of hepatocytes. Such processes may therefore contribute to the 
hepatocarcinogenicity of peroxisome proliferators.
3.8 4.2 Oxidative stress
Oxidative stress is central to the proposed mechanisms of action of peroxisome 
proliferators. It is thought that Wy-14,643 induction of the peroxisomal fatty acid 13- 
oxidation cycle leads to the production of hydrogen peroxide that may cause DNA 
damage (section 1.2.2 3.2). In addition, Wy-14,643 has been shovm to activate 
NADPH oxidase within Kupffer cells resulting in the production of superoxide, 
ultimately causing increased production of TNFa and the induction of hepatocyte 
proliferation (section 1.2.2.3.2).
Selenoprotein P (24 hours), super oxide dismutase (12 hours), both shown to be up- 
regulated and glutathione peroxidase (12 hours), shown to be down-regulated, all may 
be linked to the oxidative stress hypothesis and share several properties.
Selenoprotein P is a selenium-containing protein distinct from glutathione peroxidase. 
It is an extracellular heparin binding protein that is synthesised and secreted by the 
liver very rapidly, and has been localised to the vicinity of endothelial cells (Burk et 
al, 1997). The function of selenoprotein P has not been established, but evidence 
continues to accumulate that the protein functions to protect against oxidative damage 
of the extracellular membrane (Burk et a l, 1995a; 1995b).
Cytosolic superoxide dismutases are thought to play a pivotal role in protecting cells 
from free radical damage (Fridovich, 1989).
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Glutathione peroxidase (like selenoprotein P) is a selenium-dependent enzyme which 
catalyses the reduction of hydrogen peroxide. It has been implicated in the protection 
of cell membranes and possibly DNA by reducing and eliminating highly reactive 
organic hydroperoxides and hydrogen peroxide (Reddy et a l, 1988).
If affected by peroxisome proliferators, it would be expected that levels of glutathione 
peroxidase would increase in an attempt to combat any increase in hydrogen peroxide. 
However, this is not the case and it has previously been shown that in the rat, the 
administration of peroxisome proliferators can lead to a reduction in certain cytosolic 
selenium-dependent enzyme activities. In accordance with the SSH result, selenium- 
dependent hepatic glutathione peroxidase activity has been reported to be halved 
following treatment with hypolipidaemic drugs such as ciprofibrate (Cirioli et al, 
1982; Conway era/., 1989).
Thus, three genes closely linked to the oxidative stress hypothesis and the elimination 
of peroxisome proliferator-induced production of hydrogen peroxide have therefore 
been identified as being differentially expressed. One of these genes {glutathione 
peroxidase) has previously been shown to be linked to peroxisome proliferators.
3.8.4.3 Cell growth and development
Fetuin {rat phosphorylated N-glycoprotein, pp63) was found to be down-regulated 
12 hours after one dose of Wy-14,643. pp63 structurally and functionally belongs to a 
large family of mammalian fetuins (Rauth et al, 1992), and is an efficient inhibitor of 
the insulin receptor tyrosine kinase activity. Insulin receptor-like molecules are 
known to play a crucial role during growth, development and differentiation 
(Auberger et a l, 1989; Rauth et al, 1992).
Interestingly, pp63 has been shown to inhibit growth of a highly differentiated rat 
liver-derived tumour cell line (Fao cells) (Auberger et a l, 1989). In addition, normal 
adult rat hepatocytes which exhibit virtually no proliferation in vivo, produced pp63. 
As these latter studies indicate that pp63 inhibits cell proliferation, the observed 
down-regulation would correlate with peroxisome proliferator action, possibly 
contributing to the recorded increase in proliferation as a potential restraint is 
removed.
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Cathepsin H  was found to be up-regulated 24 hours after one dose of Wy-14,643. As 
previously mentioned, cathepsins are thought to be involved in cell growth (Barrett, 
1977).
3.8.4.4 Cell proliferation
Metallopanstimulin was found to be up-regulated 24 hours after one dose of Wy-
14,643. This is as would be expected as the metallopanstimulin protein is a good 
marker for cell proliferation and active oncogenic processes. It has been reported to 
be overexpressed in human colonic carcinoma (Ganger et al, 1997), and in human 
prostatic carcinoma (Femandez-Pol et a l, 1997). Metallopanstimulin may play a role 
as a potentially important mediator of cellular proliferative responses to various 
growth factors and other environmental signals. It has been suggested that 
metallopanstimulin may be a nucleic acid-binding protein involved in mediating some 
of the cellular responses to transforming growth factor Pi and to a variety of other 
growth factors and environmental signals (Femandez-Pol et a l, 1993).
Arginine vasopressin receptor (Via) was found to be down-regulated 24 hours after 
one dose of Wy-14,643.
Arginine vasopressin is a neurohypophyseal hormone with diverse actions. Vlas are 
vascular/hepatic receptors that act through phosphatidylinositol hydrolysis to mobilise 
intracellular calcium ions (Murasawa et a l, 1995a). The Via receptor mediates 
physiological effects such as cell contraction and proliferation, platelet aggregation, 
coagulation factor release, and glycogenolysis (Murasawa er a/., 1995a; 1995b).
3.8.4.5 Kupffer cells
Up-regulation of the Kupffer cell receptor (24 hours) is of potential interest due to the 
recent hypothesis that Kupffer cells are causally responsible for the hepatocyte 
mitogenic effect of peroxisome proliferators (see section 1.2.2.3.2 for further details). 
It is therefore possible that regulation of the identified receptor may in some way be 
involved in the hypothesis already postulated.
This specific receptor is found only on the surface of Kupffer cells and is a 
carbohydrate receptor, having an affinity for fucose and galactose (Hoyle and Hill, 
1988). Little is known regarding its precise functional role, although a number of 
possible actions have been indicated. The Kupffer cell receptor is one of a number of
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carbohydrate receptors found in the liver and it has been suggested that the 
carbohydrate recognition system of the liver may be involved in the homeostatic 
function of the regulation of the cell numbers of liver tissue (Ashwell and Harford, 
1982). Other carbohydrate receptors include the hepatocyte asialoglycoprotein 
receptor, the Kupffer cell galactose receptor, the endothelial cell galactose receptor, 
and the macrophage mannose/N-acetylglucosamine receptor. Each of these latter 
receptors have demonstrated involvement in, and modulation of, apoptosis (Ashwell 
and Harford, 1982; Dini et al., 1992, 1993, 1995; Ruzittu et a l, 1999). As the 
Kupffer cell receptor has an affinity for galactose it may play a similar role to the 
Kupffer cell galactose receptor in apoptosis. In addition, apoptotic cells isolated from 
neonatal rat liver cells and 208F fibroblasts were reported to expose levels of mannose 
and fucose residues on their surface, in addition to the high levels of N- 
acetylgalactosamine (Dini et a l, 1992). As the Kupffer cell receptor has an affinity 
for fucose it is possible that it too may play a role in apoptotic cell recognition. A 
potential role of the Kupffer cell receptor in apoptosis may be significant as it has 
been suggested that suppression of apoptosis by peroxisome proliferators contributes 
to their mechanism of action as liver growth agents and ultimately hepatocarcinogens 
(Roberts et a l, 1995). Further investigations into the roles and actions of the 
identified Kupffer cell receptor would therefore be of interest regarding actions of 
peroxisome proliferators.
3.S.4.6 Other identified differentially expressed genes
There are a number of other genes identified as being differentially expressed 
following Wy-14,643 treatment that cannot be grouped functionally with others. 
However, changes in these genes may be significant and their possible functions are 
described below.
Up-regulated genes identified 24 hours following Wy-14,643 treatment:
Transcription factor IID (TFIID) is a transcription initiation factor that plays a major 
role in the activation of eukaryotic genes transcribed by RNA polymerase II. TFIID 
binds specifically to the tata box promotor element that lies close to the position of 
transcription initiation. (Kao era/., 1990)
Transferrin is an iron binding transport protein responsible for the transport of iron
from sites of absorption and haem degradation to those of storage and utilisation.
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Serum transferrin may also play a role in stimulating cell proliferation by acting as a 
growth factor. However, contradictory to my study. Hertz et a l, 1996, demonstrated 
both plasma and mRNA levels of transferrin to be down-regulated following 
treatment of male rats with peroxisome proliferators.
Preproalbumin is also known as rat serum albumin (Sargent et al, 1981). Its up- 
regulation may not necessarily indicate an increase in liver albumin levels as previous 
studies have demonstrated peroxisome proliferators to have no such effect (Rockett et 
al, 2000). As albumin is such an abundant liver protein, the identification of up- 
regulation of its precursor may be due to the fact that more is being synthesised as the 
liver is growing.
Slow myosin binding protein-C is a myosin-associated protein of unknown function 
found in the cross-bridge-bearing zone (C region) of A bands in striated muscle. It 
may serve as a regulator of muscle contraction; or may participate as a structural 
element of the sarcomere, possible involved in A band assembly. (Weber et a l, 1993) 
Human mitchondrial genes for several tRNAs wqtq also found to be up-regulated by 
Wy-14,643. The up-regulation of tRNAs is indicative of a resultant increase in protein 
expression.
Down-regulated genes identified 24 hours following Wy-14,643 treatment:
Apolipoprotein E is a glycoprotein which interacts with specific cell surface receptors 
which mediate the uptake of lipoproteins by cells and so regulate the metabolism of 
cholesterol and other lipids (Fukazawa et a l, 1986; Fung et a l, 1986).
Up-regulated genes identified 12 hours following Wy-14,643 treatment:
D-dopachrome tautomerase was first isolated from rat liver cells and although its 
natural function is unknown, it shares homology with macrophage inhibitory factor 
(MIF), which could suggest a role of D-dopachrome tautomerase in inflammation. 
More specifically it may therefore have an effect on Kupffer cells, the macrophages in 
the liver. MIF is also thought to be of importance in cell growth and differentiation 
(Zhang et a l, 1995).
Down-regulated genes identified 12 hours following Wy-14,643 treatment:
The carboxylesterase (hydrolase S) gene identified is one of five liver
carboxylesterases that have been cloned, all of which are known to hydrolyse a
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variety of xenobiotic and endogenous substrates including lipids (Long et a l, 1988). 
4 of these carboxylesterases are found in the lumen of the endoplasmic reticulum, the 
fifth (hydrolase S) as isolated in this study, has been shown to be a serum esterase 
(Robbi and Beaufay, 1992; Alexson et a l, 1994; Yan et a l, 1995). Serum 
carboxylesterases have been found to play an important role in lipid metabolism and 
detoxification of organophosphates. Interestingly, gene expression of 
carboxylesterases have already been shown to be regulated by a variety of xenobiotics 
(Ashour et a l, 1987; Hosokawa et a l, 1988; Zhu et a l, 2000).
3.8.5 Summary
The four compounds investigated in study 1, namely phénobarbital, Wy-14,643, 
dexamethasone and cyproterone acetate, each exerted the expected increases in rat 
liver size and weight. For PB, Wy-14,643 and CPA this increase in liver weight 
coincided with a significant increase in hepatocyte cell proliferation, in conjunction 
with a minor suppression of apoptosis. In contrast, marked significant suppression of 
apoptosis was observed during DEX-induced liver growth Avith no change in cell 
proliferation rates. It was concluded that these changes in cell proliferation and 
apoptosis were likely to be major factors in the increase in liver weight observed 
following each of the compound treatments.
The gene-hunting exercise, SSH, isolated a wide variety of potentially interesting 
genes demonstrated to be differentially expressed following Wy-14,643 treatment. 
With regard to the investigation of mechanisms of Wy-14,643-induced liver effects 
such as peroxisome proliferation, liver growth and carcinogenesis, interesting genes 
identified included: cathepsin H, carboxylesterase, ubiquitin activating enzyme El, 
fetuin, glutathione peroxidase, the Kupffer cell receptor and metallopanstimulin. 
These genes have demonstrated involvement in a variety of processes including 
protein degradation, oxidative stress, cell proliferation, and apoptosis. However, 
before such gene changes may be accepted as true, additional confirmatory and 
quantitation experiments must be carried out.
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Chapter 4 
Results 2
Quantitation and further investigation of differentially expressed genes
identified in rat liver
4.1 RT-PCR Analysis
RT-PCR was carried out on all previously identified differentially expressed 
sequences that matched to specific genes of known function following a BLAST 
search, and all RT-PCR reactions were performed at optimum conditions (Table 2.3). 
It was not possible to quantitate changes in expression of glutathione peroxidase and 
TFIID due to difficulties in primer optimisation.
8 pi of each RT-PCR product was run on a 2 % agarose gel. A typical reaction is 
shown in Figure 4.1. Densitometry was then performed on each of the bands and 
relative intensities calculated using albumin as the standard.
Band intensity of target mRNA in control and treated samples were measured, 
normalised to albumin, and fold changes in target mRNA levels following treatments 
as compared to control were calculated. Fold changes in mRNA levels of all genes 
investigated may be seen in Figure 4.2-4.3.
Figure 4.1 RT-PCR of arginine vasopressin receptor and albumin in control and 
Wy-14,643-treated samples
1 kb
651 bp 
product
Top gel : Albumin
Bottom gel : Arginine vasopressin receptor 
L : Ikb DNA marker
Lanes 1-4 
Lanes 5-8
; Controls
: Wy-14,643-treated
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Figure 4.2 Fold changes in mRNA levels of selected genes identified 24 hours
after one 50 mg/kg dose of Wy-14,643 as determined by RT-PCR
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Figure 4.2: Each bar represents the mean fold change in mRNA levels o f selected genes in rat 
liver identified 24 hours following one 50 mg/kg i.p. dose of Wy-14,643 as compared to control 
(4 animals in each group). All experiments were performed in triplicate. Statistical analysis 
was carried out using a Student’s t-test where asterisks (**) represent a P value < 0.01.
Error bars = SEM
1 Apolipoprotein E 7 Ubiquitin activating enzyme E l
2 Preproalbumin 8 Cathepsin H
3 Transferrin 9 Metallopanstimulin
4 Slow myosin binding protein C 10 Kupffer cell receptor
5 Via arginine vasopressin receptor 11 M itochondrial transfer RNAs
6 Selenoprotein P
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Figure 4.3 Fold changes in mRNA levels of selected genes identified 12 hours
after one 50 mg/kg dose of Wy-14,643 as determined by RT-PCR
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Figure 4.3: Each bar represents the mean fold induction o f mRNA levels o f selected genes in rat 
liver identified 12 hours following one 50 mg/kg i.p. dose o f Wy-14,643 as compared to control 
(5 animals in each group). All experiments were perfomied in triplicate. Statistical analysis was 
carried out using a Student’s t-test where asterisks (**) represent a P value < 0.01.
Error bars = SEM
1 Carboxylesterase
2 Fetuin
3 D-dopachrome tautomerase
4 Superoxide dismutase
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4.2 Taqman analysis
Four genes were selected for further investigation by Taqman analysis, as their known 
functions were thought to be interesting in terms of possible mechanisms of liver 
growth. They were carboxylesterase, cathepsin H, the Kupjfer cell receptor and 
ubiquitin activating enzyme El. These genes were selected on the basis of their 
known functions and possible links to a mechanism of compound-induced liver 
growth (implications are fully discussed in section 4.4). Changes in mRNA levels of 
each of these four genes were investigated in all liver samples over 5 time-points: 
2, 12,24, 48 and 72 hours.
4.2.1 Preparation of cDNA for quantitation
Total RNA was first extracted from 80-100 mg of each liver from study 1 using the 
Bio/RNA-XCell ™ total RNA isolation system as described. RNA samples were 
quantified by spectrophotometry and 100 ng separated on a 1 % agarose gel. In each 
sample two distinct bands representing rRNA could be seen and an example of this 
may be seen in Figure 4.4.
Total RNA was then converted to cDNA as previously described (section 2.2.4.2.2). 
Figure 4.4 Total RNA extraction from rat liver
_ _ _ _ _ _ _ _ _ _ _ _    2 8 S r R N A
1 kb —
1 8 S r R N A
L : Ikb DNA ladder
R l, R2 : total RNA samples derived from rat liver
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4.2.2 Taqman quantitation
Taqman experiments were performed for all liver samples from the 5 time-points listed 
above using the optimised primer and probe conditions as described previously 
(section 2.2.4.2.4).
Copy numbers of target mRNA in both control and treated samples were obtained, and fold 
changes in target mRNA levels in treated samples as compared to control calculated. 
Changes observed may be seen in Figure 4.5-4,8.
Figure 4.5 Changes in liver carboxylesterase mRNA levels as determined by
Taqman analysis
change
Time course (hours)
Figure 4.5 Each bar represents the mean fold change in carboxylesterase mRNA levels o f 5 
treated animals as compared to control over the time course. Statistical analysis was carried out 
using a Student’s t-test where asterisks (*) represent: * P < 0,05, **? < 0.01. Error bars = SEM
Phénobarbital (50 mg/kg/day) 
Wy-14,643 (50 mg/kg/day)
□Dexamethasone (100 mg/kg/day)
I I Cyproterone acetate (60 mg/kg/day)
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Figure 4.6 Changes in liver cathepsin H  mRNA levels as determined by Taqman
analysis
Fold
change
-2
-4
Time course (hours)
Figure 4.6 Each bar represents the mean fold change in cathepsin H  mRNA levels o f 5 treated 
animals as compared to control over the time course. Statistical analysis was carried out using a 
Student’s t-test where asterisks (*) represent P values: * P < 0.05, **P < 0.01. Error bars = SEM
Phénobarbital (50 mg/kg/day) 
Wy-14,643 (50 mg/kg/day)
□ Dexamethasone (100 mg/kg/day)
I I Cyproterone acetate (60 mg/kg/day)
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Figure 4.7 Changes in liver Kupffer cell receptor mRNA levels as determined by
Taqman analysis
* *  * *
* * * *
**
**Fold 
change“5
* *
-10
Time course (hours)
Figure 4.7 Each bar represents the mean fold change in Kupffer cell receptor mRNA levels 
o f 5 treated animals as compared to control over the time course. Statistical analysis was 
carried out using a Student’s t-test where asterisks (*) represent P values: * P < 0.05, 
**P < 0.01. Error bars = SEM
Phénobarbital (50 mg/kg/day) 
Wy-14,643 (50 mg/kg/day)
Dexamethasone (100 mg/kg/day) 
CH Cyproterone acetate (60 mg/kg/day)
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Fold
change
Figure 4.8 Changes in liver ubiquitin activating enzyme E l mRNA levels
as determined by Taqman analysis
Time course (hours)
Figure 4.8 Each bar represents the mean fold change in ubiquitin activating enzyme E l mRNA 
levels o f 5 treated animals as compared to control. Statistical analysis was carried out using a 
Student’s t-test where asterisks (*) represent: * P < 0.05, **P < 0.01. Error bars = SEM
Phénobarbital (50 mg/kg/day) 
Wy-14,643 (50 mg/kg/day)
□ Dexamethasone (100 mg/kg/day)
I I Cyproterone acetate (60 mg/kg/day)
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4.3 RT-PCR V Taqman
As the gene expression quantitation achieved by RT-PCR for Wy-14,643 samples 
(12 and 24 hours after 1 dose) was repeated in the Taqman studies, the data were 
compared. The collated results are shown in Table 4.1.
Fold changes obtained for cathepsin H  and ubiquitin activating enzyme E l via 
RT-PCR were replicated in the Taqman study, with only minor inter-study differences 
in the magnitude of change in expression observed.
The down-regulation observed in carboxylesterase mRNA levels at 12 hours by RT- 
PCR was not observed in Taqman investigations.
As the 2 methods provided opposing statistically significant results for the Kupffer 
cell receptor mRNA quantitation, studies were designed in an attempt to discover the 
reason for this difference.
Table 4.1 Comparison of RT-PCR and Taqman data
Gene Tlme-point
investigated
RT-PCR Taqman
Carboxylesterase 12 h i  2.44** t l . l
Cathepsin H 24 h 1 1.7** 1 1.6
Kupffer cell receptor 24 h T3.8** 4r 1.5*
Ubiquitin activating enzyme El 24 h 1 1.5** Î2 .0 *
Table 4.1: Results are represented as mean fold changes as compared to control, derived from 
5 animals. Each experiment was performed in triplicate. Statistical analysis was carried out 
using a Student’s t-test where asterisks (*) represent P values of: *P < 0,05; **P < 0.01. 
t  and 'I refer to up- and down-regulation respectively
151
4.3.1 Confirmation of RT-PCR and Taqman products
RT-PCR and Taqman products were sequenced and subjected to a BLAST search in 
order to confirm their identity. This was performed for all 4 genes.
The BLAST search results are shown in Table 4.2
Table 4.2 BLAST searches of RT-PCR and Taqman products
Expected (a) RT-PCR 
and (b) Taqman 
products
Gene & 
Accession number
MATCH 
Score Length
Sequence
homology
la Carb 343 351/429 81%
Carb M20629
lb 811 423/425 99%
2a C atH 743 539/591 91%
C atH Y00708
2b 797 402/402 100%
3a KCR 936 579/611 94%
KCR J03734
3b 898 453/453 100%
4a UbEl 182 96/103 93%
UbEl D10576
4b 206 104/104 100%
Table 4.2 la -  4a: RT-PCR BLAST search results 
lb -  4b: Taqman BLAST search results
1 Carb: Carboxylesterase
2 CatH: Cathepsin H
2 KCR: Kupffer cell receptor 
4 UbEl: Ubiquitin activating enzyme E l
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4.3.2 RT-PCR using Taqman components
As indicated in Table 2.8, the components of the RT-PCR and Taqman reactions 
differ. RT-PCR reactions were therefore performed substituting components in order 
to replicate Taqman reaction conditions. mRNA was therefore replaced with the 
same total RNA as used in the Taqman quantitation, and gene-specific primers were 
replaced with random hexamers for the reverse transcription step.
All quantitation results obtained for the Kupffer cell receptor are summarised in 
Figure 4.9, represented as fold change as compared to control.
Figure 4.9 Summary of quantitation of changes in Kupffer cell receptor 
mRNA levels
3
Fold
change
2
**
- Ï -
1 2 3L _ t----
Gene
Figure 4.9 Each bar represents the mean fold induction of Kupffer cell receptor mRNA 
levels as compared to control derived from 5 animals per group.
Statistical analysis was performed using a Student’s t-test where asterisks (*) represent 
P values: *P < 0.05; **P < 0.01. Error bars = SEM
1 : Taqman using total RNA and random hexamers
2 : RT-PCR using mRNA and gene-specific primers
3 : RT-PCR using total RNA and random hexamers
4 : RT-PCR using total RNA and gene-specific primers
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4.4 Discussion
Following a gene hunting exercise such as SSH, it is essential to quantify the changes 
in the genes identified, in order to both confirm differential expression as well as 
assess the statistical and biological significance of such changes. This further 
confirmation is necessary as it is easy to become preoccupied with lists of genes, and 
as no subtraction method will be 100 % efficient, it may be that some of the changes 
identified so far are false positives.
In my study, two methods of RNA quantitation were utilised, namely 
semi-quantitative RT-PCR and Taqman. Both work on the same basis i.e. RNA is 
extracted from the samples, a reverse transcriptase step is performed to convert the 
single-stranded RNA to single-stranded complementary DNA, and then a typical PGR 
reaction is carried out.
4.4.1 Semi-quantitative RT-PCR
Semi-quantitative RT-PCR was carried out first, using mRNA extracted from the 
control and Wy-14,643 liver samples from the time-points at which the genes were 
first identified as being differentially expressed (12 or 24 hours following 1 dose of 
Wy-14,643). This was performed in order to confirm and quantify the SSH and dot 
blot data. Albumin was used as the reference gene, as it has been widely used before 
and has previously shown to be only marginally affected, if at all, following 
peroxisome proliferator treatment as in this study (Miller et al., 1996; Nemali et al, 
1989; Rockett et al, 2000; Rumsby et a l, 1994). It is important that the reference 
gene is not affected by the drug treatment regime, as this would result in incorrect 
conclusions of the effects of the drug on the species tested. The results obtained for 
each of the genes were also normalised to nanograms of RNA used per reaction (data 
not shown), which produced virtually identical data to that following normalisation to 
albumin.
On the whole, most of the up- or down-regulated transcripts identified from the dot
blots were confirmed via RT-PCR, and this differential expression was demonstrated
to be statistically significant, ranging between 1.3- and 4.4-fold depending on the
gene investigated (Figures 4.2-4.3). However, some proved to be false positives as
there was little difference between the treated and the untreated samples. Examples of
such genes include apolipoprotein E and preproalbumin, which may have arisen as
contaminants in the subtracted populations due to their high abundance in the original
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samples. In accordance with the dot blot data, RT-PCR indicated slow myosin- 
binding protein C to be up-regulated, but this change was found to be insignificant. 
This was probably due to it being present at only very low levels and so signal to 
noise ratio was sufficiently poor to prevent a clear analysis to be made. Dot blots also 
indicated that transferrin was up-regulated, but little difference was found following 
RT-PCR. Interestingly, previous studies have reported transferrin to be down- 
regulated following peroxisome proliferator treatment (Hertz et a l, 1996). In either 
study, it may be that the actual clone isolated was a close relative, splice variant or 
isoform of transferrin. Indeed, single genes have been shown to generate a number of 
different transcripts, each of which encode the same protein. Such transcripts may be 
generated via processes including alternative splicing as observed with the rat 
fibronectin gene (Tamkun et al, 1984), or the selective use of multiple 3' 
polyadenylation signals as observed with the mouse opsin gene (Al-Ubaidi et al., 
1990). The possibility of the generation of a number of different transcripts by 
specific genes emphasises the importance of the use of protein studies in conjunction 
with such mRNA investigations. Northern blot analysis would have helped to 
determine whether the transcript isolated was indeed transferrin. Northern blotting is 
another mRNA quantitation technique which involves the immobilisation of RNA by 
agarose gel electrophoresis, followed by transfer to a nitrocellulose membrane either 
electrically or by capillary action with a high salt solution. A labelled probe specific 
for the target mRNA sequence is then incubated with the blot. Like RT-PCR, 
Northern blotting can be used to determine the abundance of the immobilised nucleic 
acid, but in contrast, it also determines the size. This method is therefore able to 
detect alternatively spliced transcripts as well as being able to distinguish between 
members of multi-gene families. Indeed, it would be beneficial to correlate the dot 
blot and RT-PCR data obtained for each of the identified gene transcripts with 
Northern blot analysis, not only to confirm differential expression, but also to confirm 
identity. Interestingly, Northern blots have already been carried out for many of the 
identified differentially expressed transcripts including human ubiquitin activating 
enzyme E l (Handley et a l, 1991), mouse cathepsin H  (Lafuse et a l, 1995), rat 
Kupjfer cell receptor (Hoyle and Hill, 1988), rat selenoprotein P (Hill et a l, 1992), 
rat D-dopachrome tautomerase (Zhang et a l, 1995), rat copper/zinc super oxide
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dismutase (Hsu et al., 1992) and rat Via arginine vasopressin receptor (Morel et al., 
1992)
4.4.2 Taqman
4.4.2.1 Study design
Defining the functions of SSH genes (section 3.8.4) enables the selection of 
potentially interesting genes for further investigation. As it was beyond the scope of 
this project to study all genes of potential interest in more detail, four were initially 
selected, namely carboxylesterase (Carb), cathepsin H (CatH), the Kupffer cell 
receptor (KCR) and ubiquitin activating enzyme E l (UbEl). These were chosen for a 
number of reasons. CatH and UbEl were highlighted as potentially interesting as 
they both share an involvement in protein degradation, and were affected similarly by 
Wy-14,643 treatment -  i.e. could peroxisome proliferators act by disrupting 
degradation of specific proteins? Carb gene expression has already been shown to be 
affected by a number of xenobiotics (Ashour et a l, 1987; Hosokawa et a l, 1988; Zhu 
et a l, 2000), but it is not, as yet, known why. Interestingly, Carb is thought to be 
responsible for the metabolism and detoxification of a number of different 
compounds. The observed change in KCR was particularly interesting due to the 
recent hypothesis that Kupffer cells are responsible for the mitogenic effect of 
peroxisome proliferators (Rose et al, 1997a). Could the Kupffer cell receptor be 
involved in such a mechanism and if so is it involved in the process of liver growth 
induced by other compounds?
Following the RT-PCR study, total RHA extracted from all treated and control livers
from animals in study 1 at 5 different time-points: 2, 12, 24, 48 and 72 hours, was
analysed by Taqman. All 4 compound treatments, namely phénobarbital (PB), Wy-
14,643, dexamethasone (DEX) and cyproterone acetate (CPA) were investigated.
Each of these compounds are known to cause growth of the liver, and in some cases
hepatocarcinogenesis in rats by mechanisms which remain undefined.
It was initially decided to investigate possible changes in the 4 identified genes
following treatment with each of the four compounds in order to determine whether
changes observed with Wy-14,643 were common to other compounds known to
induce liver growth in rats. If similar changes were observed it was reasoned that it is
possible that the compounds may share similar mechanisms of action, with the
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identified genes playing roles in this. Investigating other time-points was of potential 
interest in terms of discovering a general pattern of change of the identified gene. 
Interesting time-points and more significant changes may occur, yet to be identified. 
Due to the choice of time-points for SSH and subsequent RT-PCR, the changes in 
gene expression initially observed were those occurring proceeding the onset of cell 
proliferation and growth of the liver. It may be that the observed changes contribute 
in some way to the initiation of this. It would be interesting to discover whether the 
changes identified are maintained once growth has begun.
For each of the four genes investigated, further changes in gene expression were 
observed following the onset of cell proliferation and growth occurring during 
Wy-14,643 treatment (see below). This indicates the importance of studying gene 
changes over a time course rather than just at one specific time-point. By simply 
studying differential gene expression at one time-point, inappropriate conclusions 
may be reached -  if a gene was shown to be up-regulated it may be concluded that the 
treatment being investigated simply increases mRNA levels of that gene. This is true, 
but only at that time-point, it may be that in actual fact, as for many genes, mRNA 
levels may be up- and down-regulated over the time course by the compound 
treatment.
Taqman studies identified differential expression in all of the genes by all of the 
compounds at at least 1 of the time-points (Figure 4.5-4.8), with some interesting 
similarities in differential expression being observed between compounds.
4.4.2.2 Changes in Cathepsin H  and Ubiquitin activating enzyme E l  mRNA levels
For Wy-14,643, significant increases in gene expression of CatH and UbEl were
observed at 48 hours in addition to that already observed at 24 hours by SSH and
RT-PCR (Figure 4.6 & 4.8), with no major changes occurring either side of these
time-points. Interestingly, the onset of the increase in liver weight (Table 3.1)
occurred at the time these gene changes were observed. Therefore, could the
two genes involved in protein degradation be involved in this?
Similar increases in UbEl gene expression were observed for three out of the four
compounds (Wy-14,643, DEX and CPA), 24 hours following 1 dose of each (Figure
4.8), which may possibly indicate a role of this gene in the compounds shared actions.
However, this increase was only maintained with Wy-14,643, expression of UbEl
being significantly reduced to less than control by 72 hours for both DEX and CPA.
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Expression of UbEl may be related to the increases in liver weight observed 
following each of the compound treatments, in that peak liver weights for both DEX 
and CPA were reached by 48 hours where UbEl levels returned to control, whereas 
for Wy-14,643 where increases in UbEl mRNA levels were maintained for longer, 
liver weight was still increasing. It may be that UbEl is in some way involved in the 
onset or maintenance of this compound-induced liver growth.
DEX administration resulted in similar changes in both CatH and UbEl expression. 
Significant increases were observed at 24 hours, which levelled to control values by 
48 hours with a significant decrease in expression by 72 hours. It is possible that 
protein degradation may play a role in the actions of DEX on the rat liver, as 2 genes 
involved in this process have demonstrated to be similarly regulated.
CPA administration resulted in a significant decrease in CatH at 48 and 72 hours. 
This regulation occured once the peak liver weight had been reached which may 
indicate an involvement in this.
In contrast, a significant increase in UbEl was seen 2 hours following 1 dose of PB, 
falling to a significant decrease at 24 hours before levelling to control values at 
48 hours. A similar pattern was observed with PB for CatH gene expression 
(Figure 4.6), the other gene involved in protein degradation. It may be noted that the 
effects of PB on protein degradation and possible mechanistic role of the related 
genes may therefore be very different than that of the other 3 compounds.
4.4.2.3 Changes in Carboxylesterase and Kupffer cell receptor mRNA levels
Compound administration resulted in many significant changes in rat liver Carb and 
KCR gene expression.
For both genes only minor changes were observed following PB administration, more 
significant changes being observed after dosing with the other 3 compounds 
(Figure 4.5 & 4.7).
Wy-14,643 and DEX appeared to induce similar changes in expression of both Carb
and KCR, levels of both genes decreasing over the time-course. Greatest significant
changes were observed following DEX administration, with a 6-fold and 8-fold
decrease in Carb and KCR respectively, at 72 hours. Down-regulation of both mRNA
and protein levels of various liver carboxylesterases has already been shown to occur
following treatment of rats with DEX (Zhu et a l, 2000). Interestingly, the existence
of a major species difference regarding the regulation of Carb gene expression by
158
DEX has been suggested. Zhu and co-workers also demonstrated that nanomolar 
concentrations of DEX were sufficient to markedly decrease the levels of various 
immunoreactive carboxylesterases in cultured rat hepatocytes whereas micromolar 
concentrations resulted in a minor inductive effect in human hepatocytes. It may be 
that this differential expression of Carb observed between species may help contribute 
to the mechanism of DEX-induced liver growth in rats. It would be interesting to 
determine if a similar response in Carb gene expression was seen between species 
following treatment with other compounds that are known to cause growth of the 
liver.
CPA administration resulted in the same pattern of change in KCR as seen with Wy- 
14,643 and DEX, but in contrast resulted in significant increases in Carb gene 
expression levels at 24 and 48 hours.
As a link between Kupffer cells and liver growth has already been indicated 
(Rose et a l, 1997a), and 3 compounds known to cause hepatomegaly each produced a 
significant down-regulation in mRNA levels of a Kupffer cell-specific gene over a 
time-course, it may be hypothesised that the changes in this gene are in some way 
related to compound-induced liver growth.
4.4.3 Taqman V RT-PCR
As the RT-PCR quantitation performed for Wy-14,643 was repeated by Taqman, data
were compared (Table 4.1). For both UbEl and CatH similar results were obtained,
expression levels of both being up-regulated 24 hours following one dose of
Wy-14,643. This provided confidence in the data obtained. However, the
down-regulation observed for Carb 12 hours following one dose of Wy-14,643 was
not seen in the subsequent Taqman experiments. Instead, no change was observed in
Carb gene expression at this time-point. This may be due to experimental variation.
As the change observed by RT-PCR was relatively small it is possible that it may
have been masked in the Taqman experiments, possibly as a result of the dilution
procedures necessary for Taqman. Interestingly, RT-PCR and Taqman experiments
for KCR produced contradictory results -  a significant up-regulation was observed
with RT-PCR, whereas a significant down-regulation was observed with Taqman 24
hours following one dose of Wy-14,643. Investigations were carried out in order to
determine why this was so. First of all, RT-PCR products were sequenced and
subjected to BLAST searches in order to confirm if the required product had been
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obtained. This was carried out for all 4 genes, all of which produced a direct match to 
the appropriate gene of interest, with sequence homologies ranging between 81-94%, 
(Table 4.2). The design specificity of Taqman primers and probes only allows for 
amplification of the required gene amplicon. However, BLAST searches were still 
performed on the products that would be obtained following such a Taqman reaction, 
and accordingly, sequence homologies of 99-100% were obtained (Table 4.2). It was 
noted that sequence homologies obtained for RT-PCR products were not as great as 
those obtained for Taqman. However, when RT-PCR sequencing results were 
examined it was concluded that this was mainly due to sequencing failures, and 
therefore BLAST search matches for both RT-PCR and Taqman were accepted as 
reliable.
It was noted that there are differences between the components of the RT-PCR and 
Taqman reactions in these investigations (Table 2.8), and it is possible that these 
differences may contribute to the production of contradictory data. Taqman uses total 
RNA whereas RT-PCR uses mRNA. Taqman also uses random hexamers for the 
reverse transcription step, whereas RT-PCR uses the gene-specific primers for the 
whole reaction. Neither of these are intrinsic requirements for the specific methods, 
therefore RT-PCR was carried out using Taqman components. First of all, both RNA 
and primers were substituted and RT-PCR carried out. This provided results that 
matched those obtained with Taqman (Figure 4.9). The contradictory data may 
therefore be a result of the different priming methods used. It is possible that the 3' 
end of the mRNA may not have been fully intact due to partial degradation of the 
extracted RNA. Clearly, if the primer-annealing sequence was located within this 3' 
region, this would have affected priming with gene-specific primers. RT-PCR was 
then carried out again using total RNA as used in the Taqman experiments, but this 
time using gene-specific primers. Therefore the only difference between the 
components of the experiments was the RNA. This again provided results very 
similar to those achieved with Taqman (Figure 4.9). It was therefore concluded that 
the contradictoiy data may have occurred because of the use of different RNA 
samples and may be due to the RNA extraction methods. This left: the problem 
regarding which data should be accepted as true. Taqman is often the method of 
choice, due to its high throughput, high specificity and reproducibility. Taqman data 
were confirmed via later repeat experiments (section 5.2.2), and further investigations
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regarding Kupffer cell receptor expression (section 6.3). A third method of mRNA 
quantitation such as Northern blot analysis could also have been used in order to 
address this problem.
4.4.4 Summary
The importance of quantitation experiments following gene-hunting exercises such as 
SSH has been indicated. Such investigations confirmed and quantified much of the 
differential expression identified via SSH, although a small number of false positives 
were eliminated.
Taqman investigations of the changing mRNA levels of 4 selected potentially 
interesting genes proved beneficial in terms of the elucidation of compound-induced 
similarities and differences, as well as providing an indication of changes in gene 
expression over a time course. Most notably, similarities in compound-induced 
differential gene expression were recorded following Wy-14,643, dexamethasone, and 
cyproterone acetate treatment; with phénobarbital commonly exerting its own 
different, individual effects on the selected genes. This may indicate common 
mechanisms of action regarding the 3 compounds, with PB potentially acting via 
entirely different pathways.
It is now necessary to deduce what these changes may mean in terms of liver growth. 
It is not yet known whether these genes are involved in the onset of the growth, 
involved in maintaining growth, or are simply a consequence of growth or 
administration of xenobiotic compounds. However, the patterns identified and known 
functions of the genes (section 3.8.4) do indicate a potential involvement in the 
growth process.
Further experiments need to be performed in order to understand the importance of 
the changes observed. How can a direct involvement in liver growth be determined? 
It was hypothesised that investigation into the liver specificity of these gene changes 
may provide some clues.
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Chapter 5 
Results 3
Study 2 -  Determination of liver-specificity of identified differential gene 
expression following xenobiotic treatment
Study 2 w as p er fo rm ed  a t the University o f  Surrey, Guildford.
5.1 Organ weights (study 2)
Organs were weighed immediately upon removal before being frozen in liquid 
nitrogen. Organ weights were calculated as the percentage of the total body weight. 
Weights are represented in Table 5.1 as % change as compared to control.
Table 5.1 Percentage change in organ weights following compound administration as compared 
with control
Liver Spleen Kidney Heart Lung Testes Brain
Wy-14,643
(50 mg/kg/day)
24 h 
48 h 
72 h
+17 ±3** 
+28 ±9** 
+45 ± 10**
+3 + 12 
+11+6
+1±3
+13+3
+11+6
-7±3 
+2 + 5
+39 + 15 
+8 + 6 
-2 ±14
+6 ± 4 
+12 ±3 
+5 ±2
-11 ±5 
-12 ±6 
+17 ±7
Dexamethasone
(100 mgdcg/day)
24 h 
48 h 
72 h
+46 + 4* * 
+67 ±10** 
+52 + 9**
-44 ± 5** 
-56 ±7** 
-57 + 3**
+6 + 4 
+19 ±5** 
+48 + 3**
+14 ±5 
+7±2 
+19 ±2**
+56 ±20 
+8±6 
-21 ± 10
-2 ±3
+14 ±4 
+10 ±7
+37 ±5** 
+4 ±4 
+55 ±2**
Cyproterone
acetate
(60 mg/kg/day)
24 h 
48 h 
72 h
+18 ±2** 
+34 + 4** 
+42 + 3**
-4 ± 9 
+11±7 
-14 ±2
+6 ±4 
+9 ±2 
+5 ±2
+10 ±5 
+5 + 3
+2 ±4 
-17 ±8
+1 ±3 
+6±1 
+7±2
+13 ±7 
+21 ±8 
+19±6
Table 5.1: Data represents mean percentage change in organ weights as compared to control ± SD, derived 
from 5 animals per treatment group. Statistical analysis was performed using an ANOVA, were asterisks (**) 
represent P < 0.01.
- : represents no change in weight as compared to control.
Mean absolute organ weights (g) ± SD are shown below for control groups:
Time-point Liver Spleen Kidney Heart Lung Testes Brain
24 h 13.7 + 0.4 0.9+ 0.1 2.7 + 0.2 1.4+ 0.2 1.8+ 0.3 2.8 + 0.2 1.5 + 0.3
48 h 14.1 + 0.6 0.9+ 0.1 2.7+ 0.1 1.5+ 0.2 2.1 + 1.2 2.9 + 0.2 1.6+ 0.4
72 h 15.1 + 1.2 1.0+ 0.2 2.8+ 0.1 1.5+ 0.1 3.2+1.2 2.8 + 0.2 1.6+ 0.2
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5.2 Taqman analysis
The 4 genes initially selected for quantitation in study 1 {carboxylesterase, cathepsin 
H, Kupffer cell receptor and uhiquitin activating enzyme E l) were further examined 
by Taqman analysis in this study, covering an increased organ profile. In addition to 
these 4 genes, 2 other genes were selected for quantitation, namely nek2 and 
p21/wafl. As no measurements of DNA synthesis or apoptosis were made in study 2, 
changes in mRNA levels of these additional 2 genes were investigated as they may act 
as alternative markers for these biological functions (see section 5.3.3 for full 
explanation).
The effects of 3 compound treatments, namely Wy-14,643 (50 mg/kg/day), 
dexamethasone (100 mg/kg/day) and cyproterone acetate (60 mg/kg/day), were 
investigated over a 72 hour time-course. Changes in mRNA levels of each of the 4 
previously identified genes were investigated in 5 different organs, namely the liver, 
spleen, kidney, testes and heart. By investigating the gene expression changes in 
organs other than the liver it was hypothesised any liver-specificity of the changes 
would be identified. If liver-specificity for regulation of any of the 4 genes was 
confirmed, it was hypothesised that this may indicate a potential role in liver growth 
(section 5.3.1). Changes in nek2 andp21/wafl were only investigated in the liver.
5.2.1 Preparation of cDNA for quantitation
Total RNA was first extracted from 80-100 mg of each of the 5 organs from study 2 
listed above using the Bio/RNA-XCell total RNA isolation system as described. 
Again, 10 pi of each RNA sample was separated on a 1 % agarose gel and quantified 
by spectrophotometry. In each sample two distinct bands representing rRNA could be 
seen as indicated in Figure 4.4. Total RNA was then reverse-transcribed to cDNA as 
previously described (section 2.2.4.2.2).
5.2.2 Taqman quantitation
Taqman experiments were performed for all organ samples from the 3 time-points 
listed above using the optimised primer and probe conditions as described previously 
(section 2.2.4.2.4). Copy numbers of target mRNA in both control and treated 
samples were obtained, and fold changes in target mRNA levels in treated samples as 
compared to control calculated.
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Changes observed in liver mRNA levels of nek2 and p21/wafl are shown in Figure 
5.1-5.2; those observed in each of the 4 previously identified genes in Figure 5.3-S.6. 
Changes observed in mRNA levels of cathepsin H  and ubiquitin activating enzyme El 
in the spleen, testes, kidney and heart are shown in Figure 5.7-5.10. As expected the 
liver-specific genes carboxylesterase and the kupffer cell receptor were not detected 
in any other organ except for the liver.
Figure 5.1 Changes in liver nek2 mRNA levels as determined by Taqman analysis
13
Fold 1 
change
-5
-9
-13
48 72
Time course (hours)
Figure 5.1; Each bar represents the mean fold change in nek2 mRNA levels of 5 treated animals as 
compared to control over the time course. Statistical analysis was carried out using a Student’s t-test 
where asterisks (*) represent P values; * P<0.05, **P<0.01. Error bars = SEM
Wy-14,643 (50 mg/kg/day) □ Dexamethasone (100 mg/kg/day)
|j;, Cyproterone acetate (60 mg/kg/day)
165
Figure 5.2 Changes in liver p21 mRNA levels as determined by Taqman analysis
change
Time course (hours)
Figure 5.2: Each bar represents the mean fold change in p21 mRNA levels o f 5 treated animals as 
compared to control over the time course. Statistical analysis was carried out using a Student’s t- 
test where asterisks (*) represent P values: * P<0.05, **P<0.01. Error bars = SEM
I S  Wy-14,643 (50 mg/kg/day)
I I Cyproterone acetate (60 mg/kg/day)
□ Dexamethasone (100 mg/kg/day)
1 6 6
Figure 5.3 Changes in liver carboxylesterase mRNA levels as determined by
Taqman analysis
Fold 
change -5
Time course (hours)
Figure 5.3: Each bar represents the mean fold change in carboxylesterase mRNA levels o f 5 
treated animals as compared to control over the time course. Statistical analysis was carried 
out using a Student’s t-test where asterisks (*) represent P values: * P<0.05, **P<0.01.
Error bars = SEM
Wy-14,643 (50 mg/kg/day)
I I Cyproterone acetate (60 mg/kg/day)
I I Dexamethasone ( 1 0 0  mg/kg/day)
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Figure 5.4 Changes in liver cathepsin H  mRNA levels as determined by Taqman
analysis
Fold
change
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Figure 5.4: Each bar represents the mean fold change in cathepsin H  mRNA levels o f 5 treated 
animals as compared to control over the time course. Statistical analysis was carried out using a 
Student’s t-test where asterisks (*) represent P values: * P<0.05, **P<0.01. Error bars = SEM
ESI Wy-14,643 (50 mg/kg/day) EZl Dexamethasone ( 1 0 0  mg/kg/day)
I I Cyproterone acetate (60 mg/kg/day)
168
Figure 5.5 Changes in liver Kupffer cell receptor mRNA levels as determined
by Taqman analysis
Fold
change
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Figure 5.5: Each bar represents the mean fold change in Kupffer cell receptor mRNA levels of 
5 treated animals as compared to control over the time course. Statistical analysis was carried 
out using a Student’s t-test where asterisks (*) represent P values: * P < 0.05, **P < 0.01. 
Error bars = SEM
Wy-14,643 (50 mg/kg/day)
I I Cyproterone acetate (60 mg/kg/day)
I I Dexamethasone ( 1 0 0  mg/kg/day)
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Figure 5.6 Changes in liver ubiquitin activating enzyme El mRNA levels as
determined by Taqman analysis
Time course (hours)
Figure 5.6: Each bar represents the mean fold change in ubiquitin activating enzyme E l  
mRNA levels o f 5 tieated animals as compaied to control over the time course. Statistical 
analysis was carried out using a Student’s t-test where asterisks (*) represent P values: 
* P < 0.05, **P <0.01. Error bars = SEM
S  Wy-14,643 (50 mg/kg/day)
I I Cyproterone acetate (60 mg/kg/day)
I I Dexamethasone ( 1 0 0  mg/kg/day)
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Figure 5.7 Changes in spleen mRNA levels as determined by Taqman analysis
Figure 5.7a Cathepsin H
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Figure 5.7b Ubiquitin activating enzyme E l
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Figure 5.7: Each bar represents the mean fold change in 5 treated animals as compared to 
control over the time course. Statistical analysis was canied out using a Student’s t-test 
where asterisks (*) represent P values: * P < 0.05, **P < 0.01. Error bars = SEM
N a Wy-14,643 (50 mg/kg/day)
I I Cyproterone acetate (60 mg/kg/day)
□ Dexamethasone (100 mg/kg/day)
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Figure 5.8 Changes in testes mRNA levels as determined by Taqman 
analysis
Figure 5.8a Cathepsin H
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Figure 5.8b Ubiquitin activating enzyme E l
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Figure 5.8: Each bar represents the mean fold change in 5 treated animals as compared to 
control over the time course. Statistical analysis was carried out using a Student’s t-test where 
asterisks (*) represent P values: * P < 0.05, **P < 0.01. Enor bars = SEM
Wy-14,643 (50 mg/kg/day) d ]  Dexamethasone (100 mg/kg/day)
Cyproterone acetate (60 mg/kg/day)
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Figure 5.9 Changes in kidney mRNA levels as determined by Taqman analysis
Figure 5.9a Cathepsin H
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Figure 5.9b Ubiquitin activating enzyme E l
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Figure 5.9: Each bar represents the mean fold change in 5 treated animals as compared to 
control over the time course. Statistical analysis was carried out using a Student’s t-test where 
asterisks (*) represent P values: * P < 0.05, **P < 0.01. Error bars = SEM
I If e i  Wy-14,643 (50 mg/kg/day) 1__ I Dexamethasone (100 mg/kg/day)
[~~| Cyproterone acetate (60 mg/kg/day)
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Figure 5.10 Changes in heart mRNA levels as determined by Taqman analysis
Figure 5.10a Cathepsin H
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Figure 5.10b Ubiquitin activating enzyme E l
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Figure 5.10; Each bar represents the mean fold change in 5 treated animals as compared to 
control over the time course. Statistical analysis was carried out using a Student’s t-test 
where asterisks (*) represent P values: * P < 0.05, **P <0.01. Error bars = SEM
[ 2  Wy-14,643 (50 mg/kg/day) d ]  Dexamethasone (100 mg/kg/day)
d l  Cyproterone acetate (60 mg/kg/day)
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5.3 Discussion
5.3.1 Study 2 design
Study 2 was performed in order to both confirm data obtained from study 1 and to 
further investigate these data in terms of organ distribution. It was hoped that 
identification of any liver-specificity of the changes in transcript levels would indicate 
a potential role of such genes in the observed liver growth.
Those compounds and time-points that provided most statistically significant data in 
the previous study were included in study 2. In an attempt to limit the number of 
animals and only pursue findings of specific interest both the number of compound 
treatments and time-points chosen were reduced.
The 3 compounds selected were Wy-14,643, dexamethasone (DEX) and cyproterone 
acetate (CPA). Many significant changes in the differentially expressed genes 
investigated were observed following these treatments in study 1 as compared to 
phénobarbital (Figure 4.5-4.8): therefore phénobarbital was eliminated from this 
second study. Wy-14,643 was selected on the basis that this had been the original 
compound used to identify the genes investigated so far {via SSH). CPA was selected 
as, like Wy-14,643, it is also a hepatocyte mitogen and non-genotoxic carcinogen 
(Roberts et a l, 1995). It would therefore be beneficial to determine whether these 
compounds exert similar changes in gene expression -  are the effects on the 
expression of the genes investigated common to all non-genotoxics, or are they 
chemical-type specific? DEX was selected as it exerts hepatomegaly caused by 
hypertrophy only, with no increase in DNA synthesis or cell proliferation taking place 
(Nagy et a l, 2001). In fact, DEX has actually been shown to suppress DNA synthesis 
in liver cells (Nagy et a l, 1998; 2001). DEX may therefore be expected to act via 
different mechanisms and affect the expression of different genes compared to 
compounds that cause hepatomegaly through hyperplasia. However, some 
similarities regarding the effects DEX exerted on gene expression as compared to 
Wy-14,643 and CPA were noted in study 1 (Figure 4.5-4.8). These similarities may 
indicate that the genes identified contribute to a general mechanism of growth of the 
liver, whether it be through hyperplasia or hypertrophy or a combination of both. It is 
useful to investigate compounds exerting different actions on the liver, all of which 
result in an increase in size as a common underlying mechanism may be identified.
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The time-points selected for study 2 were also chosen as those where most significant 
changes were observed in study 1 (Figure 4.5-4.8). These being 24, 48 and 72 hours 
(24 hours following 1,2 and 3 daily doses).
The 4 genes investigated by Taqman in study 1 were also investigated in study 2, 
namely carboxylesterase (Carb), cathepsin H  (CatH), the Kupffer cell receptor (KCR) 
and ubiquitin activating enzyme E l (UbEl). Compound effects on 2 additional genes 
were also investigated, namely nek2 andp21/wafl (section 5.3.3).
However, this study differs from study 1 in that changes in gene expression in organs 
other than the liver were investigated. This idea forms the rationale of this second 
study. Many changes in the 4 genes selected were observed in study 1 
(Figure 4.5-4.8). However, it is still not known how/if these changes actually 
contribute to the observed liver growth. It was hypothesised that if the gene changes 
observed were at all involved in growth of the liver, their levels should not change in 
organs that do not grow in response to the compound treatments. Therefore, are the 
changes previously identified liver-specific? In total, 7 organs were removed from 
each of the animals. Due to time constraints, 5 organs, including the liver, were 
selected for analysis as it was felt that this would be sufficient to investigate 
liver-specificity of gene expression. The 5 organs selected were liver, spleen, testes, 
kidney and heart.
5.3.2 Organ growth
Each of the three compounds investigated induced a significant increase in liver
weight at each of the time-points investigated (Table 5.1). The magnitude of the
increase in liver weight observed in both study 1 and 2 following Wy-14,643
treatment was similar, increasing over the 72 hours to 37 % greater than control in
study 1 and 45 % in study 2. However, study 2 exhibited a significant increase in
liver weight following 24 hours of Wy-14,643 treatment, but this was not seen until
48 hours in study 1. Indeed, study 2 is in accordance with the literature as DNA
synthesis and cell proliferation has previously been reported to be induced following
1 dose of Wy-14,643, peaking between 24 and 36 hours (Ohmura et a l, 1996). DEX
treatment resulted in similar effects on liver weight in both studies, the maximum
weight being achieved at the 48 hour time-point, this peaking to 70 % compared to
control in study 1, and 67 % in study 2. However, some study differences regarding
the effects of CPA on liver weight were observed. Study 1 demonstrated a rapid
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increase in liver weight peaking at 62 % as compared to control by 48 hours. Study 2, 
however, exhibited a more gradual increase in weight which still increased up to the 
72 hour time-point where it reached a much lower 42 % as compared to control. This 
inter-study variation may be due to a combination of experimental and animal 
variation, resulting in these different magnitudes of liver growth response. Study 1 
was performed at GlaxoSmithKline whereas study 2 was performed at the University 
of Surrey, therefore differences existed between compound preparations administered, 
precise housing conditions as well as the animals involved.
For both Wy-14,643 and CPA, no significant changes in weight as compared to 
control were observed in other organs. However, DEX administration resulted in 
statistically significant increases in the percentage of the total body weight 
represented by the kidney, heart and brain at a number of time-points, observed to be 
due to a decrease in the total body weight of these animals as compared to control as 
specific organs weights were not affected. Interestingly, following each of the 3 
doses, the spleen was noted to dramatically decrease in size, with weights half that of 
control. This rapid and marked decrease in spleen weight following treatment of rats 
with DEX has previously been reported (Kelly and Goldspink, 1982; Lupp et ah, 
1999; Orzechowski et a l, 2000), and is consistent with an observed elevation of 
protein degradation in the spleen (Kelly and Goldspink, 1982).
5.3.3 Changes in liver nek2 and p21Avafl mRNA levels
In this study, although each of the compound treatments resulted in the expected 
increases in liver weight (Table 5.1), no measurements of DNA synthesis or apoptosis 
were made as for study 1. Therefore, alternative potential markers, namely nek2 and 
p21/wafl, for the biological fimctions, were used in Taqman analysis instead.
nek2
nek2 is a member of the nimA family which have previously been associated with
various stages of the cell cycle. NimA was first identified in the filamentous fimgus
Aspergillus nidulans (Osmani et a l, 1988). Nek2 is a mammalian serine/threonine
kinase that is most closely related to NimA. Nek2 is cell cycle regulated with activity
peaking during S and G2 phases. It is involved in the centrosome cycle where
overexpression of active nek2 leads to a splitting of the centrosome (Fry et a l, 1998).
High expression of nek2 was previously demonstrated in tissues that are mitotically
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active such as testis, intestine and skin, and it was shown that nek2 may play a role in 
both mitosis and meiosis (Rhee and Wolgemuth, 1997; Tanaka et a l, 1997). Nek2 
expression therefore has the potential to be used as a biomarker of cell proliferation. 
p21AVafl
p21AVafl is a cyclin-dependent kinase inhibitor, capable of blocking cell cycle 
progression. DNA damage leads to the accumulation of transcriptionally active p53 
that induces expression of p21 mRNA and protein. p21 expression has been 
correlated with cell cycle arrest, senescence, differentiation or apoptosis in a number 
of systems (Blagosklonney et a l, 1997; McDonald et al, 1996; Somasundaram and 
El Deiry, 1997; Tong et a l, 1998). p21 has also been shown to regulate hepatocyte 
cell cycle progression in models of liver regeneration (Fausto, 2000), and it has been 
suggested that it may be involved in a mechanism to regulate hepatocyte proliferation 
after mitogenic stimuli (Albrecht et a l , 1998).
A previous study within GlaxoSmithKline (K. Kramer - personal communication) in 
rats demonstrated Wy-14,643 and CPA to induce nek 2 expression, coincidental with 
an increase in cell proliferation, whereas DEX was shown to decrease nek2 
expression. Wy-14,643 and CPA also had little effect on p21 expression, whereas 
DEX dramatically increased expression. DEX induction of p21 has shown to be at 
least partially due to a glucocorticoid responsive region in the promotor (Cha et al, 
1998).
Study 2 provided similar data to that previously observed. Wy-14,643 and CPA both
increased nek2 gene expression although different patterns were exhibited by the 2
compounds (Figure 5.1). Wy-14,643 treatment resulted in a significant increase in
expression by 48 hours which was increased further at the 72 hour time point;
whereas CPA caused its greatest significant increase at 24 hours, smaller increases
occurring at 48 and 72 hours. Although the initial change in cell proliferation rate is
the greatest, this continual increase in nek2 mRNA levels may mean that the rate of
cell proliferation is gradually increasing throughout the dosing schedule for
Wy-14,643, which correlates with the increase in liver weight observed over the
dosing regime (Table 5.1). For CPA, maximum nek2 induction was seen at 24 hours
indicating that cell proliferation was at its maximum at this time-point, the induction
being of a smaller magnitude following further dosing. This may explain the smaller
magnitude of increase in liver weight observed in study 2 as compared to
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study 1 (Table 5.1 and 3.1). In contrast DEX administration resulted in significant 
decreases in nek2 expression following all 3 doses, the magnitude of decrease 
correlating with the number of doses administered (Figure 5.1). DEX is known to 
have a negative effect on cell proliferation and actually inhibits DNA synthesis (Nagy 
et a l, 1998; 2001). This may be a reflection of there being decreased expression of 
nek 2, which is known to play a role in meiosis and mitosis (Rhee and Wolgemuth, 
1997; Tanaka et a l , 1997).
In contrast to the previous study (K. Kramer -  personal communication), Wy-14,643 
and CPA administration both resulted in minor, but significant, increases in p21 gene 
expression as compared to control (Figure 5.2). As p21 expression has been 
correlated with cell cycle arrest and it has been shown to play a role in the regulation 
of hepatocyte proliferation (Albrecht et a l, 1998), it was hypothesised that the 
observed increase in expression may be an attempt to combat the proliferative effects 
of these compounds. However, the magnitude and extent of this increase was not as 
great as the increase in nek2 expression and was not observed over all the doses, 
indicating that possible attempted inhibition of the proliferative effects of the 
compounds was outweighed by the positive proliferative signals. In contrast, large 
up-regulation of p21 gene expression as compared to control was observed following 
DEX treatment, this being particularly apparent following 1 and 3 doses (Figure 5.2). 
This up-regulation of p21 expression may be related to the inhibition of apoptosis 
known to occur following DEX treatment (Qiao and Farrell, 1999; Buenemann et a l, 
2001).
5.3.4 Differential gene expression in the liver
On the whole, changes observed in liver expression of most of the genes investigated 
in study 2 were confirmatory of those changes recorded in study 1. However, some 
differences were noted.
5.3.4.1 Cathepsin H
The significant changes observed in CatH gene expression in study 1 were not 
replicated in study 2 (Figure 4.6 and 5.4). As the changes seen in study 1 were 
relatively small, many being less than 2-fold, it was felt that they may have been 
masked in the second study due to experimental and animal variation.
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5.3.4.2 Ubiquitin activating enzyme E l
The effects of the 3 compounds on UbEl levels observed in study 1, appeared to 
occur later in the time course in study 2. In study 1, significant, similar magnitudes of 
increase in UbEl mRNA levels were observed between compounds at 24 hours; 
whereas such changes were not observed until 48 hours in study 2. Likewise, the 
Wy-14,643-induced increase in UbEl levels maintained through to 48 hours in study 
1, was observed through to 72 hours in study 2. This may be related to the differences 
in observed liver weight increases following Wy-14,643 treatment between studies -  
in study 1 liver weight reached a peak at 48 hours, whereas in study 2 weight was still 
increasing at 72 hours.
5.3.4.3 Carboxylesterase
Very similar changes in Carb gene expression were observed for each of the 
3 compounds between the 2 studies (Figure 4.5 and 5.3). Significant decreases were 
observed for both DEX and Wy-14,643 throughout study 2 (Figure 5.3), the only 
differences between studies being the magnitude of change. DEX exerted the largest 
effect on Carb gene expression reaching a maximum of an 8.3-fold decrease by 
72 hours in study 2. In contrast, the maximum decrease of 6.7-fold was observed by 
48 hours in study 1. A peak 3.5-fold decrease in expression was observed following 
Wy-14,643 treatment in both studies
In contrast to Wy-14,643 and DEX, CPA exerted a significant increase in Carb 
expression by 24 hours in both studies.
5.3.4.4 Kupffer cell receptor
Again, very similar changes in KCR gene expression to those observed in study 1
were recorded following treatment with both Wy-14,643 and DEX, this being a
general decrease in expression with the magnitude of change being much greater with
DEX than that observed with Wy-14,643 (Figure 4.7 and 5.5). However, the
significant decrease in KCR expression observed with CPA treatment in study 1
(Figure 4.7), was not replicated in study 2 (Figure 5.5) -  decreases in expression were
seen, but these were not found to be significant. This may be due to there being
slightly greater inter-animal variation in study 2 as compared to study 1. However, if
KCR is somehow involved in the process of liver growth, it is possible that this
observation may be related to the magnitude of the increase in liver weight following
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CPA treatment observed in study 2 (Table 5.1) being much smaller than that observed 
in study 1 (Table 3.1).
It may therefore be noted that relatively consistent data was obtained between studies 
for 3 out of the 4 genes, so confirming the differential gene expression exerted by the 
3 compounds. Variabilities observed were only in the size of a change, not the 
direction; and are probably attributable to inter-animal or inter-experimental 
variation.
5.3.5 Differential gene expression in other organs
5.3.5.1 Kupffer cell receptor and Carboxylesterase
As expected, KCR and Carb mRNA levels were not detected in any of the other 4 
organs investigated (spleen, testes, kidney and heart). Although these genes are 
known to be liver-specific (Hoyle and Hill, 1988; Long et a l, 1988), it is still of use 
to investigate potential changes in expression. Not only does a lack of detection 
indicate the specificity of the Taqman primers and probes, it also demonstrates the 
liver-specificity of these genes. It may have been that the genes are in fact expressed 
at extremely low levels in other organs which may have become detectable following 
compound treatment, or various xenobiotics actually result in these genes being 
switched on in abnormal conditions. This, however, was not the case, and their liver- 
specificity and therefore possible growth-specificity was confirmed by study 2.
5.3.5.2 Cathepsin H  and Ubiquitin activating enzyme E l
In contrast, both cathepsin H  and ubiquitin activating enzyme E l were detected in 
each of the other 4 organs investigated, with additional significant changes in 
expression following compound treatment being observed. Most significant changes 
were identified in the kidney, the least in the testes. Indeed no changes in UbEl 
expression in the testes were observed, with only minor changes in CatH being noted 
(Figure 5.8).
Administration of each of the 3 compounds exerted significant changes in gene 
expression of either/both cathepsin H  and ubiquitin activating enzyme E l in each of 
the 4 organs other than the liver (Figure 5.7-5.10). It was therefore concluded that as 
the gene changes were not found to be liver-specific it is unlikely that these 2 genes 
play a significant role in a mechanism of liver growth for these compounds.
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5.3.6 Summary
Study 2 has both confirmed and expanded on the data obtained in the previous RT- 
PCR and Taqman investigations. This second study has indicated consistent 
reproducible changes in ubiquitin activating enzyme El, the Kupffer cell receptor and 
carboxylesterase gene expression following treatment of rats with Wy-14,643, 
dexamethasone or cyproterone acetate. Any slight variabilities in data observed 
between studies were typically only in the size of the change, not the direction. The 
changes in cathepsin H  mRNA levels observed in study 1 appeared to be masked in 
study 2, which due to the changes being only small, is probably attributable to inter­
animal or inter-experimental variation, and demonstrates the limitations of this 
quantitation technique.
UbEl and CatH were both detected and exhibited differential expression in organs 
other than the liver following each of the 3 compound treatments. This indicates that 
it is unlikely that these genes are involved in a mechanism of liver growth for these 
compounds.
Liver-specificity of expression and differential regulation of the Kupffer cell receptor 
and carboxylesterase were confirmed for each of the three compounds, indicating a 
potential role of these genes in a mechanism of liver growth. One of these genes, the 
Kupffer cell receptor, which was demonstrated to exhibit similar expression changes 
following each of the compound treatments, has been selected for further 
investigation.
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Chapter 6 
Results 4
Determination of the cause of the observed Kupffer cell receptor differential 
expression following compound treatments: A change in number of receptors or
of Kupffer cells?
6.1 Immunocytochemistry
Immunocytochemistry experiments were performed on both rat and human liver 
sections using an antibody to human CD68 as described (section 2.2.5.1), in an attempt 
to count Kupffer cells present. However, no antibody staining was observed on 
sections from either species over the range of concentrations tested. This was thought 
to be due to the section preparation - sections available were formalin-fixed whereas 
acetone fixation was recommended for use with this antibody.
6.2 In situ hybridisation
In situ hybridisation was attempted for both the Kupffer cell receptor and the positive 
control, CYP4AI, using sections from control-, Wy-14,643-, dexamethasone- and 
cyproterone acetate-treated livers. A positive result was obtained for CYP4A1, but for 
the Kupffer cell receptor the result was unclear due to background staining. The final 
in situ hybridisation results obtained may be seen in Figures 6.2-6.3.
It is possible that the use of direct visualisation methods may have improved the clarity 
of the in situ hybridisation result (Wilkinson, 1992). Liquid film emulsion 
autoradiography is a widely used technique thought to be more sensitive than 
traditional autoradiography. Liquid film emulsions, which are essentially silver halide 
crystals dispersed in a gelatine matrix, can be used to coat autoradiography film or 
radioactively-probed tissue sections on slides. By placing the emulsion on the tissue 
section, a photographic latent image is generated over the cell expressing the target 
mRNA, which may then be developed to form a visible image as for a standard film. 
A variety of non-isotopic probes may also be used including the highly sensitive 
biotin-, digoxigenin- or fluorescein-labelled probes. Counter-staining with an 
appropriate coloured or fluorescent stain may also be used to further amplify the target 
signal.
6.2.1 Probe preparation
Following ligation of the required target sequence into pGEM®-T Easy vector (section 
2.2.5.2.2), a restriction digest was performed in order to distinguish the orientation of 
the DNA insert within the vector. For both CYP4A1 and KCR, the enzyme selected 
was Sad, which for both genes, depending on the insert orientation, would produce 
one of two sets of products:-
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For
if the insert had ligated in the forward direction, 2 products of 2935 bp and 376 bp; 
if the insert had ligated in the reverse direction, 2 products of 3222 bp and 89 bp. 
ForKŒ,
if the insert had ligated in the forward direction, 2 products of 3078 bp and 530 bp; 
if the insert had ligated in the reverse direction, 2 products of 3378 bp and 230 bp. 
The products obtained following digestion are shown in Figure 6.1.
Figure 6.1(a&b) Restriction digest to determine orientation of insert within the 
vector
Figure 6.1a CYP4A1 Figure 6.1b KCR
376 bp product 
^ -----  89 bp product
250 bp
230 bp 
product
L; 1 kb DNA ladder 
A; Insert in forward direction 
B: No visible insert 
C: Insert in reverse direction
L: 1 kb DNA ladder 
D: Insert in reverse direction
Before transcription was performed, the plasmid was first linearised. Linearisation was 
performed in both directions so that a sense and antisense probe could be made. In the 
case of CYP4A1 the forward-ligated plasmid was selected (Figure 6.1a; lane A), 
therefore for the antisense probe, the plasmid was cut with the restriction enzyme 
NcoP, and for the sense probe, the plasmid was cut with the restriction enzyme Sail, 
(Figure 2.2). For KCR, the reverse-ligated plasmid was selected (Figure 6. lb: lane D), 
therefore the reverse was true.
A radiolabelled transcription was then carried out as described. In the case of 
CYP4A1, for the sense probe T7 polymerase was used, and for the antisense probe SP6 
polymerase was used. Again, for KCR the reverse was true.
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On completion, a DE81 test was performed in order to estimate the incorporation of 
radiolabelled nucleotide in both the antisense and sense probes. Counts per second on 
washed and unwashed filters were determined and percentage incorporation of 
[35s]UTp calculated. The results obtained for CYP4A1 and the Kupffer cell receptor 
may be seen in Table 6.1.
Table 6.1 DE81 test results estimating incorporation of radiolabelled nucleotide 
for CYP4A1 and the Kupffer cell receptor (KCR)
Probe Washed
(cps)
Unwashed
(cps)
%
incorporation
CYP4A1 sense 60 80 75
CYP4A1 antisense 80 125 64
KCR sense 100 140 71
KCR antisense 60 90 67
A percentage incorporation of > 60% was required for use in the in situ hybridisation, 
therefore all of these probes were suitable.
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Figure 6.2 In situ hybridisation result for CYP4A1
B
D
Figure 6.2 In situ hybridisations were performed on 48 hour liver sections using sense and antisense probes 
designed to CYP4A1 as follows
A: Control (com oil) - antisense
C: Wy-14,643 (50 mg/kg/day) - anti sense
E: Dexamethasone (100 mg&g/day) - antisense
B: Control (com oil) - sense
D: Wy-14,643 (50 mg/kg/day) - sense
F: Dexamethasone (100 mg/kg/day) - sense
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Figure 6.3 In situ hybridisation result for the Kupffer cell receptor
A B
C D
Figure 6.3 In situ hybridisations were performed on 48 hour liver sections using sense and anti sense probes 
designed to the Kupffer cell receptor as follows
A: Control (com oil) - antisense B: Control (com oil) —sense
C: Wy-14,643 (50 mg/kg/day) - antisense D: Wy-14,643 (50 mg/kg/day) - sense
E: Dexamethasone (100 mg/kg/day) - antisense F; Dexamethasone (100 mg/kg/day) - sense
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6.3 Kupffer cell number quantitation
Kupffer cells were counted in both treated and control rat liver sections using a light 
microscope. Photographs illustrating an example of a haematoxylin and eosin (H&E) 
liver section for each of the compound treatments may be seen in Figure 6.4a-d.
Both the number of hepatocytes and the number of Kupffer cells in each of 10 
randomly selected fields per slide were counted, and the ratio of hepatocytes:Kupffer 
cells per field determined. Mean numbers of cells and hepatocyte:Kupffer cell ratio 
per field are shown in Figures 6.5a-c for each of the compound treatments as well as 
control.
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Figure 6.4a H&E liver section taken from rat treated with corn oil for 3 days (x400)
EC
KG
m
EC: Endothelial cell 
KC: Kupffer cell
Figure 6.4b H&E liver section taken from rat treated with 50 mg/kg Wy-14,643 for 
3 days (x400)
V
%
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Figure 6.4c H&E liver section taken from rat treated with 100 mg/kg dexamethasone
for 3 days (x400)
H: Hepatocytes exhibiting vast enlargement due to cytoplasmic glycogen infiltration 
Very few Kupffer cells are visible
Figure 6.4d H&E liver section taken from rat treated with 60 mg/kg cyproterone acetate 
for 3 days (x400)
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Figure 6.5(a-c) Analysis of Kupffer cell and hepatocyte numbers following compound
treatments
a) Kupffer cells
12
10
**
8
Number 
of Kupffer 
cells/field
**
**6
**4
2
0
24 48 72
Time course (hours)
b) Hepatocytes
60
50
40
Number of 
hepatocytes/ 
field 30
* *
20
10
0
24 48 72
Time course (hours)
Figure 6.5a&b: Each point represents the mean number of cells/field derived from 10 fields per 
animal (5 animals per treatment group). Statistical analysis was carried out using an ANOVA 
where asterisks (*) represent P values: *P < 0.05; **P < 0.01.
Error bars = SEM.
Com oil
Wy-14,643 (50 mg/kg/day)
Dexamethasone (100 mg/kg/day) 
Cyproterone acetate (60 mg/kg/day)
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c) Hepatocyte:Kupffer cell ratio
Hepatocyte: 5  
Kupffer cell 
ratio
24 48
Time course (hours)
72
Figure 6.5c: Each point represents the mean number of cells/field derived from 10 fields per 
animal (5 animals per treatment group). Statistical analysis was carried out using an ANOVA 
where asterisks (*) represent P values: *P < 0.05; **P < 0.01.
Error bars = SEM.
Com oil
Wy-14,643 (50 mg/kg/day)
Dexamethasone (1 0 0  mg/kg/day) 
Cyproterone acetate (60 mg/kg/day)
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6.4 Discussion
In the previous chapters, two genes, namely carboxylesterase and the Kupffer cell 
receptor, initially identified by SSH (chapter 3), were both demonstrated to exhibit 
significant liver-specific changes in their mRNA levels in response to a variety of 
compounds known to cause liver growth. It was decided to select one of these genes to 
investigate further. Little is known regarding the precise function of either of the two 
genes. However, the Kupffer cell receptor is of particular interest in the context of this 
project due to recent research implicating a connection between peroxisome 
proliferator mechanism of action and Kupffer cells (Rose et al, 1999a; Parzefall et al, 
2001). Not only have peroxisome proliferators been shown to activate Kupffer cells in 
vivo (Bojes and Thurman, 1996), but this cell type have actually been suggested to be 
causally responsible for the mitogenic effect of this class of compounds in the liver 
(Rose et a l, 1997a). However, a precise role of Kupffer cells in a mechanism of cell 
proliferation and liver growth has not yet been clarified. Interestingly, three out of the 
four compounds, namely Wy-14,643, dexamethasone and cyproterone acetate 
demonstrated a common effect on Kupffer cell receptor mRNA expression. It is 
possible that this compound-induced decrease in Kupffer cell receptor mRNA levels 
may be involved in a mechanism of liver growth, or indeed the changes seen may 
simply be a consequence of an action of the compounds on Kupffer cells themselves.
6.4.1 Immunocytochemistry
Experiments were designed to determine whether the changes in Kupffer cell receptor 
mRNA observed following the various compound treatments were due to a true effect 
on the actual receptor number, or were a consequence of an effect on the absolute 
number of Kupffer cells. Such a determination is an important first step in determining 
how these changes may be involved in the observed hepatomegaly.
It was decided to quantify the number of receptors present in control and treated tissue 
sections using immunocytochemistry. However, this did not prove to be straight­
forward. As no Kupffer cell receptor-specific antibody could be found, a Kupffer cell 
marker was employed instead, to quantify cell number. An antibody to the 
macrophage-specific CD68 antigen, a 110 kD intracellular glycoprotein associated 
with the cell membranes of macrophages, was finally selected as it had previously been 
used to successfully quantify Kupffer cell number in monkey liver sections (Lapis et
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al., 1995). However, as no rat CD68 antibody exists, a human antibody was used. For 
the immunocytochemistry studies tissues from study 2 were analysed. No successful 
binding was observed over a range of antibody concentrations on the control rat 
sections. Immunocytochemistry was therefore performed using human liver sections 
(stocks at University of Surrey), but likewise no binding was observed. This was 
thought to be due to the fixation technology used - the sections available were 
formalin-fixed whereas it was recommended to use acetone-fixed sections with the 
CD68 antibody. This technique was therefore abandoned and different methods 
attempted.
6.4.2 In situ hybridisation
In situ hybridisation was selected as the second method to address this issue. As RT-
PCR primers had already been designed and optimised for the Kupffer cell receptor
(section 2.2.4.1), these were used in the production of a specific probe
(section 2.2.5 2). CYP4AI was selected as a positive control, as again specific RT-
PCR primers had previously been optimised in the Molecular Toxicology laboratory at
the University of Surrey (section 2.2.5.2). CYP4A1 is widely distributed over the
hepatocyte population, and has shown to be markedly induced following treatment of
rats with the potent peroxisome proliferator, methylclofenapate (Bell et a l, 1991). For
the in situ hybridisation studies, liver tissue from study 2 was used due to availability.
In study 2, the greatest significant down-regulation in Kupffer cell receptor mRNA
levels was observed in liver sections from animals treated with 2 doses of Wy-14,643
or dexamethasone (Figure 5.5). Therefore these tissues were selected for initial
analysis. Sections were hybridised with an antisense RNA probe in order to identify
target mRNA species, or a sense RNA probe in order to eliminate background. Results
for the CYP4A1 probed sections (Figure 6.2) demonstrated only minor differences in
binding between the antisense and sense probed sections for both control- and
dexamethasone-treated tissues. In addition, little difference in binding was observed
between these two treatments. However, as expected, dark staining over the whole of
the antisense-probed section from Wy-14,643 treated tissue as compared to control was
observed, indicating an up-regulation of CYP4A1 mRNA levels. This is in accordance
with the literature. Bell and co-workers demonstrated an increase in CYP4A1 mRNA
levels and enzyme activity in rat liver following 4-day methylclofenapate
administration as compared to control (Bell et a l, 1991). They performed
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immunocytochemistry to determine the lobular distribution of induction. Livers from 
control animals showed minimal staining for CYP4A1 protein; whereas submaximal (2 
or 5 mg/kg) methylclofenapate treatment resulted in increased CYP4A1 
immunostaining mainly in the centrilobular area, whereas a maximal inducing dose 
(25 mg/kg) of methylclofenapate caused panlobular induction of the protein.
However, for the Kupffer cell receptor probed sections (Figure 6.3) some staining was 
equivocal; thus interpretation of the results was difficult. This is possibly due to the 
sensitivity of the technique -  the mRNA being investigated is only present in a small 
population of cells, therefore copy number as a percentage of the total message would 
be low. However, RNAs have been detected at a concentration of mRNA 
approximately 0.02% that of the total message distributed in the tissue (Augerer and 
Augerer, 1992).
6.4.3 Kupffer cell counting
Archived haematoxylin and eosin-stained liver sections from study 1 were available 
(GlaxoSmithKline, Welwyn), so it was decided that any change in actual Kupffer cell 
number would be quantified by physically counting Kupffer cells present in these 
sections using a light microscope. Hepatocytes and Kupffer cells present in a number 
of randomly selected fields within each liver section were counted, so that any change 
in hepatocyte iKupffer cell ratio may be recorded. Numbers of each cell type were 
assessed by counting the number of nuclei present. Hepatocyte identification and 
quantitation was straight-forward, but identification of Kupffer cells was more 
problematic with potential miscounting. Problems arose in distinguishing between 
Kupffer cells and endothelial cells, as when stained with haematoxylin and eosin they 
share similar properties, with both being located in the sinusoids (section 1.1.2). 
However, Kupffer cells were differentiated from endothelial cells by analysis of the 
nuclei for intensity of staining, size, shape and location. Encouragingly, two separate 
blind studies gave the same results.
Sections from livers from animals treated with 1, 2 and 3 doses (24, 48, and 72 hours 
respectively) of Wy-14,643, dexamethasone or cyproterone acetate as well as control 
were selected for analysis, and all sections were ‘blinded’.
The cell-counting data obtained may be seen in Figure 6.5a-c. Significantly less
Kupffer cells per field as compared to control were observed following each of the
three treatments. Specifically, less Kupffer cells were recorded following 1, 2 and 3
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daily doses of dexamethasone; following 3 daily doses of cyproterone acetate; and 
following 2 and 3 daily doses of Wy-14,643 (Figure 6.5a). Differences in hepatocyte 
counts as compared to control were also noted with significantly less hepatocytes 
recorded per field following 1, 2 and 3 daily doses of dexamethasone; significantly 
more following 1 daily dose of Wy-14,643 and significantly less following 2 daily 
doses (only minor changes); with no significant differences observed following 
cyproterone acetate treatment (Figure 6.5b). These observed changes in cell number 
resulted in the hepatocyteiKupffer cell ratio being significantly greater following 
3 doses of each of the 3 compounds, and 1 dose of Wy-14,643 (only a minor 
difference) (Figure 6.5c). It may be noted that the ratio of hepatocytes:Kupffer cells 
observed in control tissue is higher than would probably be expected. It averages 
around 5, which is a little low as hepatocytes are thought to constitute 60-65 % of liver 
cells, with Kupffer cells ranging between 8-12 % (Gebhardt, 1992). This difference 
may be due to species or strain differences, or due to some inaccurate differentiation 
between Kupffer cells and endothelial cells. However, the observations that control 
numbers remain relatively constant, all error bars are small, and 2 separate blind 
studies provided the same results, indicates that counting was consistent.
6.4.3,1 Kupffer cell receptor
The data obtained indicates that it is likely that the increase in hepatocyte:Kupffer cell 
ratio is responsible for the differential expression, although not providing a conclusive 
explanation for all changes in Kupffer cell receptor mRNA levels observed following 
each of the compound treatments. This is because on the whole the change in ratio 
appears to correlate with the change in mRNA levels. Little change was observed in 
the ratio of hepatocytes:Kupffer cells following 1 and 2 daily doses of Wy-14,643 and 
cyproterone acetate (Figure 6.5c), which is reflected in there being only small changes 
in Kupffer cell receptor mRNA levels at these time-points (Figure 4.7). However, the 
significant increase in ratio observed by 3 daily doses of Wy-14,643 or CPA (Figure 
6.5c) is accompanied by much greater magnitudes of down-regulation of Kupffer cell 
receptor mRNA levels following treatment with these compounds (Figure 4.7). With 
DEX, although the magnitude of down-regulation in Kupffer cell receptor mRNA 
levels was comparatively large following 1 and 2 doses, a much greater magnitude of 
mRNA down-regulation was demonstrated following 3 doses (Figure 4.7), the same
dose at which the hepatocyte:Kupffer cell ratio was significantly greater (Figure 6.5c).
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6.4.3.2 Wy-14,643- and Cyproterone acetate-induced changes in cell numbers
Hepatocyte cell counts revealed little change in hepatocyte numbers per field following 
treatment of rats with either Wy-14,643 or cyproterone acetate. A slight increase in 
numbers was observed following 1 dose of Wy-14,643, with a slight decrease 
following 2 doses; and no changes following cyproterone acetate treatment (Figure 
6.5b). No comment can be made regarding ploidy states of hepatocytes following the 
compound treatments. Using these data, it may be concluded that the recorded 
reduction in the number of Kupffer cells per field is responsible for the increased 
hepatocyte.Kupffer cell ratios observed following 3 doses of the compounds (Figure 
6.5a). However, despite the observation that there was little change in hepatocyte 
number per field, it may be noted that the absolute number of hepatocytes over the 
entire liver are likely to be increased due to the hyperplastic effects of these 
compounds (Figure 3.1b) (Reddy and Lalwani, 1983, Roberts et a l, 1995). The 
Kupffer cells originally present in ‘normal’ tissue would therefore be more widely 
distributed throughout the tissue, which may contribute towards the observed decrease 
in numbers per field.
It is possible that the decrease in Kupffer cell number per field may be partly attributed 
to hypertrophy of the existing hepatocytes. This explanation may hold in part for Wy- 
14,643, as marked hypertrophy following treatment has been reported due to 
proliferation of peroxisomes and endoplasmic reticulum (Reddy and Lalwani, 1983). 
However, liver growth following cyproterone acetate treatment is thought to be solely 
due to hyperplasia (Schulte-Hermann et a l, 1980b) with the presence of only minor 
hypertrophy due to proliferation of endoplasmic reticulum (Roberts et al., 1995). 
Indeed, this explanation does seem unlikely, as for hepatocyte hypertrophy to be 
sufficient to decrease the number of Kupffer cells per field, a resultant decrease in the 
number of hepatocytes per field would be expected -  this was not the case, with no 
change in hepatocyte number being observed.
An alternative and possibly more plausible explanation may be that Wy-14,643 and 
cyproterone acetate are causing a reduction in actual Kupffer cell number. The only 
way of exhaustively confirming this would be to count absolute cell numbers across a 
total liver lobule.
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6.4.3.3 Dexamethasone-induced changes in ceil numbers
Dexamethasone treatment resulted in a different effect on cell distribution, in that 
although Kupffer cell numbers per field were found to be significantly reduced 
following treatment, in conjunction with this, hepatocyte numbers were also similarly 
significantly reduced. It may be concluded that the substantial hypertrophy of the 
hepatocytes observed (Figure 6.4c) resulted in this reduction in the number of Kupffer 
cells per field. However, the hepatocyte :Kupffer cell ratio did become significantly 
greater by 3 doses (Figure 6.5c), although when cell numbers were examined it was 
apparent that they only changed marginally.
6.4.4 Summary
All three compound treatments resulted in a decreased number of Kupffer cells per 
field following examination of sections of rat liver, which correlated with and therefore 
provided an explanation for the down-regulation in Kupffer cell receptor mRNA 
observed following treatment of rats with each of the 3 compounds.
The increased hepatocyte;Kupffer cell ratio per field recorded in rat liver sections 
following Wy-14,643 or cyproterone acetate treatment may be attributed to a dilution 
of the original number of Kupffer cells over a larger liver due to the hyperplastic 
effects of these compounds, or may be due to a reduction in the absolute number of 
Kupffer cells. In constrast, little change was observed in the hepatocyte.Kupffer cell 
ratio following dexamethasone treatment, and the reduction in numbers of Kupffer 
cells per field observed was due to substantial hypertrophy of the hepatocytes.
This investigation has highlighted an effect of various compounds known to cause 
hepatomegaly on numbers/distribution of Kupffer cells. As Kupffer cells have been 
shown to be important in the homeostasis of the liver, capable of the release of various 
cytokines and growth factors (Decker, 1990), a decrease in numbers or change in 
distribution of these cells may clearly disrupt liver homeostatic balance. Interestingly, 
Kupffer cells have previously been shown to be causally responsible for the mitogenic 
effect of Wy-14,643 on the liver (Rose et ah, 1997a). It is possible that the observed 
Kupffer cell effects may be related in some way to the actions of these compounds on 
the liver, and a hypothesis is presented in chapter 7.
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Chapter 7
Final Discussion
Humans are exposed to a variety of xenobiotics that are widely known to cause liver 
growth, some of which ultimately lead to hepatocarcinogenesis in rats and mice 
(Schulte-Hermann, 1974). Examples of such compounds include a variety of drug 
treatments as well as some herbicides and solvents, demonstrating the likelihood of 
human exposure and thus an associated risk of hepatocarcinogenesis. For many of 
these chemicals, their precise molecular mechanisms of action remain undefined. A 
variety of investigations have characterised the effects of such compounds on possible 
mechanistic contributory factors including cell proliferation, hypertrophy, apoptosis, 
tumour initiation/promotion and enzyme induction. In some cases, specific genes 
shown to be regulated by specific classes of such compounds, have been identified as 
potential biomarkers (Bell et a l, 1991; Rockett et a l, 2000; Waxmann and Azaroff, 
1992; Pinkus et a l, 1993). However, although the actions of many of these 
compounds have been defined, it is not known why or indeed how these effects are 
stimulated. It is thought that the elucidation of the precise molecular mechanisms 
underlying this compound-induced liver growth and the definition of specific 
biomarkers of this process, should aid in a better risk estimation for humans exposed 
to such xenobiotics.
7.1 Study 1
Study 1 was designed to investigate the molecular mechanism of liver enlargement 
with the aim of identifying molecular markers for the prediction of non-genotoxic 
hepatocarcinogenesis in vivo. The objective of this study was to characterise the 
effect of four well documented compounds which cause liver enlargement 
(phénobarbital (PB), Wy-14,643, dexamethasone (DEX) and cyproterone acetate 
(CPA)) on cell proliferation, apoptosis and differential gene expression.
7.1.1 Compound-induced changes in liver weight, cell proliferation and apoptosis
Administration of each of the 4 compounds to rats resulted in characteristic increases
in liver weight. Table 3.1 indicates the change in liver weights observed over the time
course as compared to control. Dex and CPA treatment resulted in the most marked
liver weight increase, with significant changes observed at as little as 12 hours
compound administration, peaking at 48 hours. In contrast, significant Wy-14,643-
and PB-induced increases in liver weight were not observed until 48 hours of
compound administration, with further increases in weight recorded over the
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remainder of the time course following Wy-14,643 treatment. These differences in 
liver growth patterns may be related to different mechanisms of compound-induced 
liver growth, may be a reflection of the different doses administered or may be due to 
variability in the pharmacokinetic and pharmacodynamic behaviour of each 
compound.
Figures 3.1 and 3.2 illustrate likely contributory factors to the observed increases in 
liver weight, such as changes in cell proliferation and apoptosis. Disruption of these 
biological processes would clearly have the potential to affect cell numbers and 
therefore size and weight of the liver. In accordance with the literature, Wy-14,643, 
CPA and PB treatment all resulted in a significant increase in hepatocyte cell 
proliferation, with DEX treatment statistically significantly suppressing apoptosis 
(Busser and Lutz, 1987; Marsman et al., 1988; Schulte-Hermann et a l, 1988; Evans- 
Storms and Cidlowski, 2000). The expected suppression of apoptosis (Roberts et al, 
1995; Kolaja et al, 2000) was observed following Wy-14,643, CPA and PB 
treatment, however this was not shown to be statistically significant. This was 
reasoned to be due to it being a relatively subtle effect and a decrease on an already 
low level of apoptosis seen in the liver (Roberts et a l, 1995; Kolaja et a l, 2000). 
Using these data, it was therefore concluded that the increases in liver weight 
recorded following Wy-14,643, DEX and CPA in study 1 may be partly attributed to 
the observed increases in hepatocyte cell proliferation in conjunction with minor 
suppression of apoptosis; by comparison, it is likely that DEX-induced increases in 
liver weight are partly due to the marked suppression of apoptosis observed.
7.1.2 Identification of differentially expressed genes
Altered gene expression occurs in affected cells compared to their normal state in
response to xenobiotic exposure. It was hypothesised that the identification of novel
differentially expressed genes following administration of various hepatomegalic
compounds to rats may aid in the understanding of the precise molecular changes that
occur in such cells in response to specific xenobiotics. Furthermore, common
mechanisms shared by such compounds may also be identified.
One compound was selected for the initial gene-hunting experiments, namely
Wy-14,643. Wy-14,643 is a potent peroxisome proliferator, known to cause both
hypertrophy and hyperplasia of rat liver, chronic treatment leading ultimately to
hepatocarcinogenesis (Reddy and Lalwani, 1983). Peroxisome proliferators have
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recently aroused much interest, and it was reasoned that if specific genes affected by 
Wy-14,643 could be isolated, this may potentially provide a ‘standard’ for other 
compounds of this class, and possibly identify molecular mechanisms involved in 
xenobiotic-induced liver growth for all classes of these compounds, not just 
peroxisome proliferators.
The open gene-hunting method SSH (section 2.2.2), performed on liver isolated fi*om 
Wy-14,643-treated rats killed at times preceding the onset of cell proliferation (12 and 
24 hours) (Figure 3.1) identified many potential differentially expressed gene 
sequences. Dot blots performed eliminated a number of false positives and BLAST 
searches identified a number of potentially interesting rat genes (Table 3.2-3.3). 
Many of the genes isolated are involved in functions that are not inconsistent with 
known effects of peroxisome proliferators (Reddy and Lalwani, 1983; Reddy and 
Rao, 1989; Lake, 1995a). Genes isolated included cathepsin H, ubiquitin activating 
enzyme El, carboxylesterase, fetuin and glutathione peroxidase, which are known to 
be involved in a variety of processes including protein degradation, cell growth and 
development, cell proliferation and oxidative stress (Figure 3.6). A receptor found on 
the surface of Kupffer cells was identified as being differentially expressed which is 
of particular interest regarding liver growth, as Kupffer cells have recently been 
suggested to be causally responsible for the mitogenic response of hepatocytes to 
peroxisome proliferators (Rose et al., 1997a). Due to the time points selected for 
analysis, it was hypothesised that these identified genes may contribute to the onset of 
liver growth following Wy-14,643 treatment. However, no matches were obtained for 
some of the sequences following BLAST searches and these sequences were classed 
as novel, as they appeared to have, as yet, unknown functions. Such genes of 
unknown function and matches may be equally as important as those that matched to 
known rat genes, and must not be ignored, as they may uncover potentially vital clues 
regarding a mechanism of liver growth.
Although such studies identify a number of potential differentially expressed genes, it 
must be considered that differences in mRNA levels may be caused by differences in 
transcription rate and/or in mRNA stability. Ultimately, it is therefore important to 
determine if the identified change in mRNA level is reflected in the subsequent 
protein levels of that specific gene.
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7.1.3 RT-PCR quantitation
Confirmation and quantitation of differential expression identified via SSH was 
carried out by semi-quantitative RT-PCR. This was attempted for all SSH sequences 
that had been matched to known genes (Table 3.2-3.S). Most RT-PCR investigations 
proved to be successful, and provided confirmatory data in support of the SSH and 
dot blot results (Figure 4.2-4.3). However, 2 genes, namely apolipoprotein E  and 
preproalbumin were revealed as false positives with little difference being observed 
between treated and control samples on RT-PCR analysis. In accordance with the dot 
blot data, RT-PCR indicated slow myosin-binding protein C to be up-regulated. 
However, this change was found to be insignificant. This was thought to be due to it 
being present at only very low levels, resulting in signal to noise ratios sufficiently 
poor to prevent a clear analysis to be made. Dot blots indicated transferrin to be up- 
regulated following Wy-14,643 treatment, however little difference was recorded 
following RT-PCR investigation. Previous studies have reported transferrin to be 
down-regulated following rat treatment with peroxisome proliferators (Hertz et al,
1996). It is hypothesised that in either study the actual clone isolated may not have 
been transferrin, but may have been a close relative, splice variant or isoform. 
Indeed, single genes have been shown to generate a number of different transcripts, 
each of which encode the same protein. Such transcripts may be generated via 
processes including alternative splicing as observed with the rat fibronectin gene 
(Tamkun et a l, 1984), or the selective use of multiple 3' polyadenylation signals as 
observed with the mouse opsin gene (Al-Ubaidi et a l, 1990). The possibility of the 
generation of a number of different transcripts by specific genes emphasises the 
importance of carrying out protein studies in conjunction with such mRNA 
investigations. Northern blot analysis would have helped to determine whether the 
transcript isolated was indeed transferrin. Like RT-PCR, Northern blotting can be 
used to determine the abundance of the target mRNA transcript, but in contrast, it also 
determines the size. This method is therefore able to detect alternatively spliced 
transcripts as well as being able to distinguish between members of multi-gene 
families. Indeed, it would be beneficial to correlate the dot blot and RT-PCR data 
obtained for each of the identified gene transcripts with Northern blot analysis, not 
only to confirm differential expression, but also to confirm identity. Interestingly, 
Northern blots have already been carried out for many of the identified differentially
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expressed transcripts including human ubiquitin activating enzyme E l (Handley et al., 
1991), mouse cathepsin H  (Lafuse et al., 1995), rat Kupffer cell receptor (Hoyle and 
Hill, 1988), rat selenoprotein P (Hill et al., 1992), rat D-dopachrome tautomerase 
(Zhang et al., 1995), rat copper/zinc superoxide dismutase (Hsu et al., 1992) and rat 
Via arginine vasopressin receptor (Morel et al., 1992)
It may be concluded that RT-PCR is a successful, although time-consuming method 
of quantitation and the few discrepancies the method highlighted emphasise the 
importance of such quantitation experiments following gene-hunting exercises. This 
investigation has also indicated where it may be useful to employ a number of 
different quantitation techniques, in order to both confirm abundance as well as 
identity of specific transcripts.
7.1.4 Gene selection
Defining the functions and confirming differential expression of genes isolated by 
SSH, enabled the selection of potentially interesting genes for further investigation. 
Genes were selected on the basis of their role and magnitude of differential 
expression. Two genes with roles in protein degradation were selected, namely 
cathepsin H (CatH) and ubiquitin activating enzyme El (UbEl), both of which were 
shown to be up-regulated following one dose of Wy-14,643. Cathepsin H is a 
member of the lysosomal cysteine proteinases (Barret, 1977) and has been 
demonstrated to act as both an endopeptidase and an aminopeptidase (Kirschke et al., 
1977; Rothe and Dodt, 1992). Ubiquitin activating enzyme El is the rate-limiting 
enzyme in the ubiquitin protein degradation pathway (Finley and Chau, 1991; 
Hershko and Ciechanover, 1992). As two genes involved in protein degradation were 
demonstrated to be similarly affected by Wy-14,643 treatment, it was hypothesised 
that peroxisome proliferators may act in some way via the disruption of degradation 
of specific proteins. Possibly of significance, with regard to a mechanism of liver 
growth, is the evidence that the ubiquitin pathway has been shown to be involved in 
the degradation and turnover of several cell cycle regulatory proteins (Goebl, 1988; 
Hershko and Ciechanover, 1992; Pagano, 1995).
Carboxylesterase (Garb), shown to be down-regulated 12 hours following one dose of 
Wy-14,643, was selected as potentially interesting due to its role in the hydrolysis and 
detoxification of various xenobiotics (Long et al., 1988); and its previously identified
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regulation by a variety of xenobiotics (Ashour et al., 1987; Hosokawa et al., 1988; 
Zhu et al., 2000).
The final gene to be chosen for further investigation was the Kupffer cell receptor 
(KCR). Kupffer cells, on activation, have the potential to release a variety of 
bioactive substances including various cytokines and growth factors, being closely 
involved in the maintenance of the liver homeostatic balance (Decker, 1990). 
Additionally, Kupffer cells, not only have been shown to be activated by peroxisome 
proliferators (Bojes and Thurman, 1996), but a mechanism of action has been 
hypothesised (section 1.2.2.3) indicating Kupffer cells to be responsible for the 
mitogenic effect of peroxisome proliferators on the liver (Rose et al., 1997a). Little is 
known regarding the precise function of the identified Kupffer cell receptor examined 
herein. However, it is known to be Kupffer cell specific, located on the surface of 
these cells, and is a carbohydrate receptor with affinity for fucose and galactose 
(Hoyle and Hill, 1988). Interestingly, other liver carbohydrate receptors have been 
indicated in the process of apoptosis (Ashwell and Harford, 1982; Dini et al., 1992; 
1993; 1995; Ruzittu et a l, 1999); and it has been suggested that the carbohydrate 
recognition system of the liver may be involved in the homeostatic function of the 
regulation of the cell numbers of liver tissue (Ashwell and Harford, 1982). Could this 
Kupffer cell receptor identified as being differentially expressed play a role in 
apoptosis and subsequently be important in the maintenance of liver homeostasis? 
Clearly, differential expression of a gene with such a role may result in deleterious 
effects on the liver, which indeed may affect its size.
7.1,5 Taqman quantitation
mRNA levels of the 4 selected genes were investigated by Taqman in liver from rats 
treated with each of the 4 study 1 compounds over the 72 hour time course.
This was carried out to determine whether the changes observed with Wy-14,643 
treatment were common to other compounds known to induce liver growth in rats, 
and also to discover the changing pattern of expression of the selected genes over a 
time course. If similar gene changes were observed between a number of compounds 
known to cause hepatomegaly, it was reasoned that this may indicate that such genes 
are in some way involved in the growth of the liver.
Taqman studies identified differential expression in all of the genes by all of the
compounds at at least 1 of the time-points with some notable similarities in
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differential expression being observed between 3 of the compounds, namely 
Wy-14,643, DEX and CPA (Figure 4.5-4.S).
Taqman results were in agreement with the RT-PCR quantitation of UbEl and CatH 
following Wy-14,643 treatment already performed, so confirming the up-regulation of 
mRNA levels observed at 24 hours.
Interestingly, similar changes in liver mRNA levels of UbEl were observed following 
administration of three of the compounds, namely Wy-14,643, DEX, and CPA, which 
may indicate a role of this gene in their shared actions on the liver. In addition, the 
up- and down-regulation observed in mRNA levels of the 2 genes involved in protein 
degradation {UbEl and CatH) over the time-course, appeared to correlate with the 
ability of the 3 compounds to maintain increases in liver weight. For example, where 
an up-regulation of UbEl and CatH mRNA levels was observed, the liver continued 
to increase in size; whereas levels of these genes were demonstrated to return to 
control or less than control levels at the time at which the peak liver weight was 
recorded. In contrast, PB exerted an individual pattern of change similar for both 
UbEl and CatH.
For Carb and KCR, only minor changes were observed in mRNA levels following PB 
treatment, more significant changes being observed after dosing with the other 
3 compounds.
Wy-14,643, DEX, and CPA appeared to induce similar changes in expression of KCR,
with mRNA levels decreasing over the time-course, indicating another common
action of these 3 compounds. However, it may be noted that contradictory results for
Wy-14,643-induced changes in KCR mRNA levels were obtained between the two
experimental techniques, with an up-regulation obtained at 24 hours with RT-PCR,
and a down-regulation observed via Taqman. Further experiments, however, suggest
that these contradictory data were due to the RNA samples, and the different
extraction methods utilised. In addition, later repeat experiments and further
investigations concerning Kupffer cell receptor expression (section 5.2 and 6.3)
support the Taqman data obtained. This emphasises the requirement for consistent
experimental protocols and rigorous use of repeat experiments on multiple animals.
Wy-14,643 and DEX administration both resulted in down-regulation of Carb mRNA
levels. Down-regulation of both mRNA and protein levels of various liver
carboxylesterases has already been shown to occur following treatment of rats with
DEX (Zhu et a l, 2000). Interestingly, the existence of major differences regarding
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the regulation of Carb gene expression by DEX between rats and humans has been 
indicated, and as carboxylesterases have been indicated in the metabolism and 
detoxification of various xenobiotics, this may contribute to the species difference in 
liver response. In contrast, a significant increase in Carb mRNA levels was observed 
following CPA treatment.
In summary, study 1 Taqman investigations identified similarities in differential gene 
expression for 3 out of the 4 compounds known to cause hepatomegaly, namely 
Wy-14,643, dexamethasone and cyproterone acetate, which may indicate shared 
mechanisms of action of these compounds. These similarities being most prominent 
for KCR. In contrast, PB appeared to exert its own individual effects on each of the 
4 genes, which may imply that it acts by different mechanisms of action as compared 
to the other 3 compounds.
7.2 Study 2
Study 2 was designed to address the importance of the gene changes observed in 
study 1 regarding a mechanism of compound-induced liver growth. It was 
hypothesised that if the gene changes so far observed were involved in growth of the 
liver, their levels should not change in organs that do not grow in response to the 
compound treatments.
The three compound treatments, namely Wy-14,643, DEX and CPA, that resulted in 
potentially interesting significant changes in the 4 genes in study 1, were included in 
this second study, and their effects on expression of the same 4 genes in the liver, 
testes, kidney, heart and spleen investigated over a 72 hour time course.
7.2.1 Compound-induced changes in organ weight, hepatocyte proliferation and 
apoptosis
Administration of each of the 3 compounds to rats resulted in the characteristic
increases in liver weight as observed in study 1 (Table 5.1). Similar magnitudes of
liver weight increases were observed between the 2 studies for Wy-14,643 and DEX,
although the magnitude of increase following CPA treatment in study 2 was not as
marked as that observed during study 1. However, study 2 exhibited a significant
increase in liver weight following 24 hours of Wy-14,643 treatment (1 dose), but this
was not seen until 48 hours in study 1 (2 doses). Indeed, study 2 is in accordance with
the literature as DNA synthesis and cell proliferation has previously been reported to
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be stimulated following 1 dose of Wy-14,643 (Ohmura et al., 1996). For both Wy- 
14,643 and CPA, no significant changes in weight were observed in other organs as 
compared to control. However, DEX administration resulted in a marked decrease in 
spleen weight and size at each of the time-points investigated which is in agreement 
with previous studies (Kelly and Goldspink, 1982; Lupp et al., 1999; Orzechowski et 
al, 2000).
In this study, although each of the compound treatments resulted in the expected 
increases in liver weight, no measurements of DNA synthesis or apoptosis were made 
as for study 1. Therefore, alternative markers, namely nek2 and p21/wafl, for these 
biological functions, were used in Taqman analysis instead, nek 2 is a member of the 
nimA family which have previously been associated with various stages of the cell 
cycle. nek2 is thought to play a role in both mitosis and meiosis and being expressed 
at high levels in mitotically active tissues has the potential for use as a marker of cell 
proliferation (Rhee and Wolgemuth, 1997; Tanaka et al, 1997). p21/wafl is a 
cyclin-dependent kinase inhibitor, capable of blocking cell cycle progression, the 
expression of which has been correlated with cell cycle arrest and apoptosis 
(Blagosklonney et a l, 1997; McDonald et a l, 1996; Somasundaram and El Deiry,
1997).
Taqman data obtained for these 2 genes was as expected (Figure 5.1-5.2), most
notable changes being Wy-14,643- and CPA-induced significant increases in nek 2
expression, and DEX-induced increases in p21/wafl expression; which correlate with
the known actions of these compounds on cell proliferation and apoptosis (Reddy and
Lalwani, 1983; Roberts et a l, 1995; Qiao and Farrell, 1999; Buenemann et ah, 2001).
DEX administration also resulted in significant decreases in nek2 expression, which
due to the potential involvement of nek2 in meiosis and mitosis (Rhee and
Wolgemuth, 1997; Tanaka et al, 1997), is likely to be related to the property of DEX
inhibiting DNA synthesis (Nagy et a l, 1998; 2001). Interestingly, Wy-14,643 and
CPA administration both resulted in minor, but significant, increases in p21 gene
expression as compared to control. As p21 expression has been correlated with cell
cycle arrest and it has been shown to play a role in the regulation of hepatocyte
proliferation (Albrecht et al, 1998), it was hypothesised that the observed increase in
expression may be an attempt of the liver to combat the proliferative effects of these
compounds. However, the magnitude and extent of this increase was not as great as
the increase in nek2 expression and was not observed over all the doses, indicating
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that possible attempted inhibition of the proliferative effects of the compounds was 
overwhelmed by the positive proliferative signals.
7.2.2 Taqman quantitation of organ gene expression
On the whole, changes observed in liver expression of most of the genes investigated 
in study 2 (Figure 5.3-5.6) were confirmatory of those changes recorded in study 1 
(Figure 4.5-4.8). The significant decreases previously recorded in liver Carb and 
KCR expression were remarkably similar following both Wy-14,643 and DEX 
treatment in study 2. The slight variabilities in data observed between studies were 
typically only in the size of the change, and not the direction, and are probably 
attributable to inter-animal or inter-experimental variation. In addition, the significant 
increase in Carb mRNA levels observed following CPA treatment in study 1 was 
confirmed in the second study.
However, the gradual significant decrease in liver KCR expression observed with 
CPA treatment in study 1 was not observed in study 2 -  decreases in expression were 
seen, but these were not found to be significant. This may be due to greater animal 
variation in the second study, or, if indeed the changes in KCR are involved in growth, 
may be related to the magnitude of the increase in liver weight observed in study 2 
being much smaller than that observed in study 1.
The up-regulation in liver UbEl levels observed for each of the 3 compounds in study 
1 was observed in study 2, but appeared to occur 24 hours later. However, no 
significant changes were observed in liver CatH in study 2. It is thought that the 
small changes observed in study 1 for this gene may have been masked in study 2 due 
to experimental and animal variation, and demonstrates the limitations of this 
technique.
Analysis of mRNA levels of these 4 genes in the other 4 organs (spleen, testes, kidney 
and heart) provided valuable data (Figure 5.7-5.10). As expected, Carb and KCR 
were not identified in any other organ following any of the compound treatments, 
which not only confirms their liver specificity but also indicates a potential 
involvement of the genes in the shared actions of the compounds. Additionally, the 
lack of detection of these liver-specific genes in other organs demonstrates the 
specificity of the Taqman primers and probes.
In contrast, UbEl and CatH were not only detected in all other organs, they were also 
shown to be differentially expressed following the various compound treatments.
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This was most notably so for the kidney (Figure 5.9) with very few changes observed 
in the testes (Figure 5.8). As the gene changes were not liver-specific, they do not 
appear to be growth-specific, and therefore it may be concluded that CatH and UbEl 
are unlikely to be involved in a general mechanism of compound-induced 
hepatomegaly. ;
7.3 What do the observed gene changes mean?
As compound-induced changes in mRNA levels of Carb and KCR proved to be 
highly reproducible and liver-specific, with similar patterns of change observed 
between a number of compounds known to cause hepatomegaly, it is likely that these 
2 genes are in some way related to the shared actions of these compounds. As a link 
between Kupffer cells and liver growth has already been reported (Rose et a l, 1997a; 
1999a), and 3 compounds known to cause hepatomegaly each produced a significant 
down-regulation in mRNA levels of a Kupffer cell-specific gene over a time-course, it 
may be hypothesised that the changes in this gene are in some way related to 
compound-induced liver growth.
As changes in UbEl and CatH mRNA levels did not appear to be liver-specific, it 
may be concluded that it is unlikely that these genes play a major role in a general 
mechanism of compound-induced liver growth. Changes in the levels of these 
2 genes may simply be a consequence of xenobiotic exposure. It may be that changes 
in expression of the genes contribute in some way to the compound-induced effects 
on the liver, but are not involved in the growth process as changes were shown not to 
be liver- or therefore growth- specific.
7.4 Kupffer cell receptor investigation
7.4.1 Kupffer cell quantitation
Having identified, confirmed, quantified and determined liver-specificity of various 
gene changes following compound treatments, why such gene changes occur and how 
they may be related to compound-induced liver growth was then considered. Due to 
the possible link between Kupffer cells and liver growth (Rose et aL, 1997a; 1999a), 
and the observation that three of the compounds known to cause hepatomegaly 
exerted a down-regulation of a Kupffer cell-specific receptor, this receptor was 
selected for further investigation.
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Experiments were designed to determine whether the changes in Kupjfer cell receptor 
mRNA observed following the various compound treatments were due to a true effect 
on the actual receptor number, or were a consequence of an effect on the absolute 
number of Kupffer cells. Such a determination is an important first step in 
determining how these changes may be involved in the observed hepatomegaly. 
Studies involving the quantitation of Kupffer cells and hepatocytes within randomly 
selected fields of ‘blinded’ sections of liver from control, Wy-14,643-, 
dexamethasone-, and cyproterone-treated animals served to address this problem. 
These studies indicated that the cause of the decrease in KCR mRNA levels observed 
was likely to be a reflection of an effect on actual Kupffer cell number, as analysis of 
liver sections revealed a decrease in Kupffer cell number per field following each of 
the 3 compound treatments as compared to control (Figure 6.5a).
For each of the liver sections, mean hepatocyterKupffer cell ratios per field were 
determined (Figure 6.5c).
7.4.1.1 Wy-14,643 and cyproterone acetate
Data obtained for Wy-14,643 and CPA indicated that these compounds caused an 
increase in hepatocyte:Kupffer cell ratio that was clearly due to the decrease in 
Kupffer cell number per field (Figure 6.5a) as hepatocyte number did not appear to 
change (Figure 6.5b). However, it must be remembered that the ratios determined are 
only per field and do not represent total liver cell numbers. Indeed, both Wy-14,643 
and cyproterone acetate are known to cause hepatocyte hyperplasia (Reddy and 
Lalwani, 1983; Roberts et al, 1995) as indicated in study 1 (Figure 3.1). It may also 
be noted that no comment can be made regarding ploidy states of hepatocytes 
following the compound treatments.
There are a number of possible explanations for the decrease in Kupffer cell number 
observed per field: -
(i) It is possible that hypertrophy of hepatocytes may be a contributory factor. Indeed, 
Wy-14,643 has previously demonstrated marked hypertrophy reported to be due to 
proliferation of peroxisomes and endoplasmic reticulum (Reddy and Lalwani, 1983); 
with the occurrence of minor hypertrophy following cyproterone acetate treatment 
due to proliferation of endoplasmic reticulum being observed (Schulte-Hermann et 
<3/ . ,  1980b; Roberts et <3/ . ,  1995). This explanation seems unlikely though, as for 
hepatocyte hypertrophy to be sufficient to decrease the number of Kupffer cells per
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field, a decrease in the number of hepatocytes per field would also be expected -  this 
was not the case, with no change in hepatocyte number being observed.
(ii) A more plausible explanation is that due to the hyperplastic effects of these 
compounds on hepatocytes (Figure 3.1b), the Kupffer cells originally present in 
‘normal’ tissue may be more widely distributed throughout the ‘larger’ liver (Table 
3.1; 5.1) resulting in this decrease in number per field.
(iii) Another possible explanation is that the compounds may be causing a decrease in 
absolute Kupffer cell number. The only way of exhaustively confirming whether this 
may be the underlying cause of the decrease in Kupffer cell number per field would 
be to count absolute cell numbers across a total liver lobule.
7.4.1.2 Dexamethasone
DEX caused different effects on cell numbers compared to Wy-14,643 and CPA. As 
the Kupffer cell number decreased significantly so did the numbers of hepatocytes. 
However, a slight significant increase in hepatocyte:Kupffer cell ratio did become 
apparent following 3 doses of DEX, but as cell numbers only changed marginally, it 
was concluded that changes observed in Kupffer cell number were likely to be due to 
the substantial hypertrophy of hepatocytes observed following DEX treatment 
(Figure 6.4c).
7.4.2 Kupffer cell role in xenobiotic-induced liver growth
The identification and analysis of compound-induced changes in mRNA levels of a 
Kupffer cell surface receptor in these investigations has highlighted an effect of these 
compounds on Kupffer cells themselves.
Due to the vital roles of Kupffer cells within the liver, the compound-induced 
down-regulation of these cells may have a significant effect on the liver as a whole. 
Kupffer cells are extremely important in the maintenance of liver homeostasis, 
capable of secreting various cytokines and growth factors on activation (Decker, 
1990, and Table 1.1). Kupffer cells are known to interact with hepatocytes through 
factor-mediated communication, receptor-mediated endocytosis as well as 
gap-junctional communication to perform vital roles in liver surveillance (Decker, 
1990; Winwood and Arthur, 1998). Clearly, any changes in Kupffer cell number/ 
distribution/activation are likely to result in disruption of the homeostatic balance of 
the liver.
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Using the data obtained in this study and with regard to the ultimate actions on the 
liver of each of the compounds investigated, an interesting novel phenomenon 
involving a role of Kupffer cells in mediating the effects of such compounds has been 
highlighted.
7.4.2.1 Role in Wy-14,643-induced liver growth
Previously, a role of Kupffer cells in Wy-14,643-induced liver growth has been 
hypothesised. Peroxisome proliferators have been shown to activate Kupffer cells 
in vivo (Bojes and Thurman, 1996) and, interestingly, Kupffer cells have been 
observed to take up carcinogenic compounds (Munthe-Kass, 1979). With regard to 
the fact that Wy-14,643 is an example of a non-genotoxic carcinogen (Reddy et al., 
1980; Roberts et al., 1995), it may be that the Kupffer cells actually take up such 
compounds which results in the activation of these cells (Bojes and Thurman, 1996). 
Kupffer cells have been suggested to be causally responsible for the mitogenic effect 
of peroxisome proliferators on the liver (Rose et al., 1997a) and much evidence has 
accumulated in support of this hypothesis (Bojes and Thurman, 1996; Bojes et al., 
1997; Rose et al., 1997a, b; Rose et a l, 1999a, b). It has been demonstrated that 
peroxisome proliferators are unable to increase DNA synthesis in isolated 
hepatocytes; but when incubated with conditioned medium from Kupffer cells 
incubated with Wy-14,643, DNA synthesis was increased (Parzefall et a l, 2001). 
Therefore, it was concluded that increases in DNA synthesis due to peroxisome 
proliferators as reported in the literature may likely be due to parenchymal cell 
contamination with Kupffer cells.
How Kupffer cells are able to stimulate DNA synthesis in their neighbouring
hepatocytes was then addressed. It is known that following peroxisome proliferator
stimulation, Kupffer cells release mitogenic cytokines, such as TNFa, and it is
thought that such cytokines are responsible for the stimulation of the increase in
hepatocyte DNA synthesis (Rose et al, 1999a). In support of this hypothesis,
pretreatment of rats with antibodies to TNFa has been shown to completely inhibit
the increase in cell proliferation induced by Wy-14,643 (Bojes et al., 1997). In
addition, Parzefall and co-workers demonstrated various peroxisome proliferators to
have no effect on isolated hepatocytes, but addition of TNFa markedly increased cell
proliferation, this increase being further doubled following Wy-14,643 treatment
(Parzefall et a l, 2001). However, some contradictory data have been presented in the
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literature, indicating typical peroxisome proliferator effects including increases in 
liver weight, DNA synthesis and cell proliferation to still occur in TNFa-receptor- 
knockout or TNFa-knockout mice (Wallenius et al., 2000; Lawrence et al., 2001). It 
is hypothesised that compensatory pathways involving other cytokines may be 
stimulated which are able to mediate these observed changes. Indeed, it is likely that 
TNFa may be one of a number of cytokines involved in the initiation of cell 
proliferation as indicated by Hasmall and colleagues (Hasmall et al, 2000).
However it must not be forgotten that in conjunction with increased hepatocyte 
proliferation and hepatomegaly, peroxisome proliferators also increase the number 
and size of peroxisomes in parenchymal cells (Rao and Reddy, 1987). This is 
mediated through the peroxisome proliferator activated receptor-alpha (PPARa) 
(section 1.2.2.3) which has also been shown to be required for the mediation of the 
increased hepatocyte proliferation and hepatomegaly (Kliewer et al., 1994; Lee et a l, 
1995). Indeed, an increase in DNA synthesis does not occur in PPARa knockout 
mice following Wy-14,643 administration (Peters et a l, 1997). However, PPARa is 
not present in Kupffer cells and is restricted to hepatic parenchymal cells (Peters et 
al, 2000)). This indicates that Kupffer cells, whilst being required for stimulation of 
hepatocyte proliferation, are not solely responsible for the observed peroxisome 
proliferator effects.
In summary it is thought that parenchymal cell PPARa and Kupffer cell-released 
mitogenic cytokines are both required for maximal peroxisome proliferator-stimulated 
DNA synthesis.
The data presented in my study, has highlighted an additional, novel action of 
Wy-14,643 on Kupffer cells. Following treatment of rats with this compound, a 
decrease in the number of Kupffer cells per field within liver sections was recorded, 
possibly supporting the idea of a peroxisome proliferator-Kupffer cell interaction. As 
previously indicated, such interactions of xenobiotics with Kupffer cells would result 
in the release of cytokines and growth factors which may include TNFa (Rose et a l, 
1999a; Hasmall et al, 2000). Evidence suggests that this initial compound.Kupffer 
cell interaction results in the release of cytokines and growth factors which induce the 
increase in hepatocyte DNA synthesis and proliferation following administration of 
this compound to rats (Rose et al, 1999a; Hasmall et a l, 2000). Using the results of
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my study, it is therefore hypothesised that following this initial Kupffer cell activation 
and resultant stimulation of hepatocyte DNA synthesis, a reduction or dilution of the 
growth-inducing cytokines and growth factors occurs as a result of the observed 
increase in hepatocyteiKupffer cell ratio. This would account for the pattern of 
hepatocyte DNA synthesis and cell proliferation observed following treatment of rats 
with peroxisome proliferators -  a rapid, initial wave of hepatocyte DNA synthesis and 
cell proliferation takes place which then slows and approaches control rates even if 
the compound is continually administered (Reddy and Lalwani, 1983). In fact this 
increase in hepatocyterKupffer cell ratio may explain the growth response of the liver 
to peroxisome proliferators, in that a peak liver weight is attained within just a few 
days of administration (Reddy and Lalwani, 1983).
However, it may be noted that in rats, chronic treatment of Wy-14,643, unlike many
other compounds of its class, is able to sustain a low consistent level of increased
DNA synthesis following the initial burst of replicative DNA synthesis (Marsman et
a l, 1988; Eacho et al, 1991). This is thought to be responsible for the potency of
Wy-14,643 as an hepatocarcinogen (Marsman et a l, 1988; Lake et a l, 1993). If
Kupffer cell release of mitogenic cytokines is responsible for peroxisome proliferator-
induced hepatocyte DNA synthesis, and levels of such cytokines are subsequently
reduced whether it be through a reduction in cell number or a gradual dilution of the
cells over a larger area, how is the Wy-14,643-induced lower level of increased DNA
synthesis maintained at a constant rate? Surely the gradual decrease in the level of
mitogenic cytokines would ultimately result in cessation of hepatocyte proliferation?
Interestingly, Marsman and co-workers demonstrated rat liver weights to be
remarkably similar at all time-points following treatment with either Wy-14,643 or
DEHP, a less potent peroxisome proliferator which does not cause this sustained
increase in rate of DNA synthesis (Marsman et a l, 1988). It has therefore been
suggested that chronic Wy-14,643 treatment may result in loss of hepatocytes through
toxicity (Marsman et a l, 1988), which would counterbalance the effect of the
sustained lower level of increased rate of DNA synthesis. DNA synthesis and
subsequent cell proliferation may therefore be occurring simply to replace dead cells,
and no further increase in hepatocyte numbers would occur despite the presence of an
increased rate of DNA synthesis (Marsman et a l, 1988). If dilution of Kupffer cells
due to hepatocyte hyperplasia is responsible for the observed decrease in Kupffer cell
number per field, this theory postulated by Marsman and colleagues would result in
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there being no further dilution of Kupffer cells and therefore no resultant changes in 
the levels of mitogenic cytokines. Consistency in the levels of such cytokines would 
account for the consistent lower level of increased DNA synthesis. In addition, an 
increase of hepatocellular ploidy cannot be excluded as a possible explanation.
It is also possible that other non-parenchymal cells may also be involved in the 
maintenance of increased hepatocyte DNA synthesis. Indeed, Ito cells 
(section 1.1.2.3) are known to produce a number of hepatotrophic and homeostatic 
cytokines important for both normal liver growth and regeneration as well as for the 
response to injury (Ankoma-Sey and Friedman, 1998). Such cytokines produced by 
Ito cells include TGFa, EOF, and HGF (Bachem et a l, 1992; Maher, 1993; 
Mullhaupt et a l, 1994).
Interestingly, PPARa has been shown to be required for Wy-14,643-induced 
hepatocyte DNA synthesis (Peters et a l, 1997) and it may be that PPARa activation 
is responsible for the maintenance of the sustained, consistent lower level of increased 
DNA synthesis. PPARa effects on the hepatocyte cell cycle may therefore replace 
the role of Kupffer cells once they have been depleted. This may provide an 
explanation as to why although Kupffer cells have been shown to be responsible for 
the onset of hepatocyte DNA synthesis and cell proliferation (Rose et a l, 1997a), 
PPARa must also be present (Peters et al, 1997).
In summary, it appears that the reduction in numbers of Kupffer cells per field, results 
in a reduction or dilution in the initial release of mitogenic stimuli, which causes the 
initial wave of DNA synthesis and cell proliferation to slow down resulting in the 
liver reaching a maximum possible size.
The question still remains as to which cytokine(s) is responsible for the induction of 
growth. The contradictory literature suggests that for Wy-14,643 it is unlikely that 
TNFa is solely responsible (Hasmall et a l, 2000; Wallenius et a l, 2000; Lawrence et 
al, 2001). IL-1 and IL-6 are other likely candidates that may be involved in the 
stimulation of cell proliferation and growth, as like TNFa they are released by 
Kupffer cells and are known to induce the hepatic acute-phase response (Bauer et al, 
1985; Perlmutter et a l, 1986; Beutler and Cerami, 1987; Gauldie et a l, 1987). 
Hepatocytes undergoing the acute phase response have been shown to require 
exogenous IL-6 (Kohase et a l, 1987). Growth factors released by activated Kupffer 
cells include TGFa, which in cultured hepatocytes appears to be the major factor in
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Kupffer cell-conditioned media which increases DNA synthesis (Mead and Fausto, 
1989). HGF has also been shown to be a key growth factor in the initiation of 
hepatocyte proliferation, and the most potent mitogen for rat hepatocytes in culture 
(Michalopoulos and Zamegar, 1992; Maher, 1993). EGF has also been shown to 
stimulate DNA synthesis in hepatocytes in culture (Braun et a l, 1988). It is likely 
that a number of these Kupffer cell-released factors act in conjunction to exert the 
increase in cell proliferation observed. Activated Kupffer cells may also release 
TGFP which is known to inhibit hepatocyte proliferation and induce apoptosis (Braun 
et al., 1988; Bursch et al., 1992; Bayly et al., 1994). Release of this factor may occur 
in an attempt to limit the effects of such compounds, but its potential effects are 
ultimately overwhelmed by the rapid proliferation of hepatocytes. The reduction in 
Kupffer cell number may assist by decreasing/diluting levels of this factor, which 
possibly contributes to the gain in liver size observed following treatment with such 
compounds.
7.4.2.2 Role in cyproterone acetate-induced liver growth
In contrast to Wy-14,643, no direct evidence regarding a role of Kupffer cells in
cyproterone acetate-induced liver growth has been presented. In fact, a study
performed under serum-free, defined conditions suggested that cyproterone acetate or
a metabolite of the steroid, induced DNA synthesis and mitosis in primary cultures of
isolated hepatocytes by direct actions (Parzefall et al., 1989). In addition, cell
proliferation and liver growth have also been shown to occur in the absence of a
change in TNFa mRNA levels and in TNFa-knockout mice following cyproterone
acetate treatment (Menegazzi et al., 1997; Wallenius et al., 2000). Therefore in the
case of cyproterone acetate treatment, it may be that Kupffer cells are not essential for
the induction of hepatocyte DNA synthesis and cell proliferation. However, my
studies have indicated an interaction of cyproterone acetate with Kupffer cells
resulting in a similar pattern of decreased numbers per field as observed following
Wy-14,643 treatment. This may therefore indicate that Kupffer cells are activated by
cyproterone acetate as observed with Wy-14,643 treatment, and that the release of
cytokines and growth factors, whilst not being essential for the induction of DNA
synthesis, may in fact contribute to the response of hepatocytes. Indeed, for
cyproterone acetate-induced liver growth no studies investigating a role of Kupffer
cells have been performed, and only in vitro studies involving isolated hepatocytes
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have been carried out. It is interesting that treatment of rats with cyproterone acetate 
results in the same pattern of DNA synthesis and liver growth response as that 
observed following peroxisome proliferator treatment -  an initial rapid burst of DNA 
synthesis and cell proliferation that slows and approaches control levels within just a 
few days, in conjunction with the growth of the liver reaching a maximum size 
(Schulte-Hermann et al., 1980b). This may imply that the increase in 
hepatocyte:Kupffer cell ratio observed is responsible for this decrease in hepatocyte 
proliferation rate as hypothesised for Wy-14,643.
7.4.2.3 Role in dexamethasone-induced liver growth
The theory outlined above may also explain the lack of cell proliferation observed 
following DEX treatment. As the hepatocyte:Kupffer cell ratio remains relatively 
constant following DEX treatment, this indicates that DEX has no effect on the actual 
cells and therefore no activation of Kupffer cells occurs. However, the dilution of 
Kupffer cells over a larger area due to the substantial hypertrophy of hepatocytes 
would still dilute out Kupffer cell mRNA and so explain the decrease in Kupjfer cell 
receptor mRNA observed via Taqman quantitation studies. In addition, DEX has 
actually been shown to inhibit Kupffer cell release of arachidonic acid metabolites, 
prostaglandins and leukotrienes including TNFa, IL6 and ILl (Kawada et a l, 1990; 
Chensue et a l, 1991; Nagy et a l, 1998). If Kupffer cell activation and release of such 
factors may account for hyperplastic growth in rats by various xenobiotics, inhibition 
of release of such factors may explain the lack of hyperplastic action of DEX.
7.4.3 Kupffer cells, liver disease, and carcinogenesis
The increase in hepatocyteiKupffer cell ratio observed may also explain the 
carcinogenic potential of Wy-14,643 and CPA (Reddy and Lalwani, 1983; Roberts et 
al, 1995), and lack of carcinogenesis following DEX treatment (Thatcher and 
Caldwell, 1994). Depletion of Kupffer cells has been observed in various liver 
disease states, including hepatocarcinogenesis. This emphasises the importance of 
Kupffer cells within the liver, and may indicate a vital role in the maintenance of liver 
homeostasis and size. Using lysozyme as an immunohistochemical marker for cells 
of the mononuclear phagocyte system, a pronounced depletion of Kupffer cells in 
liver lobules in chronic hepatitis, primary biliary cirrhosis, and other types of cirrhosis 
has been demonstrated (Manifold et a l, 1982; 1983). It is thought that the close
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apposition of hepatocytes and Kupffer cells in the normal liver may afford some 
protection against hepatocellular carcinogenesis, and therefore the depletion of 
Kupffer cells observed in cirrhosis might therefore allow neoplastic transformation of 
hepatocytes and explain the higher incidence of liver cell carcinoma. Indeed, Kupffer 
cells have been demonstrated to exert a number of antitumour actions and have been 
suggested as being capable of destroying cells that exhibit abnormal growth properties 
(Hibbs et a l, 1987; Tzung and Cohen, 1992). Hibbs and co-workers tested the 
cytotoxic activity of activated mouse macrophages against mouse embryo fibroblasts 
before and after spontaneous transformation of the fibroblasts in vitro. Activated 
macrophages caused little or no destruction of untransformed fibroblasts but were 
markedly cytotoxic to the same fibroblasts after spontaneous transformation (Hibbs et 
al., 1987). A number of factors produced by Kupffer cells have been identified as 
being involved in macrophage-mediated tumour-cell killing and these include 
arginase, hydrogen peroxide, superoxide, IFNa/p, and the C3a component of 
complement (Nathan et a l, 1980; Tzung and Cohen, 1992). It has been suggested 
that one stimulus for Kupffer cell cytotoxicity may be the existence of an excessive 
replication rate (Manifold et al, 1982; 1983).
A progressive depletion of Kupffer cells has also been recorded in compound-induced 
hepatocarcinogenesis. Of possible significance is the observation that Kupffer cells 
do in fact take up carcinogenic compounds (Munthe-Kass, 1979). Using the 
Solt-Farber model of hepatocarcinogenesis in rats, Janossy and co-workers recorded a 
gradual decrease in Kupffer cell number from the non-transformed liver parts to the 
foci (Janossy et a l, 1986). The altered cell foci contained fewer Kupffer cells than 
the normal untreated rats and the non-transformed liver areas, with a high reduction in 
the number of detectable Kupffer cells in the hepatocellular carcinomas. 
Additionally, when compared to untreated rat liver, a reduction in the volume 
occupied by Kupffer cells in both focal and non-focal tissue following a single 
initiating dose of diethylnitrosamine followed by promotion with phenobarbitone has 
been observed (Jack et al, 1990).
What causes this reduction in Kupffer cell number is not known. It has been 
suggested that humoral factors are produced by transformed hepatocytes which may 
be able to kill the Kupffer cells (Munthe-Kass, 1979; Janossy et a l, 1986), or exert a 
negative chemotactic effect on them (Synderman and Pike, 1976). It has also been
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hypothesised that the loss of Kupffer cells may possibly result from capillarisation of 
the sinusoids, which has been observed during the process of liver cirrhosis and 
carcinogenesis (Lough et a l, 1987).
With regard to the data obtained in my study, a loss or change in distribution of 
Kupffer cells has been indicated following administration of Wy-14,643 and CPA, 
two non-genotoxic carcinogens (Reddy and Lalwani, 1983; Roberts et a l, 1995), to 
rats. Could this effect on Kupffer cells explain the development of carcinogenesis 
following chronic administration of these compounds to rats? This may be so, as 
evidence has accumulated regarding the potential antitumour actions of Kupffer cells, 
and the depletion of Kupffer cell numbers in liver cancer has become a common 
phenomenon. These observations may also explain the lack of carcinogenic action of 
DEX as compared to the other hepatomeglic compounds. No real change in 
hepatocyte:Kupffer cell ratio per field was observed in my study, therefore it is 
possible that Kupffer cells were able to maintain the homeostatic balance of the liver. 
This raises interesting questions regarding a possible role of Kupffer cells as a 
safeguard against the process of carcinogenesis in the liver. It would be interesting to 
determine whether Kupffer cell depletion following administration of these 
compounds occurs or not in species that are non-responsive to the hyperplastic and 
hepatocarcinogenic effects of such compounds.
Using the data obtained in this study in conjunction with evidence provided in 
previous studies. Figure 7.1 illustrates a proposed hypothesis for the involvement of 
Kupffer cells in the pattern of liver growth and resultant hepatocarcinogenesis 
following treatment of rats with Wy-14,643. It has been suggested that Kupffer cells 
may play a similar role in cyproterone acetate-induced liver growth, and so it is 
possible that this hypothesis may also apply for other mitogenic compounds known to 
cause hepatomegaly; a hypothesis which remains to be experimentally addressed.
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Figure 7.1 Proposed model indicating a role of Kupffer cells in liver growth and 
hepatocarcinogenesis in rats following administration of Wy-14,643.
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Rapid release of
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^  TNFa. IL-1, IL-6
Hepatocyte
t  Peroxisomes
ooCell ijcle t  / R a p id  tin hepatocyte ^
DNA synthesis /  \  /  V 
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Kupffer cell activation
Y
i number/dilution of 
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release/dilution of__ 
mitogenic cytokines o i  in initial rate of DNA synthesisand ^  
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"tumour protection'
Other actions 
e.g. apoptosis suppression
Growth of liver 
to peak size
Hepatocarcinogenesis
Figure 7.1 It is hypothesised that peroxisome proliferators, such as Wy-14,643 exert hepatomegaly 
partly through an increase in hepatocyte proliferation which is mediated via the activation of 
Kupffer cells and through an interation with PPARa. Activated Kupffer cells release mitogenic 
cytokines such as TNFa, IL-1 or IL-6, which rapidly stimulate a high rate o f hepatocyte DNA 
synthesis and cell proliferation. Wy-14,643 also interacts with PPARa to cause peroxisome 
proliferation and enhances the effects o f Kupffer cell-released cytokines on hepatocyte DNA 
synthesis and proliferation. Following initial Wy-14,643-induced Kupffer cell activation, a 
reduction in Kupffer cell number and/or dilution o f Kupffer cells due to hepatocyte proliferation 
then takes place. This means there is a reduction or dilution in the initial release o f mitogenic 
cytokines which results in a reduction in the initial rate of DNA synthesis and cell proliferation. 
Accordingly, the rate o f growth of the liver slows and the liver eventually reaches a maximum size. 
The apparent reduction in number of Kupffer cells also limits their possible antitumour actions. 
This, in conjunction with the increased hepatocyte proliferation, and other known effects of 
peroxisome proliferators such as apoptosis suppression, may ultimately result in 
hepatocarcinogenesis.
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7.5 Future work
The work performed in this study has raised many interesting questions and 
highlighted many areas for further investigation.
Investigation of the changes observed in the Kupffer cell receptor mRNA revealed 
interesting data regarding the Kupffer cell itself, and has indicated potential novel 
roles of the Kupffer cell in a mechanism of compound-induced liver growth. There 
are many areas that may be explored further.
(a) Kupffer cell quantitation
• It would be beneficial to repeat the counting experiments using a more definitive 
method of Kupffer cell analysis. Optimisation of an immunohistochemical 
method with an appropriate antibody could be used to do this. Some studies have 
successfully used lysozyme in order to achieve this (Manifold et aL, 1982). 
Staining for endogenous peroxidase within Kupffer cells has also allowed for 
reliable quantitation (Bouwens et a i, 1986). Another method that has been 
utilised to successfully count Kupffer cells involves the injection of rats with 
carrageenan (Janossy et a l, 1986). Kupffer cells take up carrageenan which 
shows chromasy with toluidine blue staining.
• It would be of interest to count absolute Kupffer cell numbers by methods 
involving flow cytometry as this would determine the underlying cause of the 
increase in hepatocyte:Kupffer cell ratio observed -  was it due to a dilution of 
Kupffer cells over a larger area or a direct effect on total cell numbers?
(b) Kupffer cell role in liver growth
• In order to determine a precise role of Kupffer cells in a mechanism of growth, it 
would be interesting to investigate, if possible, the effects of various compounds 
in rat in vivo following Kupffer cell deactivation both before and after compound 
administration. A number of questions may be addressed. Are Kupffer cells vital 
for the growth response? Does liver growth or hepatocyte cell proliferation occur 
if Kupffer cells are inactivated before compound administration? Does growth of 
et a l, 1988, 1989). In rats, intravenous methyl palmitate is a non-metabolising 
fatty acid which has been used successfully to inactivate Kupffer cells (Rose et 
al, 1997a), as has dietary glycine (Rose et a l, 1997b). Gadolinium chloride, a 
rare earth metal ion, has also been demonstrated to inhibit Kupffer cell actions 
including the release of various cytokines (Higashitsuji et a l, 1995) as well as 
phagocytosis (Husztik et a l, 1980).
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• If Kupffer cells could be induced to proliferate or remain continually activated, it 
would be interesting to determine whether it is possible for hepatocyte 
proliferation and growth of the liver to continue for longer.
(c) Kupffer cell-releasedfactors responsible for growth
• Treatment of rats with antibodies to various Kupffer cell-released cytokines and 
growth factors that may contribute to compound-induced liver growth, before 
compound treatment may indicate whether such factors are involved in the growth 
process. This has already been pursued for TNFa (Bojes et al., 1997), but other 
cytokines such as the interleukins could be investigated.
Due to time constraints, this study has concentrated on the changes in Kupffer cell
receptor mRNA levels and Kupffer cell numbers. However, the process of SSH and
subsequent quantitation experiments identified many other potentially interesting
differentially expressed genes.
(d) Carboxylesterase
• A possible role of the differential expression of the liver-specific gene Carb has
been indicated in compound-induced liver growth. With regard to its known
functions (Long et al., 1988), it may be that its differential expression in some 
way affects the metobolism or detoxification of such xenobiotics, which is an area 
that may be investigated further.
(e) Other genes identified by SSH
• Many genes were identified by SSH that may be involved in a mechanism of liver
growth, but due to time it was not possible to pursue these genes further.
Repeating the same step-wise experiments as for the four genes selected in this 
study may prove beneficial in terms of elucidation of a potential role they may 
play in liver growth.
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7.6 Conclusions
SSH has proved to be a valuable tool in the generation of potential candidate genes 
for further interrogation regarding mechanisms of xenobiotic action.
The necessity of confirmation and quantitation of changes in mRNA levels following 
SSH identification has been highlighted.
The step-wise, selective experiments performed throughout this study have resulted in 
the identification of a possible novel role of Kupffer cells in a mechanism of 
compound-induced liver growth.
An interaction with Kupffer cells followed by a subsequent increase in 
hepatocyteiKupffer cell ratio as observed in this study may explain the pattern of 
growth following treatment of rats with the potent peroxisome proliferator 
Wy-14,643. The initial activation of Kupffer cells providing the stimulus for 
hepatocyte DNA synthesis and cell proliferation, and the observed subsequent 
reduction/dilution of Kupffer cells being responsible for the reduction in cell 
proliferation rate and achievement of peak liver size.
It appears that this theory, in part, may apply to other compounds known to cause 
hepatomegaly via hyperplasia, as exemplified by cyproterone acetate in this study. In 
this case, although the literature indicates that Kupffer cells are unlikely to be 
essential for the initiation of the hyperplastic response, they may be involved in this 
effect. The observed increase in hepatocyte:Kupfier cell ratio and the subsequent 
decrease/dilution of mitogenic cytokines may explain the similarities in the pattern of 
growth of the liver following cyproterone acetate treatment to that recorded following 
treatment with peroxisome proliferators.
This increase in hepatocyte:Kupffer cell ratio may also contribute to the 
hepatocarcinogenic potential of some hepatomegalic compounds as compared to 
others, as Kupffer cells have been demonstrated to possess antitumour properties and 
the depletion of Kupffer cells in liver cancer is a common phenomenon.
The absence of an interaction of dexamethasone with Kupffer cells may additionally 
explain the lack of hyperplastic and carcinogenic response in the liver of rats 
following treatment. My study has indicated that dexamethasone exerts virtually no 
change on the hepatocyte:Kupffer cell ratio and therefore the liver homeostatic 
balance is maintained. It may be hypothesised that compounds such as 
dexamethasone do not interact with Kupffer cells to cause any activation or reduction
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in number, resulting in no stimulation of hepatocyte DNA synthesis, cell proliferation 
and development of hepatocarcinogenesis. In support of this, dexamethasone has 
been shown to inhibit Kupffer cell release of various bioactive substances.
In conjunction with data obtained in previous studies, this investigation has resulted in 
the proposal of a working hypothesis incorporating a novel role of Kupffer cells in 
xenobiotic-induced liver growth and hepatocarcinogenesis.
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Appendix
Sequencing results of clones that gave ‘no match’ following a BLAST search (Nl^lO)
Up-regulated sequences identified 24 hours following one 50 mg/1% dose Wy-14,643:
N1
CGAGCGGCCGCCCGGGCAGGTTGAGATTTGGGAGAGACGCTCTGAACTGACTGCCCCGCATCACCG
GAGCGTCCCAGCTGCGAGGAGTGTAAACAGGAACATCGATAAGTAGTGTAAAAACTTGCACAATG
AAATCCGAAGCCAAGGATGGAGAGGAGGAGAGTCTACAGACTGCTTTCAAAAAATTAAGAGTGGA
TGCATCAGGGTCTGTAGCATCTCTGTCTGTTGGAGAAGGCACAGGTGTCAGAGCACCAGTCAGAAC
AGCAACAGATGATACCAAACCTAAAACCACATGTGCATCTAAAGACAAGGTGGCACGGGNCTACA
AAGAAAGTCTTCACGAGGAGCAGNGAGAACTCANCGGCGNCGACGTTCTAAAGNCTNCTGNCCTTC
ATNCTCCAAAGGTTATACATTGGAGTACCTCGGGCGNGAACACGCTA
N2
GATCCCTAGTAACGGCCGCCAGTGTGCTGGAATTTCGANCGGCCGGCCNGGCAGGTCGAGATTTGG
GAGANACGCTNTGAACTGACTGCCCCGCATCACCGGAGCGTCCCANCTGCGAGGAGTGTAAACAG
GAACATCGATAAGTTGTGTAAAAACTTGCACAATGAAATCCNAAGCCAAGGATGGAGAGGAGGAG
AGTCTACAGACTGCTTTCAAAAAATTAAGAGTGGATGCATCAGGGTCTGTAGCATCTCTGTCTGTTG
GAGAAGGCACAGGTGTCAGAGCACCAGTCAGAACAGCAACAGATGATACCAAACCTAAAACCACA
TGTGCATNTAAAGACAGTTGGNACGGGTCTACANGGAAGTCTTCACGAGGAGCANTGANAACTCA
GCGTCGTCGACGTTCTAAGTCTCCTGTC
N3
AGCGTGGTCGCGGCCGAGGTACTGNAATGTATAAACTTTGGAGGATGAAGGACAGGAGACTTAGA
ACGTCGACGACGCTGAGTTCTCACTGCTCCTNGTGAAGACTTCCTTGNAGACCCGTGCCAACTGTCT
TTAGATGCACATGTGGTTTTAGGTTTGGTATCATCTGTTGCTGNTCTGACTGGNGCTCTGACACCTG
NGCCTTCTCCAACAGACAGAGATGCTACAGACCCTGATGCATCCACTCTTAATTTTTTGAAAGCAGC
TGTAGACTCTCCTCCTNTNNATCCTTGGCTTCGGATTTCATTGGGCAAGGTTTTACACTACTTATCGA
TGGTCCTGNTTACACTCCTCGCAGCTGGGACGCTCCGGNGATGCGGGGCAAGCAGGTCAGAGCGGN
TNTTCCAAANATNGANCTGGCCGGGNGGGCGGTNGAAGGGGGAANTNTGGAGANATCATNACANT
GGGGGCGGTTGAGNANGCATNTAGAGGGGCCAANTNGCCTANAGGGAGGNGAATACAATTNACTG
GGCGNGGTTTACAANGGNGNGACTGGGAAAACCCTGGGGGTACCCAANTTAANNGCTTGGAGAAN
ANCCCCTTTGGCAGGTGGGGNAAAAGGAANAGGGCCGAACGANGGCCTTNCCAANAAGTGGGNAN
NCTGAAAGGGGAAAGGACNCGCCCTGGA
N4
GTGGNNGGGGGNNNNNTNTAATTTCATTCCGTTCCGACTCNGATCCCTAGTAACGGCCGCCAGTGT
GCTGGAATTTCGANCGGCCGGCCNGGCAGGTCGAGATTTGGGAGANACGCTNTGAACTGACTGCCC
CGCATCACCGGAGCGTCCCANCTGCGAGGAGTGTAAACAGGAACATCGATAAGTTGTGTAAAAACT
TGCACAATGAAATCCNAAGCCAAGGATGGAGAGGAGGAGAGTCTACAGACTGCTTTCAAAAAATT
AAGAGTGGATGCATCAGGGTCTGTAGCATCTCTGTCTGTTGGAGAAGGCACAGGTGTCAGAGCACC
AGTCAGAACAGCAACAGATGATACCAAACCTAAAACCACATGTGCATNTAAAGACAGTTGGNACG
GGTCTACANGGAAGTCTTCACGAGGAGCANTGANAACTCAGCGTCGTCGACGTTCTAAGTCTCCTG
TCCTTCATCCTCCAAAGTTTATACATTGCAGTACCTCGGCCGTGACCACGCTA
N5
TCGAGCGGNCGCCCGGGNAGGTACNTNGGCCGCGACCACGCTANNG
Down-regulated sequence identified 24 hours following one 50 mg/kg dose Wy-14,643:
N6
TCGAGCGGNCGCCCGGGCAGGTACTTTTGGCCGGTGACCACGCTA
256
up-regulated sequences identified 12 hours following one 50 mg/kg dose Wy-14,643:
N 7
TCGCCCTTNCNAGCGGCCGCCCNGNTTTGTTANAAAAAACAAACATANATGGNAAACTNGAGANTG
GTTAATAAAAAAAANNAAAAATANAAAAANAAATTTTAAACNCTTGCNGTNCNTNCNAGCGATNG
GGCNAAANNAACCAAATTTNNNTCANANANNTTGGCACATTAAACATGCATGTNNGGGGCCCAAT
TGCCCTTATTNANTGNNNTGGATCAANTANACTGGACTTTANTGTNACTCCNTAATCAAATGGGAA
AGACNTAGCAAATNCNCACANTTNTNNATNACTTGNNNAAANANTCCCCATTTGCCTNNTGGAATN
NANAACNNAATAGGGCGATACNTANNNNCNNTCCCCAACATTATTNNAAGCNTTAANTGNNGNAG
NGGCTNTCCCNCNNTTCNACNGTCNATNAAANNAGCGNNNNNNAANNCTGTTTTTCCTTNAANNTT
TTNAANNGCAAAAATTTNCNACCANANNTAATAGCCNCCNTTNCTNTTNNTAATCNTNCCNTTCCN
TTATTNCCCNNAANTTCNGCACAAATTTTCTCCCNTTTAAAANTTTANAAAATGGGGGGNTTCCNTA
TAAANNGTTCCTNTTCANNNCNTTTNNCCCCCTCTCCNGGGNCCCAAAAAACCTNNTAGGGGNNNG
NNTTTATNNACGGGGGGCATCTCCCNNNAANANGGNTTTTTCNCCTTTNANNNTGGGNTNNNCTCN
TTNANTNGGGNCTTTTGTGTCAAATGNGAANANCNTNANCCTNTTTNNGTTTTTNTT
N8
TCGCCCTTTCGAGCGGNCGCCCGGGTAGGTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAANNAAAAAAAANACNTGGTNGGGCCNCTT
TTGGGGGNANTTTTGNAGNTNTNNTTNAAANTGGCAGGCCGTTNGAGGGGTGCNTTTAGNGGGTCC
ANTNAGGCNTATAANAGNGTCATTGTTNCANTTTNTTGGANCGTTGTTTNANNNNAAAATNNTNGG
GAAACCCATGGGNTTNCCCNNGTAAANCATCNTCCNTTNANANCCCTGTTTNAAAAGCTTGGGNGN
NCNGCAAAGANGNCCGTTCNNANCNTTTTTTCAAANAGNTNGGCAAANTTGAATGGCNATTNGACG
GCCCTTTTTAACGCNCCATTAANCGGGGNTTATTANGGGTGGTTACNTTTAAATTNACCNTTAACTT
TGGCCNNGCCTTTTNNNGGCCCNGTTTTTTTTGCTTTTTTTTTCCTACNTTTTTTCNGCTTTTTTTNNG
TGGGATTTTTAAAGTTGGNGGTTTTAAAATTTNGGGGGTTCCTTTTTNGGGNNTNCAATNGAGGGGT
TTTTTACCGGAAANAATTTTCCTNAANANATTTGTTTANAGGGANTNGGTCCAAANTAAATGGGTN
AAANCGNNTTNTTAAAACGNTTTTTTTGGNCTTTAAANTTTGNNTTTAAAAGGTTTTTTANGTGGAA
ATTTTTTNCAAATTNGGCCTAATTTNGNTTTTTTTT
Down-regulated sequences identified 24 hours following one 50 mg/kg dose Wy-14,643:
N9
TCGCCCTTTNNAGCGGCCGNCCGGNTTGGTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAATTTNGATCTGGGGNGACACCACTCTNGGGGNAANTTNTGCATATNTNNATCACANTGG
GGGNCNCTAGAlvlNATGNNTATAGNGGNCNNANTTCNCNNTATAGNGAGTNNTNTNANAATNCANT
GNCCGTNTTTTTANAACGTTTGANNGTGNAAAAACNNTGGCNNNCCNNANTTNAATCNTTTTGNAA
NATATCCCTTTTTCNNCAGNTGGTNTAATAGAAAAGAGGCCCNCACANATCNCTTTTCAAAACATTT
GCACACTNTNNNNGGAAAANGGACGCCCNNTNTNGNGGCNTATNAAGCGCGGGGGNTGNGGNNN
NTACNCACAAGTNNCNCCTTATACNTTTTGNNAGCCNCTTTTAAGCCCCCCGCTTTTTTGCTTTTTNT
TTCCTTTTNTTTTCTCCNCATTTTCGNGCGGTTTTTCCNCGNTAAAATTTTTTTAAANGNGGGGGGGC
NNTTTTTGNGGGTNCCCTNNTNTAGGGNTTTTTANGGCCNTTTANCCCCAAAAAAATTTTTTTANGG
GGGNNGGNTNNCCNANTTNGGGCAATTTNCNNNTTAAAANAGGTTTTTTCCCTTTTTGATGTGNGAT
CCCCTTTTTTAAANGGGGGTTTTTTTTCNAANTTGNGAAAAATTTAAAACCTTTTTTNGNTTTTTTTT
TTTTTTN
NIO
TCGCCCTTNCNAGCGGCCGNCCNGGCGNGTNAAAAAAAAAAAAANAAAAANAAAAAAAGCAAAA
AATATAAAANANGGTTNTNNNTCTGCCGCNACNNCCTNATGGGNAANTTTTTNAAATTNCNNTAAA
ATNGNGGNCANTNAGNTATTNNNNNAANAGGGCNNANTTATCCTTTTTAGGGNTCANTGTTNNAAT
GTNAATTGGCNGCCCNTTTNNCACTNGGGGGCNNGGAAAANCCTNGGNTTANCCAAATTTNTNCCN
TTNGGACNNNNTNNCNNTTTANNNNTNNGGATNNNNANCAAAAAGGCCGGGCNCTNNNTNNATTT
TCNAAAAGGTTCCANAATCNTNATTGGCAAAGGCCCTCCCCTTTAACTGGCCNNTAAACCACAACG
GNNNGNGTGNTAACNCCAAGGTNTNCCNTNANTTNTNCGGCTTNCTAAACACCCCCNTTTTNCCAT
TTTTTCCANTCTTTANTANGACCNTCNCGNTTTTTCTCCNAAAAAGTTTTTAAANGGGGGGATTTCCT
TAAGGGGTNCCCATTTAANGGGTTTAAAGGAACCTTGACCCCCAAAAAAACTTTTNTTGGGGNGAA
GGNCCCCTAATTGGGCCATNCCCTNTANAAACNGTTTTTTGCCCTTTTTGNCTTGGGNTTNCNCCTT
NTTTAANAGGGGACCTTTTTNANAAATGGNACAACNCTTTCCCTTTTT
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